

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 November 2004 (25.11.2004)

PCT

(10) International Publication Number
WO 2004/101072 A1

(51) International Patent Classification⁷: **A61P 25/00**,
23/00, A61K 39/395, 31/00, G01N 33/48

(21) International Application Number:
PCT/CA2004/000726

(22) International Filing Date: 14 May 2004 (14.05.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/470,885 16 May 2003 (16.05.2003) US

(71) Applicant (for all designated States except US): **UNIVERSITE LAVAL** [CA/CA]; Cité Universitaire, Québec, Québec G1K 7P4 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DE KONINCK, Yves** [CA/CA]; 3770 Le Corbusier, Ste Foy, Québec G1W 4P4 (CA). **DE KONINCK, Paul** [CA/CA]; 1285 de la Monnerie, Cap Rouge, Québec G1Y 1P5 (CA). **COULL, Jeffrey** [CA/CA]; 26 rue Garneau, Apt. 5, Québec, Québec G1R 3V2 (CA).

(74) Agent: **SMART & BIGGAR**; Suite 3400, 1000 de la Gauchetière Street West, Montreal, Quebec H3B 4W5 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CNS CHLORIDE MODULATION AND USES THEREOF



(57) Abstract: Methods and products for the attenuation or treatment of pain and the reduction of nociception are described. The methods and products are based on the modulation of CNS intracellular chloride levels. The methods and products may also relate to modulation of the activity and/or expression of a chloride transporter, such as the KCC2 potassium-chloride cotransporter. Also described herein are commercial packages and uses based on such modulation. Related methods for identifying or characterizing a compound for the treatment of pain, the reduction of nociception and the diagnosis and prognostication of pain are also described.

WO 2004/101072 A1

CNS CHLORIDE MODULATION AND USES THEREOF**CROSS REFERENCE TO RELATED APPLICATIONS**

This application claims the benefit, under 35 U.S.C.

5 \$ 119(e), of United States provisional patent application
Serial No. 60/470,885 filed May 16, 2003, which is hereby
incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

10 The invention relates to the modulation of anion
levels in a central nervous system (CNS) neural cell, and
particularly relates to the modulation of CNS intracellular
chloride levels and uses thereof for treating, preventing,
diagnosing and prognosticating pain.

15

BACKGROUND OF THE INVENTION

The need for new and improved methods and agents
for pain treatment is a significant ongoing concern in
medicine. Acute pain, e.g. related to injury or disease, can
20 be severe and have critical effects on patient recovery. An
even greater concern is chronic pain, which affects a large
proportion of the population, causing not only significant
discomfort, but can result in low self-esteem, depression,
anger, and can interfere with or completely prevent a
25 sufferer from typical daily activities.

While a number of studies have been done in this
area, many mechanisms and pathways involved in pain sensation
remain poorly understood. As in the case of the sensation of
various stimuli, it has been suggested that pain sensation is
30 related to altered neuronal excitability.

Ion cotransport has in some cases been thought to
play a role in the processing of certain stimuli. For
example, Howard et al. (28) have demonstrated that mice

generated with a targeted deletion of the Slc12a6 gene, which encodes the KCC3 exporter, exhibit features of agenesis of the corpus callosum, including a locomotor deficit, peripheral neuropathy and a sensorimotor gating deficit.

5 Sung et al. (29) report that in mice where there is a disruption of the Slc12a2 gene, which encodes the NKCC1 cotransporter, sensitivity to thermal stimulus is greatly reduced, compared to both wild-type and heterozygous (NKCC1^{+/-}) mice.

10 There remains a need to better define the mechanisms involved in pain sensation to provide new strategies of therapeutic intervention in this regard.

SUMMARY OF THE INVENTION

15

This invention relates to pain and methods of treating, preventing, diagnosing and prognosticating such pain. This invention also relates to pain associated with neuropathic pain and CNS dysfunction. This invention also
20 relates to methods of decreasing an intracellular chloride level in a central nervous system (CNS) neural cell.

According to one aspect, the invention provides a method of treating or preventing pain in a subject, the method comprising decreasing an intracellular chloride level
25 in a central nervous system (CNS) neural cell of the subject. In an embodiment, the method comprises modulating the activity or expression of a chloride transporter in the CNS cell, thereby to decrease the chloride level. In a further embodiment, the chloride transporter is KCC2 the method
30 comprises increasing KCC2 activity or expression. In another embodiment, the CNS neural cell is a spinal cord neural cell. In yet another embodiment, the signal of the pain originates in a peripheral nervous system (PNS) cell or sensory fiber

transsynaptic to the CNS neural cell. In still another embodiment, the pain is neuropathic pain, and in further embodiments the neuropathic pain is associated with a nerve or tract injury or is selected from the group consisting of somatic and visceral pain. In yet another embodiment, the pain is selected from the group consisting of chronic inflammatory pain, pain associated with arthritis, fibromyalgia, back pain, cancer-associated pain, pain associated with digestive disease, pain associated with Crohn's disease, pain associated with autoimmune disease, pain associated with endocrine disease, pain associated with diabetic neuropathy, phantom limb pain, spontaneous pain, chronic post-surgical pain, chronic temporomandibular pain, causalgia, post-herpetic neuralgia, AIDS-related pain, complex regional pain syndromes type I and II, trigeminal neuralgia, chronic back pain, pain associated with spinal cord injury and recurrent acute pain.

In an embodiment, the method comprises administering to the subject a compound capable of decreasing the intracellular chloride level in the CNS cell. In yet another embodiment, the compound is capable of modulating the activity or expression of a chloride transporter in the CNS cell. In yet a further embodiment, the chloride transporter is KCC2, and yet further, the compound is capable of increasing KCC2 activity or expression. In another embodiment, the compound is an inhibitor of TrkB, such as K-252a or an anti-TrkB antibody. In another embodiment, the compound is an inhibitor of cyclic AMP-dependent kinase (PKA) (e.g. H-89). In another embodiment, the compound is an inhibitor of calmodulin-dependant kinase (CAM kinase), and further, it is KN-93. In an embodiment, KCC2 comprises an amino acid sequence substantially identical to a sequence

selected from the group consisting of SEQ ID NO: 2, 4, 6 and a fragment thereof.

According to another aspect of the present invention, there is provided a composition for the treatment or the prevention of pain in a subject, the composition comprising a compound capable of decreasing an intracellular chloride level in a CNS neural cell; and a pharmaceutically acceptable carrier. In an embodiment, the compound is capable of modulating the activity or expression of a chloride transporter in the CNS neural cell. In a further embodiment, the chloride transporter is KCC2, and further, the compound is capable of increasing KCC2 activity or expression.

According to still another aspect of the invention, there is provided a commercial package comprising the composition described herein together with instructions for its use in the treatment or prevention of pain.

According to yet another aspect of the invention, there is provided a commercial package comprising a compound capable of decreasing an intracellular chloride level in a CNS neural cell together with instructions for its use the treatment or prevention of pain. In an embodiment, the compound is capable of modulating the activity or expression of a chloride transporter in said CNS neural cell. In a further embodiment, the chloride transporter is KCC2, and further, the compound is capable of increasing said KCC2 activity or expression.

According to a further aspect of the present invention, there is provided use of the composition described herein for the treatment or prevention of pain and/or for the preparation of a medicament for the treatment or prevention of pain.

According to yet a further aspect of the present invention, there is provided use of a compound capable of decreasing an intracellular chloride level in a CNS neural cell for the treatment or prevention of pain and/or for the preparation of a medicament for the treatment or prevention of pain. In an embodiment, the compound is capable of modulating the activity or expression of a chloride transporter in said CNS cell. In a further embodiment, the chloride transporter is KCC2, and further, the compound is capable of increasing KCC2 activity or expression. In another embodiment, the compound is an inhibitor of TrkB, and further, it is selected from the group consisting of K-252a and an anti-TrkB antibody. In another embodiment, the compound is an inhibitor of cyclic AMP-dependent kinase (PKA), and further, it is H-89. In another embodiment, the compound is an inhibitor of calmodulin-dependant kinase, and further, it is KN-93.

According to still a further aspect of the invention, there is provided a method of identifying or characterizing a compound for treatment or prevention of pain, the method comprising contacting a test compound with a CNS-derived cell; and determining whether the intracellular chloride level is decreased in the presence of the test compound; wherein the decrease is an indication that the test compound may be used for treatment or prevention of pain.

According to another aspect of the present invention, there is provided a method of identifying or characterizing a compound for treatment or prevention of pain, the method comprising contacting a test compound with a CNS-derived cell expressing a chloride transporter; and determining whether activity or expression of the chloride transporter is modulated in the presence of the test compound in such a way that the level intracellular chloride is

decreased; wherein the modulation is an indication that the test compound may be used for treatment or prevention of pain. In an embodiment, the chloride transporter is KCC2, and further, the method comprises determining whether said

5 KCC2 expression or activity is increased in the presence of the test compound and the modulation is an increase. In another embodiment, KCC2 activity is determined by measuring a parameter selected from the group consisting of potassium transport, chloride transport, intracellular chloride level

10 and anion reversal potential. In still another embodiment, the pain is selected from the group consisting of chronic inflammatory pain, pain associated with arthritis, fibromyalgia, back pain, cancer-associated pain, pain associated with digestive disease, pain associated with

15 Crohn's disease, pain associated with autoimmune disease, pain associated with endocrine disease, pain associated with diabetic neuropathy, phantom limb pain, spontaneous pain, chronic post-surgical pain, chronic temporomandibular pain, causalgia, post-herpetic neuralgia, AIDS-related pain,

20 complex regional pain syndromes type I and II, trigeminal neuralgia, chronic back pain, pain associated with spinal cord injury and recurrent acute pain.

According to yet another aspect of the present invention, there is provided a method of identifying or

25 characterizing a compound for treatment or prevention of pain, said method comprising contacting a test compound with a CNS-derived cell comprising a first nucleic acid comprising a transcriptionally regulatory element normally associated with a chloride transporter gene, operably linked to a second

30 nucleic acid comprising a reporter gene capable of encoding a reporter protein; and determining whether reporter gene expression or reporter protein activity is modulated in the presence of the test compound; wherein the modulation in

reporter gene expression or reporter protein activity being an indication that the test compound may be used for treatment or prevention of pain. In a further embodiment, the chloride transporter is KCC2, and further, the reporter
5 gene expression or reporter protein activity is increased in the presence of the test compound.

According to one aspect of the present invention, there is provided a method for decreasing nociception in a subject, the method comprising decreasing intracellular
10 chloride in a CNS neural cell of the subject. In an embodiment, the method comprises modulating chloride transporter activity or expression in the CNS neural cell. In a further embodiment, the chloride transporter is KCC2, and further, the method comprises increasing KCC2 activity or
15 expression. In another embodiment, the method further comprises contacting the CNS neural cell with a compound capable of increasing KCC2 activity or expression. In yet another embodiment, the compound is an inhibitor of TrkB, and further, it is selected from the group consisting of K-252a
20 and an anti-TrkB antibody. In still another embodiment, the compound is an inhibitor of cyclic AMP-dependent kinase (PKA), and further, it is H-89. In yet another embodiment, the compound is an inhibitor of calmodulin-dependant kinase, and further, it is KN-93. In still another embodiment, KCC2
25 comprises an amino acid sequence substantially identical to a sequence selected from the group consisting of SEQ ID NO: 2, 4, 6 and a fragment thereof.

According to another aspect of the invention, there is provided a method for diagnosing or prognosticating pain
30 associated with CNS dysfunction in a subject experiencing pain, the method comprising determining whether a test CNS intracellular chloride level is increased relative to a corresponding control chloride level; wherein the increase is

an indication that the subject is experiencing pain associated with CNS dysfunction. In an embodiment, the method further comprises determining whether CNS chloride transporter activity or expression is modulated relative to a control transporter activity or expression. In another embodiment, the chloride transporter is KCC2, and further, the method comprises determining whether KCC2 activity or expression is decreased relative to the control activity or expression. In still another embodiment, the control intracellular chloride level is selected from the group consisting of an established standard; a corresponding intracellular chloride level determined in the subject at an earlier time; a corresponding intracellular chloride level determined in the subject when the subject is experiencing less pain or substantially no pain; and a corresponding intracellular chloride level determined in a control subject experiencing less pain or substantially no pain. In yet another embodiment, the control activity or expression is selected from the group consisting of an established standard of KCC2 activity or expression; a corresponding level of KCC2 activity or expression determined in the subject at an earlier time; a corresponding level of KCC2 activity or expression determined in the subject when the subject is experiencing less pain or substantially no pain; and a corresponding level of KCC2 activity or expression determined in a control subject experiencing less pain or substantially no pain. In a further embodiment, KCC2 activity is determined by measuring a parameter selected from the group consisting of potassium transport, chloride transport, intracellular chloride level and anion reversal potential. In still a further embodiment, the intracellular chloride level is determined by administering an indicator compound indicative of chloride level to the subject such that it is

contacted with a CNS neural cell of the subject; and assessing an *in vivo* signal associated with the indicator compound. In yet another embodiment, the pain associated with CNS dysfunction is neuropathic pain. In still yet
5 another embodiment, the indicator compound is a radionuclide, and further, it is selected from the group consisting of ^{201}Tl , ^{99}Tcm -tetrofosmin, ^{99}Tcm -MIBI, ^{99}Tcm -HMPAO and ^{36}Cl . In still another embodiment, the *in vivo* signal is assessed by an imaging technique. In yet still another embodiment, the
10 *in vivo* signal is the retention index of the indicator compound. In a further embodiment, the imaging technique is selected from the group consisting of single photon emission computed tomography, positron emission tomography and magnetic resonance imaging. In yet a further embodiment, the
15 indicator compound is indicative of KCC2 expression, and further, it is an antibody directed against KCC2.

According to yet another aspect of the invention, there is provided a method of treating pain associated with CNS dysfunction in a subject, the method comprising
20 diagnosing or prognosticating, according to the methods described herein, pain associated with CNS dysfunction in the subject; and decreasing an intracellular chloride level in a CNS cell of the subject.

In an embodiment, the above-mentioned subject is a
25 mammal, in a further embodiment, a human.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: Peripheral nerve injury (PNI) induced a collapse of
30 the V_{anion} in Lamina I (LI) neurons in the ipsilateral superficial dorsal horn (SDH). **a)** Chronic constriction injury of the sciatic nerve ($n = 23$), but not sham surgery ($n = 11$), caused a significant reduction in the 50% nociceptive

withdrawal threshold to mechanical stimulation of the hindpaw in rats ($p < 0.01$). **b)** Ranges of E_{anion} recorded from LI neurons of naïve (Δ) and PNI (\circ) rats. Solid symbol = mean $E_{anion} \pm SEM$. **c)** All classes of LI neurons (i.e. with phasic (P), single-spike (SS) and tonic (T) firing properties [19]) showed a shift in E_{anion} in response to PNI. Scale bar is 50 mV (y), 150 ms (x). **d)** Mean peak current measured in LI neurons from naïve (\blacktriangle) and PNI (\bullet) rats in response to applied GABA at various V_m . Horizontal standard error bars represent inter-neuron differences in recording pipette offset. Inset: Representative traces from one neuron. Scale bar is 0.6 nA (y), 1.0 s (x).

Figure 2: Switch from GlyR(receptor)-only to mixed GABA_AR- and GlyR-mediated miniature postsynaptic currents (mPSCs) following PNI in LI neurons. **a)** Raw traces of outward (left) and inward (right) miniature synaptic events from a naïve rat LI neuron. All outward mPSCs were abolished by strychnine, while all inward mPSCs (recorded in the presence of strychnine and bicuculline) were abolished by the GluR antagonist CNQX. HP - Holding Potential. Scale bar is 20 pA (y), 300 ms (x). **b)** Raw traces of inward (left) and outward (right) miniature synaptic events recorded from a PNI rat LI neuron. Unlike in naïve rats, both strychnine and bicuculline were required to abolish all outward mPSCs. Inward mPSCs remained completely sensitive to CNQX. Scale bar is 20 pA (y), 300 ms (x). **c)** left - Superimposed individual mPSCs recorded from PNI rat LI neurons. GlyR-only and GABA_AR-only and mixed GABA_AR/GlyR-mediated were clearly identifiable by their sensitivity to strychnine and/or bicuculline. Right - Averages of > 100 GlyR- and GABA_AR-mediated mPSCs recorded from a PNI rat LI neuron. Scale bar is 15 pA (y), 20 ms (x). **d)** Mean peak conductance of mPSCs recorded from naïve (N; $n =$

10 for GlyR; $n = 5$ for GluR) and PNI (P; $n = 9$ for GlyR; $n = 8$ for GluR) LI neurons. P(B) indicates GlyR-mediated mPSCs recorded in PNI rat LI neurons ($n = 12$) at 0 mV in the presence of bicuculline. **e)** Net charge carried by GlyR-mediated mPSCs in naïve rats ($n = 6$), by bicuculline-isolated GlyR-mediated mPSCs in PNI rats [PNI(Bic); $n = 4$], and by mixed GABA_AR/GlyR-mediated mPSCs in PNI rat LI neurons (PNI; $n = 12$). **f)** Cumulative probability plot illustrating the difference between the GlyR-only mPSC inter-event interval (I.E.I.) in naïve LI neurons and that of bicuculline-isolated GlyR-only mPSCs in PNI rat LI neurons [PNI(Bic)], both recorded at $E_{anion} = 0$ mV. The addition of the GABA_AR-mediated mPSCs (PNI) compensated the GlyR-only mPSC frequency decrease. Inset - No effect of PNI on the frequency of GluR-mediated mPSCs.

Figure 3: PNI-induced downregulation of KCC2 in SDH lamina I neurons ipsilateral to PNI led to GlyR/GABA_AR-mediated excitation. **a)** Brief GABA application (30 ms pressure puff) caused a tetrodotoxin (TTX) and bicuculline-sensitive rise in $[Ca^{2+}]_i$ in a LI neuron from a fura-2-am (Ca^{2+} indicator) loaded slices of a PNI rat. **b)** KCl application, but not GABA application (up to 250 ms-long pressure puffs) caused no change in $[Ca^{2+}]_i$ in a naïve rat LI neuron. In the presence of the KCC2-specific antagonist DIOA, GABA application did elicit a rise in $[Ca^{2+}]_i$ in a naïve rat LI neuron. Scale bar is 0.02 (y), 10 s (x). **c)** Percentage of LI neurons displaying a GABA-evoked increase in $[Ca^{2+}]_i$. The proportion was significantly higher in PNI rats ($\chi^2_{corrected} = 3.91$) and in the presence of DIOA in naïve rats ($\chi^2_{corrected} = 4.43$). **d)** Representative trace confirming that exogenous GABA could repeatedly elicit action potentials in a lamina I neuron. Upper scale bar is 5 mV (y), 200 ms (x). Lower scale bar is

30 mV (y), 4 s (x). Inset - response to a depolarizing pulse confirming this was a single-spike neuron (19). Scale bar is 20 mV (y), 300 ms (x). **e)** Similarly, focal stimuli (in the presence of glutamate receptor blockers) elicited

5 bicuculline-sensitive monosynaptic depolarizing postsynaptic potentials that could evoke action potentials in a lamina I neuron from PNI rats. Scale bar is 5 mV (y), 250 ms (x). Inset - response to a depolarizing pulse confirming this was a phasic neuron (19). Scale bar is 20 mV (y), 300 ms (x).

10 **f)** Left - Immunoblotting revealed that KCC2 levels were decreased in the lumbar SDH lying ipsilateral (Ipsi), but not contralateral (Con), to the site of the PNI. Right - Average intensities (\pm SEM) of KCC2 protein (normalized to actin) measured from immunoblots ($n = 4$) as in left (Ipsi normalized

15 to Con).

Figure 4: Selective blockade or knock-down of the postsynaptic KCC2 exporter in the SDH significantly reduced nociceptive threshold. **a)** Tactile nociceptive withdrawal

20 threshold as a function of time after intrathecal injections of DIOA ($n = 5$) or vehicle ($n = 3$). **b)** Thermal nociceptive withdrawal latency as a function of time after intrathecal injections of DIOA ($n = 3$) or vehicle ($n = 3$). Upon withdrawal, the rats also often licked their paw indicating

25 nociception. **c)** Spontaneous mPSCs recorded with a CsCl (cesium chloride) pipette (to clamp E_{anion} at 0mV) in a LI neuron in the presence and absence of DIOA. Scale bar is 20 pA (y), 300 ms (x). **d)** Cumulative probability plot ($n = 4$ neurons X 50 mPSCs) demonstrating that DIOA neither affected

30 the peak conductance of synaptic events ($p > 0.5$), nor GABA-evoked responses ($n = 5$; $p > 0.5$, Inset) and therefore does not act on GlyRs nor GABA_ARs. G_{peak} = peak conductance. **e)** Local lumbar spinal (intrathecal) administration of a KCC2

antisense oligodeoxynucleotide (each 12 h) caused a significant decrease in the tactile nociceptive withdrawal threshold in naïve rats ($n = 8$), compared to those that received the scrambled oligodeoxynucleotide ($n = 7$). Inset,

5 Decrease in spinal KCC2 protein levels (measured by immunoblots) following antisense (AS, 12h or 36h) or scrambled (S, 36h) oligodeoxynucleotide treatment. **f**) Lack of KCC2 immunoreactivity in dorsal root ganglia (DRG) in a naïve rat, compared to SDH. **g**) Electron micrograph
10 illustrating the selective expression of KCC2 in SDH dendrites (D), but not synaptic boutons (B) (for quantitative details see Fig. 6). Arrows point to synapses. Scale bar is 0.2 μm .

15 **Figure 5:** Computer simulations of *in vivo* synaptic conditions confirmed that sensitization of Lamina I neurons occurred as a function of the shift in the E_{anion} . **a**) Left - Computer simulations using a model neuron (see Examples) demonstrate how PNI-induced changes to GlyR- and GABA_AR-mediated PSCs
20 [PNI(GlyR+GABA_AR)] affect the output firing frequency of LI neurons as a function of GluR-mediated PSC frequency. Also shown is the result in LI neurons after PNI if only considering the effect of GlyR- mediated [PNI(GlyR-only)] or GABA_AR-mediated [PNI(GABA_AR-only)] synaptic events. Right -
25 Same data as shown in the left panel, but expressed in terms of firing frequency ratio, which was calculated as the quotient of a specific data set divided by the No Inhibition data set (i.e., a firing frequency ratio of one is equivalent to no inhibition). While the normally hyperpolarizing GlyR-mediated PSCs (mean $E_{\text{anion}} = -72.8$ mV in naïve rats) had a net
30 inhibitory effect on the output firing frequency (f_{out}), depolarizing GlyR-mediated PSCs (mean $E_{\text{anion}} = -49.0$ mV in PNI rats), enhanced f_{out} beyond that predicted to result with no

inhibition, demonstrating a net excitatory effect. This excitatory effect was more prevalent when the GABA_AR component was incorporated due to the increased charge carried by GABA_AR-mediated PSCs. **b)** Left - Effect of different values of E_{anion} (over the range observed in our study) on the firing frequency of a LI neuron after PNI. Right - Same data as left panel expressed in terms of firing frequency ratio (as above).

Figure 6: KCC2 exporter expression is restricted to dorsal horn neurons, not sensory fibres. Although the KCC2 levels are below detection by immunoblotting from DRG (Fig. 4f), we verified whether KCC2 could be preferentially shuttled away from cell bodies to central terminals of primary afferents. **a)** Electron micrograph illustrating the presence of KCC2 on dendrites (D) in lamina I of the dorsal horn. Membrane-delimited immunogold staining on the soma (S) of a lamina I neuron is also shown (arrowheads). In contrast, no KCC2 immunostaining was observed in any of the randomly selected synaptic profiles examined ($n = 171$). **b)** KCC2 immunoreactivity was also absent from central boutons ($n = 42$ randomly selected central boutons) of synaptic glomeruli in laminae I and II (type I: C_I; left; type II: C_{II}; right; arrows indicate excitatory synapses, D: dendrite) that unequivocally correspond to central terminals of primary afferents (A- and C- fibres [34,35]). Scale bars: a: 2 μm ; b; 0.5 μm (left), 0.2 μm (right).

Figure 7: Effect of various treatments on anion (bicarbonate and chloride) reversal potential (E_{anion}) recorded from lamina I neurons of naïve and PNI rats.

Figure 8: Intrathecal administration of the receptor tyrosine kinase inhibitor K-252a (6 nM) resulted in an increase in the threshold for tactile nociceptive withdrawal.

5 **Figure 9:** DNA (SEQ ID NO: 1) and polypeptide (SEQ ID NO: 2) sequences of human KCC2.

Figure 10: DNA (SEQ ID NO: 3) and polypeptide (SEQ ID NO: 4) sequences of mouse KCC2.

10

Figure 11: DNA (SEQ ID NO: 5) and polypeptide (SEQ ID NO: 6) sequences of rat KCC2.

Figure 12: Comparison of the anion (chloride and bicarbonate) reversal potential (E_{anion}) measured from lamina I neurons in slices, taken from naïve rats, perfused with BDNF, NGF or regular artificial cerebrospinal solution (ACSF; "control" in Figure). PNI - peripheral nerve injury.

15 **Figure 13:** Comparison of E_{anion} measured in slices containing lamina I neurons taken from PNI rats treated, by bath application, with an antibody directed against TrkB (P/TrkB IgG), H-89 (P/H89), K-252a (P/K252a) and KN-93 (P/KN93). PNI - peripheral nerve injury.

20

Figure 14: Comparison between the nociceptive threshold for tactile stimulation of rats treated with an adenovirus transducing BDNF (■) and rats treated with an adenovirus transducing the green fluorescent protein (○).

25

Figure 15: Comparison between the nociceptive threshold for tactile stimulation of rats treated with human recombinant

30

16

NGF (10 µg/day x 6 days) (■) and rats treated with saline vehicle(O).

Figure 16: Comparison between the nociceptive threshold for tactile stimulation of rats treated with the neutralizing anti-TrkB antibody (anti-TrkB-IgG 12 µg/2 hrs x 3) (■) and rats treated with vehicle only (O).

Figure 17: Comparison between the nociceptive threshold for mechanical stimulation of rats treated with the PKA inhibitor H-89 (380 nmol) (■) and rats treated with vehicle only (O).

DETAILED DESCRIPTION OF THE INVENTION

Described herein is a novel mechanism of disinhibition following peripheral nerve injury. It involves a transsynaptic disruption of anion homeostasis in neurons of lamina I of the superficial dorsal horn (SDH), one of the main spinal nociceptive output pathways (7). The resulting shift in the transmembrane anion gradient is shown herein to cause normally inhibitory anionic synaptic currents to be excitatory, substantially driving up the net excitability of lamina I neurons. As shown herein, peripheral nerve injury is sensed by transmission of a signal transynaptically resulting in an increase in intracellular chloride levels in central nervous system (CNS) neurons. Further, the studies described herein demonstrate that decreasing CNS neuronal chloride levels can reverse this phenomenon, as shown via local blockade or knock-down of the spinal KCC2 exporter in intact rats which markedly reduced nociceptive threshold, confirming that the reported disruption of anion homeostasis in lamina I neurons was sufficient to cause neuropathic pain.

Therefore, the studies described herein have investigated the mechanism of pain sensation via the study of downstream events following peripheral nerve injury. As such, it is shown herein that such events are transmitted transsynaptically (e.g. by a peripheral nervous system (PNS) cell or a sensory fiber) to central nervous system (CNS) neurons, in an embodiment, to spinal cord neurons. Further studies herein demonstrate that transmission of the nociceptive signal and sensation of pain is ultimately effected by a modulation of intracellular chloride level (e.g. modulated by a chloride transporter such as the potassium-chloride cotransporter KCC2) in a CNS tissue. KCC2 (see (37) for a review) is a potassium-chloride cotransporter which has been identified in rat, mouse and human (for human KCC2 see for example US Patent application Serial No. 20030027983 of Mount et al.; published February 6, 2003). Studies of homozygous and heterozygous disruptions of the KCC2 gene in mouse revealed a seizure phenotype, suggesting a possible role for KCC2 in epilepsy (38). The precise role of KCC2 in CNS function is not yet completely understood.

Applicants demonstrate herein a correlation between the intracellular chloride level (e.g. by virtue of the activity/expression of a chloride transporter such as KCC2) in a CNS cell or tissue, and the sensation of pain. As shown in the examples below, peripheral nerve injury (PNI) results in the hyperexcitation or sensitization of CNS neurons, e.g. of the spinal cord, e.g. lamina I (LI) neurons of the superficial dorsal horn (SDH). Such hyperexcitability occurs transsynaptically (i.e. downstream from the injured peripheral neuron), a phenomenon which has not been described prior to applicants' studies herein. Such hyperexcitability results in a reduction of the nociceptive threshold.

As shown herein, the hyperexcitability noted above correlates with an increase in intracellular chloride levels (e.g. modulation [e.g. decrease] in chloride transporter [such as KCC2] activity and/or expression) in the SDH. The role of KCC2 in this regard was confirmed via administration of the KCC2 blocker DIOA or a KCC2 antisense oligonucleotide to spinal tissue, both resulting in a rapid decrease in the threshold for pain sensitivity. Therefore, a reduction in KCC2 activity and/or expression, if it results in increased CNS neuronal chloride levels, may result in a decrease in the threshold for pain sensitivity, and, conversely, an increase or induction of KCC2 activity and/or expression, if it results in a decrease in CNS neuronal chloride, may result in an increase in the threshold for pain sensitivity thus providing for prevention and treatment of pain. On the other hand, it has been reported that under certain pathophysiological conditions, e.g. where $[K^+]_o$ is elevated, KCC2 may accumulate Cl^- in neurons, thereby enhancing neuronal excitability (42). Under such conditions, it is envisioned that KCC2 would have the opposite effect on CNS neuronal chloride, and thus result in an increase in CNS neuronal chloride and in turn decreased nociceptive threshold and increased pain sensation. As such, modulation of the activity and/or expression of KCC2 may, depending on the directionality of the flux of chloride ion, contribute to or alleviate a pain sensation.

Therefore, in a first aspect, the invention relates to methods and materials for the treatment of pain, based on the modulation of CNS intracellular chloride level and further the modulation of the activity and/or expression of a chloride transporter, e.g. the KCC2 potassium-chloride cotransporter. As used herein, a "chloride transporter" is defined as a polypeptide/protein or complex thereof

associated with the cell membrane that is able to effect the passage of chloride anions across the cell membrane.

"Export(er)" refers to a net passage from the inside to the outside of the cell, and "import(er)" refers to a net passage
5 from the outside to the inside of the cell.

Therefore, in an embodiment, the present invention relates to methods for treating pain by decreasing the intracellular chloride level in a cell, e.g. a CNS neural cell. In a further embodiment, modulators of a chloride
10 transporter (e.g. KCC2) can be used to decrease intracellular chloride levels. In an embodiment, the invention relates to the application, systemic or local, of compounds or drugs that decrease the intracellular level of chloride in a CNS neural cell as a means to attenuate pain. In order achieve
15 this result, the above-mentioned compounds or drugs may modulate the function or expression of the chloride transporter (e.g. KCC2 cotransporter) in CNS neurons. In yet a further embodiment, the compounds or drugs may increase the expression or activity of the chloride transporter or KCC2.

20 In an embodiment, the CNS neural cell in which the intracellular chloride levels are being modulated can be located in the superficial dorsal horn or the spinal cord. In addition, the cell may also be transsynaptic to a peripheral nerve cell or sensory fiber from which a signal
25 for pain originates.

In an embodiment, the invention also relates to the treatment of acute and chronic pain, more specifically to the treatment of neuropathic pain. "Neuropathic pain", as used herein, refers to chronic pain associated with nerve injury
30 (e.g. following crush, transection or compression of nerves or following nerve degeneration resulting from disease). In an embodiment, neuropathic pain is associated with a nerve or tract injury. In a further embodiment, the neuropathic pain

is associated with visceral and/or somatic pain. The invention further relates to decreasing CNS neuronal chloride levels (e.g. via modulation of chloride transporter [such as KCC2] activity and/or expression) to reduce nociception.

5 "Nociception" as used herein refers to the sensory component of pain. Pain may be the result of various stimuli, including but not limited to pressure, injury, thermal stimuli or chemical (e.g. ionic) stimuli. In embodiments, the pain may be associated with many conditions such as
10 chronic inflammatory pain, pain associated with arthritis, fibromyalgia, back pain, cancer-associated pain, pain associated with digestive disease, pain associated with Crohn's disease, pain associated with autoimmune disease, pain associated with endocrine disease, pain associated with
15 diabetic neuropathy, phantom limb pain, spontaneous pain, chronic post-surgical pain, chronic temporomandibular pain, causalgia, post-herpetic neuralgia, AIDS-related pain, complex regional pain syndromes type I and II, trigeminal neuralgia, chronic back pain, pain associated with spinal
20 cord injury and/or recurrent acute pain. The invention also relates to methods of diagnosis and prognostication to assess pain associated with CNS dysfunction. In an embodiment, such diagnosis/prognostication may be performed prior to the method of treatment described herein, or during a treatment
25 regimen, to further characterize the nature of the pain or its progression, and thus provide information which may be used e.g. to select a course of treatment for such pain in accordance with the results obtained from such
diagnosis/prognostication. As used herein, "pain associated
30 with CNS dysfunction" relates to a pain sensation that is caused by an alteration in ion (e.g. anion) homeostasis in a CNS tissue. In an embodiment, the anion is a chloride ion. In a further embodiment, the alteration is an increase in an

intracellular chloride level in a CNS cell. In yet another embodiment, the activity or expression of a chloride transporter may be modulated (e.g. KCC2 activity or expression may be modulated [e.g. decreased]) when a subject experiences pain associated with a CNS dysfunction.

"KCC2" as used herein refers to a particular type of potassium-chloride cotransporter expressed in neurons. In embodiments, KCC2 comprises the sequence of the polypeptide of SEQ ID NOs: 2 (human KCC2; see also Figure 9), 4 (mouse KCC2; see also Figure 10) or 6 (rat KCC2; see also Figure 11), fragments thereof or sequences substantially identical thereto. In further embodiments, KCC2 is encoded by the nucleic acid sequences capable of encoding the polypeptides of SEQ ID NO: 2, 4 or 6, or fragments thereof or sequences substantially identical thereto or related by hybridization criteria (see below). In further embodiments, such nucleic acid sequences comprise of SEQ ID NO: 1 (human KCC2 DNA; see also Figure 9), 3 (mouse KCC2 DNA; see also Figure 10) or 5 (rat KCC2 DNA; see also Figure 11), fragments thereof or sequences substantially identical thereto or related by hybridization criteria (see below).

"Chloride transport(er) activity" as used herein refers to the transport of chloride, across the cell membrane. Such transport activity may be measured by direct or indirect means using various methods known in the art, examples of which are described herein. "KCC2 activity" as used herein refers to any detectable phenotype associated with KCC2. In an embodiment, KCC2 activity includes, but is not limited to potassium transport, chloride transport, which may, for example, be determined by assessing levels (either directly or indirectly) of potassium and/or chloride inside and/or outside the cell using, for example, reversal potential measurements with patch clamping methods,

chloride/potassium sensitive dyes (see for example Haugland, R.P., *Handbook of Fluorescent Probes and Research Products*, ninth ed., 2002, Molecular Probes, Inc., Eugene, OR, USA) electrodes, etc. In addition, KCC2 activity may also affect
5 the neural cell's anion reversal potential (E_{anion}). The anion reversal potential may be determined, for example, by using gramicidin-perforated patch clamp recording.

"Chloride transporter expression" (e.g. KCC2 expression) relates both to production of a chloride
10 transporter transcript (e.g. a KCC2 transcript) or a chloride transporter polypeptide or protein (e.g. a KCC2 polypeptide or protein). Chloride transporter expression (e.g. KCC2 expression) may therefore, in embodiments, be determined by assessing protein levels directly (e.g., by
15 immunocytochemistry and/or western analysis) or a level of a chloride transporter-encoding nucleic acid (e.g. chloride transporter-encoding nucleic acid such as chloride transporter mRNA levels) that may be determined by using, for example, methods such as reverse-transcriptase polymerase
20 chain reaction [RT-PCR] methods, micro-array-based methods or by Northern analysis).

Compounds capable of decreasing intracellular chloride level in a CNS neural cell may, for example, modulate chloride transporter activity and expression (e.g.
25 KCC2 activity and expression). In an embodiment, the chloride transporter activity or expression (e.g. KCC2 activity or expression) may be increased. In an embodiment, these compounds can be administered in a way such that they contact a CNS tissue or a CNS cell. The compounds that can
30 be used include, but are not limited to, those which directly or indirectly modify the activity of the protein and those which modulate the production and/or stability of the protein (e.g. at the level of transcription, translation, maturation,

post-translational modification, phosphorylation and degradation).

One class of such compounds are those that act via modulation of phosphorylation of one or more sites on KCC2.

- 5 Upon cloning KCC2 (20), it has been reported that KCC2 does not contain consensus phosphorylation sites for PKA, yet does contain five for PKC (Thr³⁴, Ser⁷²⁸, Thr⁷⁸⁷, Ser⁹⁴⁰ & Ser¹⁰³⁴). One consensus site was identified for tyrosine protein phosphorylation (Tyr¹⁰⁸¹) in the carboxyl-terminal. This
- 10 tyrosine kinase consensus phosphorylation site is not present in the KCC1 or KCC4 isoforms, yet it is conserved in the KCC3 protein (21). As such, compounds capable of upregulating or increasing KCC2 activity include, but are not limited to, protein kinases inhibitors (e.g. N-ethylmaleimide (23-25),
- 15 staurosporine (29), and receptor tyrosine kinase inhibitors such as K-252a); antibodies or antibody fragments generated against certain kinases or kinase phosphorylation sites on KCC2, or compounds which interfere more directly (e.g. oligopeptides capable of competing with phosphorylation sites
- 20 on KCC2) or less directly (e.g. compounds which modulate kinase activity and/or expression) with KCC2 phosphorylation. In an embodiment, such a compound may act at the level of phosphorylation-mediated signaling pathways and ultimately affect KCC2 phosphorylation. In another embodiment, TrkB may
- 25 be modulated to affect KCC2 phosphorylation and ultimately modulate KCC2 activity. Thus, In an embodiment, compounds that inhibit TrkB activity may, for example, be used in this regard. Such compounds may include, but are not limited to, K-252a (commercially available from Calbiochem) or a
- 30 neutralizing antibody against TrkB (anti-TrkB antibody [e.g. IgG]) (commercially available from BD Transduction Laboratories). In yet another embodiment, modulation, e.g. inhibition, of cyclic AMP-dependant kinase or PKA may be

useful in modulating KCC2 phosphorylation and ultimately be used in the treatment or prevention of pain. For example, the PKA inhibitor H-89 (commercially available from EMD Biosciences) may be used in this regard. In a further embodiment, modulation, e.g. inhibition, of calmodulin-dependant kinase (CAM kinase, e.g. II and IV) may alleviate or prevent pain in a subject by modulating KCC2 activity, e.g. phosphorylation. Compounds capable of inhibiting such a kinase include, but are not limited to, KN-93 (commercially available from EMD Biosciences). In yet another embodiment, modulators, e.g. inhibitors, of other members of the TrkB pathway, e.g. phosphatidylinositol-specific phospholipase C or phosphatidylcholine-specific phospholipase C, e.g. phospholipase C gamma (PLC γ), may be used to decrease intracellular chloride levels in a CNS neural cell. Such compounds include, but are not limited to, tricyclodecan-9-yl-xanthogenate, 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphorylcholine, neomycin sulfate, spermine tetrahydrochloride, 1-[6-((17 β -3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl]-1H-pyrrole-2,5-dione, or 1-[6-((17 β -3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl]-2,5-pyrrolidinedione.

Further, modulation of KCC2 expression may also arise from modulation (e.g. mediated by phosphorylation) of transcription factors which regulate KCC2 expression. In a further aspect, the invention provides a method for treating pain or preventing/decreasing nociception in a subject or animal, comprising modulating, in embodiments reducing or decreasing, intracellular chloride levels in a CNS neuron or tissue. In an embodiment, such decrease in intracellular chloride levels is achieved by modulating, e.g. decreasing, activity or expression of a chloride transporter (e.g. KCC2) in a CNS neuron or tissue of the subject. In a

further embodiment, the subject is a vertebrate. In another embodiment, the subject is a mammal, in a yet further embodiment, a human. In an embodiment, the CNS tissue is spinal cord tissue and the neural cell is a spinal cord
5 neural cell.

Accordingly, the invention therefore provides methods of treating pain comprising administering a compound capable of modulating, in an embodiment, decreasing or reducing intracellular chloride levels in CNS tissue (e.g. a
10 CNS neural cell) in a subject. In an embodiment, the modulation, e.g. increase, in chloride transporter (e.g. KCC2) activity and/or expression effects the decrease in intracellular chloride level in the subject. In an embodiment, the CNS tissue is spinal cord tissue and the
15 neural cell is a spinal cord neural cell.

In an embodiment, KCC2 comprises an amino acid sequence substantially identical to a sequence set forth in SEQ ID NO: 2, 4, 6 or a fragment thereof. In another embodiment, KCC2 may be encoded by a nucleic acid
20 substantially identical to a nucleotide sequence capable of encoding SEQ ID NO: 2, 4, 6 or a fragment thereof, such as a sequence substantially identical to the sequence set forth in SEQ ID NO: 1, 3, 5 or a fragment thereof.

As noted above, a homolog, variant and/or fragment
25 of a KCC2 which retains activity may also be used in the methods of the invention. Homologs include protein sequences which are substantially identical to the amino acid sequence of a KCC2, sharing significant structural and functional homology with a KCC2. Variants include, but are not limited
30 to, proteins or peptides which differ from a KCC2 by any modifications, and/or amino acid substitutions, deletions or additions. Modifications can occur anywhere including the polypeptide backbone, (i.e. the amino acid sequence), the

amino acid side chains and the amino or carboxy termini. Such substitutions, deletions or additions may involve one or more amino acids. Fragments include a fragment or a portion of a KCC2 or a fragment or a portion of a homolog or variant of a KCC2.

With regard to increasing or upregulating expression of KCC2 in a cell, various methods of introducing KCC2-encoding nucleic acids into the cell may be used, examples of which are described below. Methods such as the gene therapy methods discussed below may be used in this regard. Examples of KCC2-encoding nucleic acids include nucleic acids capable of encoding a polypeptide of SEQ ID NO: 2, 4 or 6 (e.g. the nucleic acids of SEQ ID NO: 1, 3 and 5), or nucleic acids substantially identical thereto. The method may also comprise administering to an area or neural tissue, e.g. CNS tissue, a cell comprising such a KCC2-encoding nucleic acid, via for example transplantation or introduction of a neural cell or precursor thereto (e.g. a stem cell) comprising such a KCC2-encoding nucleic acid. Further, the method may entail administering to the subject a compound capable of modulating, e.g. unregulating or increasing, expression of a KCC2. Such a compound may for example be identified and characterized by the screening methods described below. Such a compound may further be provided as a composition comprising the compound and a pharmaceutically acceptable carrier. In an embodiment, the composition is formulated for or adapted for administration to the CNS. Such a compound or composition may be provided in a commercial package together with instructions for its use.

"Homology" and "homologous" refers to sequence similarity between two peptides or two nucleic acid molecules. Homology can be determined by comparing each position in the aligned sequences. A degree of homology

between nucleic acid or between amino acid sequences is a function of the number of identical or matching nucleotides or amino acids at positions shared by the sequences. As the term is used herein, a nucleic acid sequence is "homologous" to another sequence if the two sequences are substantially identical and the functional activity of the sequences is conserved (as used herein, the term "homologous" does not infer evolutionary relatedness). Two nucleic acid sequences are considered substantially identical if, when optimally aligned (with gaps permitted), they share at least about 50% sequence similarity or identity, or if the sequences share defined functional motifs. In alternative embodiments, sequence similarity in optimally aligned substantially identical sequences may be at least 60%, 70%, 75%, 80%, 85%, 90% or 95%. As used herein, a given percentage of homology between sequences denotes the degree of sequence identity in optimally aligned sequences. An "unrelated" or "non-homologous" sequence shares less than 40% identity, though preferably less than about 25 % identity, with any of SEQ ID NO: 1 to 6.

Substantially complementary nucleic acids are nucleic acids in which the "complement" of one molecule is substantially identical to the other molecule. Optimal alignment of sequences for comparisons of identity may be conducted using a variety of algorithms, such as the local homology algorithm of Smith and Waterman, 1981, *Adv. Appl. Math* 2: 482, the homology alignment algorithm of Needleman and Wunsch, 1970, *J. Mol. Biol.* 48:443, the search for similarity method of Pearson and Lipman, 1988, *Proc. Natl. Acad. Sci. USA* 85: 2444, and the computerised implementations of these algorithms (such as GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, Madison, WI, U.S.A.). Sequence identity may also be

determined using the BLAST algorithm, described in Altschul et al., 1990, *J. Mol. Biol.* 215:403-10 (using the published default settings). Software for performing BLAST analysis may be available through the National Center for Biotechnology Information (through the internet at <http://www.ncbi.nlm.nih.gov/>). The BLAST algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold. Initial neighbourhood word hits act as seeds for initiating searches to find longer HSPs. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extension of the word hits in each direction is halted when the following parameters are met: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program may use as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (Henikoff and Henikoff, 1992, *Proc. Natl. Acad. Sci. USA* 89: 10915-10919) alignments (B) of 50, expectation (E) of 10 (or 1 or 0.1 or 0.01 or 0.001 or 0.0001), M=5, N=4, and a comparison of both strands. One measure of the statistical similarity between two sequences using the BLAST algorithm is the smallest sum probability ($P(N)$), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. In alternative embodiments of the invention, nucleotide or amino

acid sequences are considered substantially identical if the smallest sum probability in a comparison of the test sequences is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

An alternative indication that two nucleic acid sequences are substantially complementary is that the two sequences hybridize to each other under moderately stringent, or preferably stringent, conditions. Hybridization to filter-bound sequences under moderately stringent conditions may, for example, be performed in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.2 x SSC/0.1% SDS at 42°C (see Ausubel, et al. (eds), 1989, *Current Protocols in Molecular Biology*, Vol. 1, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p. 2.10.3). Alternatively, hybridization to filter-bound sequences under stringent conditions may, for example, be performed in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1 x SSC/0.1% SDS at 68°C (see Ausubel, et al. (eds), 1989, *supra*). Hybridization conditions may be modified in accordance with known methods depending on the sequence of interest (see Tijssen, 1993, *Laboratory Techniques in Biochemistry and Molecular Biology -- Hybridization with Nucleic Acid Probes*, Part I, Chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe assays", Elsevier, New York). Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point for the specific sequence at a defined ionic strength and pH.

According to a further aspect, the invention also provides a method for decreasing nociception in a subject. In an embodiment, this method comprises modulating, e.g. decreasing, intracellular chloride levels in a cell, e.g. a

CNS cell, in a subject. In a further embodiment, the method also comprises modulating, e.g. increasing, chloride transporter activity or expression, e.g. KCC2 activity or expression. In yet another embodiment, the method also
5 comprises contacting the CNS neural cell with a compound capable of modulating chloride transporter activity. Such compounds include, but are not limited to a TrkB inhibitor (such as K-252a or anti-TrkB antibody), a PKA inhibitor (such as H-89) or a CAM kinase inhibitor (such as KN-93).

10 The invention further provides a composition for the prevention and/or treatment of pain comprising a compound capable of modulating, e.g. decreasing, intracellular chloride levels in admixture with a pharmaceutically acceptable carrier. In an embodiment, such composition may
15 modulate, e.g. increase or upregulate, chloride transporter activity, e.g. KCC2, activity and/or expression. In an embodiment, such a composition is suitable for or adapted for administration to a CNS neural cell or tissue, such as spinal cord tissue or cell. In yet a further embodiment, such a
20 composition may be an inducer of KCC2 expression or activity. As used herein, an "inducer" is a compound that upregulates or enhances directly or indirectly the expression of the KCC2 gene, stability of the KCC2 mRNA, translation of the KCC2 mRNA, maturation of the KCC2 polypeptide, transport, e.g.
25 recycling, of the KCC2 polypeptide to the cell membrane, or transporter activity of the KCC2 polypeptide. In an embodiment, the "inducer" can also down-regulate or inhibit KCC2 inhibitors.

The invention further provides a use of the above-
30 mentioned composition or the above-mentioned compound, capable of modulating, e.g. decreasing, intracellular chloride levels for the treatment or prevention of pain. The invention also provides a use of the above-mentioned

composition or the above-mentioned compound, capable of modulating, e.g. decreasing, intracellular chloride levels for the preparation of a medicament for treatment or prevention of pain. In an embodiment, the compound or composition modulates, e.g. increases or upregulates, chloride transporter (e.g. KCC2) activity and/or expression. In yet another embodiment, the compound or composition may comprise a TrkB inhibitor (such as K-252a or anti-TrkB antibody), a PKA inhibitor (such as H-89) or a CAM kinase inhibitor (such as KN-93). In yet another embodiment, the medicament may be formulated for administration to a CNS tissue, e.g. CNS cell, of a subject. Further, the compound may be, for example, an inducer of KCC2 expression or activity.

The invention further provides commercial packages comprising a compound capable of modulating, e.g. decreasing, intracellular chloride levels or the above-described composition together with instructions for its use in the treatment or prevention of pain. In an embodiment, the compound may modulate, e.g. increase or upregulate, chloride transporter or KCC2 activity and/or expression.

In various embodiments, a compound capable of modulating, e.g. decreasing, intracellular chloride levels in a CNS cell may be used therapeutically in formulations or medicaments to treat pain. The compound may, for example, modulate, e.g. increase or upregulate chloride transporter (e.g. KCC2) activity and/or expression. The invention also provides corresponding methods of medical treatment, in which a therapeutic dose of a compound capable of modulating, in an embodiment decreasing, intracellular chloride levels, is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a compound capable of modulating, in

an embodiment decreasing intracellular chloride levels, and a pharmacologically acceptable excipient or carrier. The therapeutic composition may be soluble in an aqueous solution at a physiologically acceptable pH.

5 In an embodiment, a compound of the invention is administered such that it comes into contact with a CNS tissue or a CNS neuron. As used herein, the "central nervous system" or CNS is the portion of the nervous system comprising the brain and the spinal cord (e.g. in the lumbar
10 region). By contrast, the "peripheral nervous system" or PNS is the portion of the nervous system other than the brain and the spinal cord. In an embodiment, the CNS tissue is the superficial dorsal horn, in a further embodiment, a lamina I neuron. As such, in embodiments a compound of the invention
15 can be administered to treat CNS cells *in vivo* via direct intracranial or intrathecal injection or injection into the cerebrospinal fluid. Alternatively, the compound can be administered systemically (e.g. intravenously, or orally) in a form capable of crossing the blood brain barrier and
20 entering the CNS. "Neural" and "neuronal" are used herein interchangeably and both relate to neurons and the nervous system.

The invention also provides pharmaceutical compositions (medicaments) comprising a compound capable of
25 modulating, in an embodiment decreasing intracellular chloride levels in a CNS cell. In an embodiment, such compositions include the compound, in a therapeutically or prophylactically effective amount sufficient to treat or attenuate pain, and a pharmaceutically acceptable carrier. A
30 "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as reduction of pain. A therapeutically effective amount of a compound

capable of modulating, in an embodiment decreasing, intracellular chloride levels in a CNS cell, may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also one in which any toxic or detrimental effects of the compound are outweighed by the therapeutically beneficial effects. A

"prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as preventing or inhibiting onset of pain or increases in the severity of pain. A prophylactically effective amount can be determined as described above for the therapeutically effective amount. For any particular subject, specific dosage regimens may be adjusted over time according to the individual need and the professional judgement of the person administering or supervising the administration of the compositions.

As used herein "pharmaceutically acceptable carrier" or "excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. In one embodiment, the carrier is suitable for parenteral administration. Alternatively, the carrier can be suitable for intravenous, intraperitoneal, intramuscular, intracranial, intrathecal, sublingual or oral administration. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any

conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.

5 Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration. The carrier can be a solvent or
10 dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance
15 of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable
20 compositions can be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin. Moreover, the compound capable of modulating, in an embodiment increasing or upregulating, KCC2 activity and/or expression, can be
25 administered in a time release formulation, for example in a composition which includes a slow release polymer. The active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants and
30 microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid and polylactic, polyglycolic

copolymers (PLG). Many methods for the preparation of such formulations are patented or generally known to those skilled in the art.

Sterile injectable solutions can be prepared by
5 incorporating the active compound (e.g. a compound capable of modulating, in an embodiment decreasing, intracellular chloride levels in a CNS cell) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered
10 sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable
15 solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. In accordance with an alternative aspect of the invention, a compound
20 capable of modulating, in an embodiment decreasing, intracellular chloride levels in a CNS cell, may be formulated with one or more additional compounds that enhance its solubility.

In accordance with another aspect of the invention,
25 therapeutic compositions of the present invention, comprising a compound capable of modulating, in an embodiment decreasing, intracellular chloride levels in a CNS cell, may be provided in containers or commercial packages which further comprise instructions for their use for the treatment
30 of pain.

Given that a decreased intracellular chloride level in a cell is associated with a modulation, e.g. an increase, in level/activity of chloride transporter (KCC2),

which further correlates with a decrease in pain sensation as described herein, a further aspect of the present invention is the treatment of pain by administering to a subject (e.g. to CNS tissue) a nucleic acid molecule encoding a KCC2, or a variant or fragment thereof which retains KCC2 activity. Suitable methods of administration include gene therapy methods.

A nucleic acid of the invention may be delivered to cells *in vivo* using methods such as direct injection of DNA, receptor-mediated DNA uptake, viral-mediated transfection or non-viral transfection and lipid based transfection, all of which may involve the use of gene therapy vectors. Direct injection has been used to introduce naked DNA into cells *in vivo* (see e.g., Acsadi et al. (1991) Nature 332:815-818; Wolff et al. (1990) Science 247:1465-1468). A delivery apparatus (e.g., a "gene gun") for injecting DNA into cells *in vivo* may be used. Such an apparatus may be commercially available (e.g., from BioRad). Naked DNA may also be introduced into cells by complexing the DNA to a cation, such as polylysine, which is coupled to a ligand for a cell-surface receptor (see for example Wu, G. and Wu, C. H. (1988) J. Biol. Chem. 263:14621; Wilson et al. (1992) J. Biol. Chem. 267:963-967; and U.S. Pat. No. 5,166,320). Binding of the DNA-ligand complex to the receptor may facilitate uptake of the DNA by receptor-mediated endocytosis. A DNA-ligand complex linked to adenovirus capsids which disrupt endosomes, thereby releasing material into the cytoplasm, may be used to avoid degradation of the complex by intracellular lysosomes (see for example Curiel et al. (1991) Proc. Natl. Acad. Sci. USA 88:8850; Cristiano et al. (1993) Proc. Natl. Acad. Sci. USA 90:2122-2126). Defective retroviruses are well characterized for use as gene therapy vectors (for a review see Miller, A. D. (1990) Blood

76:271). Protocols for producing recombinant retroviruses and for infecting cells *in vitro* or *in vivo* with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F. M. et al. (eds.) Greene Publishing Associates, (1989),
5 Sections 9.10-9.14 and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art. Examples of suitable packaging virus lines include .psi.Crip, .psi.Cre, .psi.2 and .psi.Am. Retroviruses have been used to
10 introduce a variety of genes into many different cell types, including epithelial cells, endothelial cells, lymphocytes, myoblasts, hepatocytes, bone marrow cells, *in vitro* and/or *in vivo* (see for example Eglitis, et al. (1985) Science 230:1395-1398; Danos and Mulligan (1988) Proc. Natl. Acad.
15 Sci. USA 85:6460-6464; Wilson et al. (1988) Proc. Natl. Acad. Sci. USA 85:3014-3018; Armentano et al. (1990) Proc. Natl. Acad. Sci. USA 87:6141-6145; Huber et al. (1991) Proc. Natl. Acad. Sci. USA 88:8039-8043; Ferry et al. (1991) Proc. Natl. Acad. Sci. USA 88:8377-8381; Chowdhury et al. (1991) Science
20 254:1802-1805; van Beusechem et al. (1992) Proc. Natl. Acad. Sci. USA 89:7640-7644; Kay et al. (1992) Human Gene Therapy 3:641-647; Dai et al. (1992) Proc. Natl. Acad. Sci. USA 89:10892-10895; Hwu et al. (1993) J. Immunol. 150:4104-4115; U.S. Pat. No. 4,868,116; U.S. Pat. No. 4,980,286; PCT
25 Application WO 89/07136; PCT Application WO 89/02468; PCT Application WO 89/05345; and PCT Application WO 92/07573).

For use as a gene therapy vector, the genome of an adenovirus may be manipulated so that it encodes and expresses a polypeptide compound of the invention, but is
30 inactivated in terms of its ability to replicate in a normal lytic viral life cycle. See for example Berkner et al. (1988) BioTechniques 6:616; Rosenfeld et al. (1991) Science 252:431-434; and Rosenfeld et al. (1992) Cell 68:143-155. Suitable

adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are well known to those skilled in the art. Recombinant adenoviruses are advantageous in that they do not require
5 dividing cells to be effective gene delivery vehicles and can be used to infect a wide variety of cell types, including airway epithelium (Rosenfeld et al. (1992) cited *supra*), endothelial cells (Lemarchand et al. (1992) Proc. Natl. Acad. Sci. USA 89:6482-6486), hepatocytes (Herz and Gerard (1993)
10 Proc. Natl. Acad. Sci. USA 90:2812-2816) and muscle cells (Quantin et al. (1992) Proc. Natl. Acad. Sci. USA 89:2581-2584).

Adeno-associated virus (AAV) may be used as a gene therapy vector for delivery of DNA for gene therapy purposes.
15 AAV is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle (Muzyczka et al. Curr. Topics in Micro. and Immunol. (1992) 158:97-129). AAV may be used to integrate DNA into
20 non-dividing cells (see for example Flotte et al. (1992) Am. J. Respir. Cell. Mol. Biol. 7:349-356; Samulski et al. (1989) J. Virol. 63:3822-3828; and McLaughlin et al. (1989) J. Virol. 62:1963-1973). An AAV vector such as that described in Tratschin et al. (1985) Mol. Cell. Biol. 5:3251-3260 may be
25 used to introduce DNA into cells (see for example Hermonat et al. (1984) Proc. Natl. Acad. Sci. USA 81:6466-6470; Tratschin et al. (1985) Mol. Cell. Biol. 4:2072-2081; Wondisford et al. (1988) Mol. Endocrinol. 2:32-39; Tratschin et al. (1984) J. Virol. 51:611-619; and Flotte et al. (1993) J. Biol. Chem.
30 268:3781-3790). Lentiviral gene therapy vectors may also be adapted for use in the invention.

General methods for gene therapy are known in the art. See for example, U.S. Pat. No. 5,399,346 by Anderson et

al. A biocompatible capsule for delivering genetic material is described in PCT Publication WO 95/05452 by Baetge et al. Methods of gene transfer into hematopoietic cells have also previously been reported (see Clapp, D. W., et al., Blood 78: 1132-1139 (1991); Anderson, Science 288:627-9 (2000); and Cavazzana-Calvo et al., Science 288:669-72 (2000)).

The invention further relates to transplantation methods, to introduce into a subject a cell comprising a nucleic acid capable of encoding a KCC2, or to introduce into a subject a cell which has been treated *in vitro* or *ex vivo* with a compound capable of decreasing intracellular chloride levels (e.g. by culturing the cell in an appropriate medium comprising the compound). In an embodiment, such a cell is a neural cell or a precursor thereof, e.g. a stem cell capable of developing/differentiating into a neural cell (neuron progenitor cell). Methods relating to neural stem cell isolation, proliferation, characterization and/or transplantation are described in for example US patents 5,851,832; 5,968,829; 5,411,883; 5,750,376; 6,040,180; 5,753,506 and 6,001,654. The nucleic acid may be present in a vector as described above, the vector being introduced into the cell *in vitro*, using for example the methods described above. In an embodiment, the cell is autologous, and is obtained from the subject. In embodiments, the cell is allogeneic or xenogeneic.

Given the correlation between intracellular chloride levels in a CNS cell and pain, compounds which are capable of modulating, e.g. decreasing, intracellular chloride levels in a CNS cell can be used for the prevention and treatment of pain. In an embodiment, compounds that modulate, e.g. increase or upregulate, chloride transporter, such as KCC2, activity/expression can be used for decreasing intracellular chloride levels and ultimately prevent or treat

pain. Therefore, the invention further relates to screening methods for the identification and characterization of compounds capable of modulating intracellular chloride levels and/or chloride transporter activity and/or expression.

5 Therefore, the invention further provides a method of determining whether a candidate compound is capable of modulating intracellular chloride levels in a cell, and in turn is useful for the prevention and treatment of pain. In an embodiment, the method comprises contacting a CNS-derived
10 cell with said candidate compound and determining whether the intracellular chloride level has decreased in the presence of the test compound. A decrease in intracellular chloride level is indicative that the test compound may be used for the treatment or the prevention of pain. As used herein, a
15 "CNS-derived cell" is a cell isolated or derived from a CNS tissue, and in embodiments includes both primary neuronal cultures, immortalized neuronal cell lines, as well as accepted *in vitro* neuronal model systems (e.g. cells differentiated into neurons *in vitro*). In an embodiment, the
20 above-mentioned cell possesses a chloride transporter or KCC2 activity. In yet a further embodiment, the cell endogenously expresses a chloride transporter (e.g. KCC2). In a further embodiment the above-mentioned cell has been genetically engineered to express a chloride transporter gene or a KCC2
25 gene. In an embodiment, the cell may be an appropriate host cell comprising an exogenously introduced source of a chloride transporter, such as KCC2. Such a host cell may be prepared by the introduction of nucleic acid sequences encoding a chloride transporter or KCC2 into the host cell
30 and providing conditions for the expression of such nucleic acid. In an embodiment, such a nucleic acid is DNA. Such host cells may be eukaryotic, such as amphibian or mammalian cells. In an embodiment, such host cells are human.

The invention also provides another method for the identification or characterization of compounds useful for the treatment and prevention of pain. In an embodiment, the method comprises contacting a CNS-derived cell with the candidate compound and determining whether chloride transporter activity has been modulated in the presence of the test compound. A modulation, e.g. increase, in chloride transporter activity is indicative that the test compound may be used for the treatment or the prevention of pain. In an embodiment, the chloride transporter is KCC2. KCC2 activity may be determined, for example, by measuring potassium transport, chloride transport, intracellular chloride levels and anion reversal potential.

The above-mentioned methods may be employed either with a single test compound or a plurality or library (e.g. a combinatorial library) of test compounds. In the latter case, synergistic effects provided by combinations of compounds may also be identified and characterized. The above-mentioned compounds may be used for prevention and/or treatment of pain, or may be used as lead compounds for the development and testing of additional compounds having improved specificity, efficacy and/or pharmacological (e.g. pharmacokinetic) properties. In an embodiment the compound may be a prodrug which is altered into its active form at the appropriate site of action, e.g. in CNS tissue (e.g. in the spinal cord). In certain embodiments, one or a plurality of the steps of the screening/testing methods of the invention may be automated.

As noted above, the invention further relates to methods for the identification and characterization of compounds capable of modulating, in an embodiment increasing, chloride transporter, e.g. KCC2, gene expression. Such a method may comprise assaying chloride transporter, e.g. KCC2,

gene expression in the presence versus the absence of a test compound. Such gene expression may be measured by detection of the corresponding RNA or protein, or via the use of a suitable reporter construct comprising a transcriptional regulatory element(s) normally associated with such chloride transporter or KCC2 gene, operably-linked to a reporter gene. A first nucleic acid sequence may "operably-linked" with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably-linked to a coding sequence if the promoter affects the transcription or expression of the coding sequences. Generally, operably-linked DNA sequences are contiguous and, where necessary to join two protein coding regions, in reading frame. However, since, for example, enhancers generally function when separated from the promoters by several kilobases and intronic sequences may be of variable lengths, some polynucleotide elements may be operably-linked but not contiguous. "Transcriptional regulatory element" is a generic term that refers to DNA sequences, such as initiation and termination signals, enhancers, and promoters, splicing signals, polyadenylation signals which induce or control transcription of protein coding sequences with which they are operably-linked. The expression of such a reporter gene may be measured on the transcriptional or translational level, e.g. by the amount of RNA or protein produced. RNA may be detected by for example Northern analysis or by the reverse transcriptase-polymerase chain reaction (RT-PCR) method (see for example Sambrook et al (1989) Molecular Cloning: A Laboratory Manual (second edition), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, USA). Protein levels may be detected either directly using affinity reagents (e.g. an antibody or fragment thereof [for methods,

see for example Harlow, E. and Lane, D (1988) *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY]; a ligand which binds the protein) or by other properties (e.g. fluorescence in the case of green
5 fluorescent protein) or by measurement of the protein's activity, which may entail enzymatic activity to produce a detectable product (e.g. with altered spectroscopic properties) or a detectable phenotype (e.g. alterations in cell growth). Suitable reporter genes include but are not
10 limited to chloramphenicol acetyltransferase, beta-D galactosidase, luciferase, or green fluorescent protein. In an embodiment, a candidate compound may further be assayed to determine if it is capable of modulating a chloride transporter-mediated process (e.g. KCC2-mediated process) or
15 chloride transporter activity (e.g. KCC2 activity). In an embodiment, such chloride transporter-mediated process is ion transport, e.g. potassium or chloride transport, as determined by for example by assessing potassium and/or chloride levels (e.g. intracellularly) or by measuring anion
20 reversal potential (electrophysiologically), membrane potential, for example as described in the examples below.

The invention also relates to the diagnosis and prognostication of pain. In an embodiment, the pain is caused by an alteration in ion, e.g. anion or chloride,
25 homeostasis in the nervous system, e.g. central nervous system, of a subject. Without wishing to being bound to any particular theory, a reduced capacity of potassium and chloride export from neurons in the central nervous system (CNS) may lead to persistent neuronal hyperexcitability and
30 ultimately pain.

The invention thus provides a method for diagnosing or prognosticating pain associated with CNS dysfunction. As used herein, "CNS dysfunction" is an alteration in neuronal

ionic homeostasis in the CNS. In an embodiment, the pain associated with such CNS dysfunction is neuropathic pain. In an embodiment, the method comprises determining an intracellular chloride level in a CNS neural cell and
5 comparing the chloride level to a corresponding control level. In this particular method, an increase in the test level relative to a control level is an indication that the subject is experiencing pain associated with CNS dysfunction. In an embodiment, the method may comprise determining whether
10 CNS chloride transporter activity or expression (e.g. KCC2 activity or expression) is modulated, e.g. upregulated or increased, relative to a control activity or expression. In yet another embodiment, the control chloride level can be selected from an established standard, a corresponding
15 chloride level determined in the subject at an earlier time; a corresponding chloride level determined in said subject when the subject is experiencing less pain (relative to the current sensation of pain noted above) or substantially no pain; or a corresponding chloride level determined in a
20 control subject experiencing less pain (relative to the current sensation of pain in the test subject noted above) or substantially no pain. In an embodiment, a subject or control subject experiencing less pain or substantially no pain presents no evident lesions to his central or peripheral
25 nervous system (e.g. neuropathic pain) or persistent pain. In yet another embodiment, the control activity or expression can be selected amongst an established standard of KCC2 activity or expression; a corresponding level of KCC2 activity or expression determined in the subject at an
30 earlier time; a corresponding level of KCC2 activity or expression determined in the subject when the subject is experiencing less pain (as above) or substantially no pain; or a corresponding level of KCC2 activity or expression

determined in a control subject experiencing less pain (as above) or substantially no pain. In an embodiment, the KCC2 activity may be determined as described above.

For example, intracellular chloride levels may be
5 determined by administering, to a subject, an indicator compound (such as a compound indicative of chloride level) that is capable of contacting a CNS neural cell of that subject. Following the administration of the indicator compound, assessment of the *in vivo* signal associated with
10 such indicator compound may be performed. In an embodiment, an indicator compound, such as a radionuclide (e.g. Thallium-201 (^{201}Tl), ^{99}Tcm -tetrofosmin, ^{99}Tcm -MIBI or $^{99\text{m}}\text{Tc}$ -HMPAO or chloride conjugates thereof) or a compound indicative of KCC2 expression (such as an immunodetection-based reagent (e.g.
15 antibody, single chain antibody or Fab fragment directed against the KCC2 polypeptide)) may be employed. In yet another embodiment, the indicator compound, upon intravenous injection, may cross the blood-brain-barrier and accumulate in neurons of the CNS analogously to potassium, i.e. to
20 reflect potassium levels. In another embodiment, the dose of such radionuclide (e.g. ^{201}Tl) may be about 100 MBq (3mCi). In yet another embodiment, the radionuclide (e.g. ^{201}Tl) may be injected 15-20 minutes prior to SPECT imaging. Following injection of the indicator compound, an imaging technique may
25 be performed to assess the *in vivo* signal associated with the indicator compound. Such imaging techniques include, but are not limited to, single photon emission computed tomography (SPECT), positron emission tomography and/or magnetic resonance imaging. The imaging technique may enable the
30 assessment of the *in vivo* signal of the indicator compound, such as the neural potassium gradient. Images can be obtained, for example, using gamma camera equipped with a high-resolution (5-7 mm) collimator and interfaced with a

dedicated computer system. In an embodiment, serial projection images can be acquired over a 180° arc. In yet another embodiment, the radionuclide (e.g. ^{201}Tl) retention by neurons can be expressed as a retention index (RI). The
5 "retention index" as described herein is defined as:

$$\frac{\text{Delayed retention-early retention}}{\text{Early retention}} \times 100$$

10 In an embodiment, the "retention" of the retention index is herein defined as the amount of indicator compound (e.g. tracer or radionuclide) retained by a specific tissue at a certain time. In a further embodiment, the early retention is assessed before the delayed retention. In a
15 further embodiment, the retention index is measured in a CNS tissue.

In an embodiment, the methods of diagnosis/prognostication noted above may be performed in conjunction with the therapeutic/prophylactic methods noted
20 above, for preventing or treating pain associated with CNS dysfunction in a subject. Such a method thus comprises the diagnosis or prognostication of pain associated with CNS dysfunction and, in accordance with the diagnosis/prognosis, decreasing intracellular chloride levels in a CNS cell of the
25 subject thereby to prevent or treat pain.

Although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such
30 modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. Numeric ranges are inclusive of the numbers defining the range. In the claims,

the word "comprising" is used as an open-ended term, substantially equivalent to the phrase "including, but not limited to". The following examples are illustrative of various aspects of the invention, and do not limit the broad aspects of the invention as disclosed herein.

Throughout this application, various references are referred to describe more fully the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure.

EXAMPLES

Example 1: Methods

Nerve Injury. Briefly, peripheral nerve injury was induced by surgically implanting a polyethylene cuff (~2 mm long, 0.7 mm inner diameter) around the sciatic nerve of adult, male, Spague-Dawley rats as previously described (16). A group of rats also received sham surgery. Only animals that showed a gradual decrease in mechanical threshold (over 14-17 days) down to 2.0 g or less were used for further experiments.

Behavioural Testing. Thermal and mechanical threshold for nociceptive withdrawal reflexes were tested as previously described (17).

Slice preparation. Parasagittal slices (300-350 μ m) of spinal cord were prepared from adult (>50 days old) male rats as previously described (9). Slices were continually superfused (2-3 ml \cdot min⁻¹) with artificial cerebrospinal fluid (ACSF) containing (in mM): 126 NaCl, 26 NaHCO₃, 10 glucose, 2.5 KCl, 2 CaCl₂, 2 MgCl₂, 1.25 NaH₂PO₄, 0.001 TTX (bubbled with 95% O₂

- 5% CO₂, pH~7.4); when measuring GABA_A/GlyR- mediated currents, 10 μ M 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and 40 μ M D2-amino-5-phosphonovaleric acid (APV) were added to block fast glutamatergic transmission.

5

Recordings. For perforated patch recordings, the pipette tip was filled with a solution containing (in mM): 130 cesium gluconate (CsGluc), 5 CsCl, 2 MgCl₂, 11 BAPTA Calcium chelator (buffer), 1 CaCl₂, 4 ATP, 0.4 GTP, 10 HEPES (pH~7.4). The
10 pipette was back-filled with this same solution supplemented with 25 μ g/ml gramicidin D (gramicidin stock was at 10 mg/ml in DMSO). Recordings in this mode were selected when access resistance was stable between 25-45 M Ω . For whole-cell voltage-clamp recordings, pipettes were filled with the above
15 solution without gramicidin D. Similarly, whole-cell current-clamp recordings were performed using pipettes filled with the same intracellular solution as with voltage-clamp, except potassium methyl sulfate (KMeSO₄) was used to replace CsGluc. To clamp E_{anion} at 0 mV, CsGluc was replaced with 110
20 mM CsCl in the intracellular solution. All whole-cell recordings at E_{anion} = 0 mV were made at V_m = -60 mV in the presence of GluR-blockers. GABA was applied locally for 30-250 ms by pressure ejection through a patch micropipette. Data acquisition and analysis of PSCs was performed as
25 previously described (9). All measurements are given as means \pm SEM, except where indicated. Statistical significance was tested using Student's t-tests for comparison of mean values, chi-square tests for contingency tables, and mixed design ANOVAs (post-hoc - Tukey's HSD) for
30 repeated measures.

Calcium Imaging. Slices were prepared from PNI and naïve rats as detailed above for electrophysiological analysis.

After 15 min incubation in ACSF, slices were loaded with 10 μ M Fura-2-AM (a fluorometric calcium indicator, AM = acetoxymethyl) in HEPES-buffered saline (+10% DMSO) for 1 hour. Slices were washed for ~15 min with ACSF before being mounted in the recording chamber, where they continued to be superfused by ACSF (2-3 ml·min⁻¹). [Ca²⁺]_i was fluorometrically measured using a Zeiss Axioscope equipped with epifluorescence optics. Images were acquired using a TILL Photonics monochromator coupled to a CCD camera and regions of interest (for ratioing) were drawn on clearly distinct neuronal cell bodies.

Immunoblotting. Horizontal slices (150 μ m) of the SDH were made from the lumbar enlargement of both PNI and naïve adult rats. Tissue extracts were prepared by homogenizing the slices with a Teflon pestle in a buffer containing 0.32 M sucrose, 0.5 mM Tris-HCl, pH 7.5, 2 mM ethylenediaminetetracetic acid (EDTA), 2.5 mM β -mercaptoethanol, and a cocktail of protease inhibitors (Complete™, Roche Diagnostics). Supernatants from 3,000 g (20 min) and 10,000 g (30 min) centrifugations were collected. Equal amounts of proteins (20 μ g/lane) diluted in sample buffer were preheated at 37°C for 30 min, resolved by SDS-PAGE, and electroblotted onto nitrocellulose membranes. Membranes were blocked 30 min in 5% nonfat dry milk in TBST buffer (150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 0.05% Tween-20) and incubated overnight at 4°C with a rabbit anti-KCC2 antibody (1:1000, Upstate Biotechnology). After several washes in TBST, membranes were incubated for 30 min at room temperature with peroxidase-labeled goat anti-rabbit antibody (1:2000). Chemiluminescent bands were detected using Super Signal Femto™ (Pierce Biotechnology). Digital images were

50

captured with the VersaDoc™ imaging system (BioRad) and data were analysed with Quantity One™ software (BioRad).

Oligodeoxynucleotides. KCC2 antisense and scrambled

5 oligodeoxynucleotides, phosphorothioated at all positions were designed as previously described (18): antisense, 5'-TCTCCTTGGGATTGCCGTCA-3' (SEQ ID NO: 7; +59 relative to the ATG starting signal); scrambled, 5'-TCTTCTTGAGACTGCAGTCA-3' (SEQ ID NO: 8).

10

Intrathecal Injections. At least three days prior to drug administration, rats were anaesthetized with sodium pentobarbital (65 mg kg⁻¹) and a lumbar spinal catheter was inserted into the intrathecal space, as previously described

15 (11). Briefly, a small opening was created at the cisterna magna, and a catheter was inserted into the subarachnoid space and caudally directed ~8 cm to the lumbar enlargement of the spinal cord. Upon recovery from surgery, lower body paralysis was induced via i.t. (intrathecal) lidocaine (2%,

20 30 µl) injection to confirm proper catheter localization.

Only animals exhibiting appropriate, transient paralysis to lidocaine, as well a lack of motor deficits were used for behavioural testing. Following drug/vehicle administration, animals were sacrificed and their vertebral column dissected

25 to visually confirm correct placement of the catheter. Drugs included DIOA (10-30 µg, in 0.9% NaCl, 10 % DMSO) and

oligodeoxynucleotides (single doses of 2 µg at 0h, 12h & 24h; 0.9% NaCl). Behavioural testing was performed as above;

normal (~15 g) mechanical threshold for withdrawal responses

30 was confirmed in naïve rats prior to receiving drug or

vehicle. At the doses used, none of the compounds produced motor disturbances or sedation as assessed by grasping,

righting and placing reflexes and behavioral observations (17).

Computer simulations. (see Figure 5) All simulations were performed with NEURON 4.3.1 using a compartment model of a generic spinal lamina I fusiform neuron with morphology and passive membrane properties based on (19). Dendrites bifurcated up to fourth order and an axon similar to that described in (19) were attached to the soma. Fast Na^+ and delayed rectifier K^+ currents based on (30) were inserted at 0.1 and 0.01 S/cm^2 , respectively, in the soma and axon initial segment and nodes; voltage threshold for spiking was -49 mV. Two sets of inhibitory synapses were distributed randomly in the perisomatic region and four sets of excitatory synapses were more distal; each set was driven by an independent Poisson process at rates extrapolated from (31) and (32).

Electron microscopy. (see Figure 6) Tissue was prepared for ultrastructural analysis as previously described (35). Briefly, rats were perfused through the aortic arch with 0.9% NaCl followed by a fixative solution containing 4% paraformaldehyde (Sigma-Aldrich, Germany). After perfusion, spinal cords were removed, coronal blocks were dissected, then 60 μm thin sections were cut cryoprotected and freeze-thawed over liquid nitrogen and rinsed several times in phosphate buffer before incubation in the primary antiserum. After incubation in blocking solution containing 2% bovine serum albumin (BSA), sections were incubated in rabbit anti-KCC2 (1:500, Upstate Biotechnology, USA) for 48 hours at 4°C. After extensive washing, sections were incubated with 1 nm gold-conjugated anti-rabbit secondary antibody (1:250, Aurion) for 12 hours at 4°C followed by silver intensification (SE-EM, Aurion). Sections were treated with

0.5% OsO₄ (20 min), dehydrated in graded ethanol, then in propylene oxide and embedded in Durcupan ACM (Fluka). After ultra-sectioning (Ultracut™ UCT, Leica, Germany), specimens were examined using an electron microscope (Philips Tecnai 12, equipped with MegaView™ CCD camera). Non-consecutive (spacing > 3 μm) ultrathin sections were analyzed in the electron microscope. Boutons with synaptic profiles were randomly selected and analyzed in laminae I & II and white matter for the expression of the KCC2 protein (36).

Intrathecal administration of K-252a. (see Figure 8) K-252a was prepared in 25 ul of 0.9% NaCl solution containing 10% DMSO. Intrathecal catheterization was performed by creating a small opening at the cisterna magna, and inserting P10 polyethylene tubing into the subarachnoid space -- caudally directed ~8 cm to the lumbar enlargement of the spinal cord.

Example 2: Results

Peripheral neuropathy was induced in rats by chronically constricting the sciatic nerve (Fig. 1a). To test whether the hyperexcitability (sensitization) of SDH neurons that follows peripheral nerve injury (PNI) is associated with modification of the anion gradient (V_{anion}), anion reversal potential (E_{anion}) was measured using gramicidin-perforated patch clamp recording. This technique avoids disrupting the intracellular anion concentration (8). Responses to exogenous GABA application showed that the anion reversal potential (E_{anion}) of lamina I (LI) neurons taken from PNI rats was -49.0 ± 2.3 mV (range: -40 to -62.2 mV, $n = 9$) compared to -72.6 ± 3.5 mV (range: -63.0 to -79.9 mV, $n = 5$; $p < 0.005$) in LI neurons from naïve rats (Fig. 1b-d). Resting membrane potential was not significantly different between

PNI (-62 ± 4 mV, $n = 7$) and naïve rat LI neurons (-61 ± 2 mV, $n = 16$; $p > 0.1$). Spontaneous and evoked postsynaptic currents (PSCs), recorded from PNI rat LI neurons in the presence of fast glutamate receptor (GluR) blockers were also inward (depolarizing from rest), their mean reversal potential increasing by 16.1 mV relative to that in lamina I neurons from naïve rats ($n = 6$, PNI; $n = 4$, naïve).

It was then investigated whether other properties of synaptic transmission were altered in the SDH after PNI. Inhibitory miniature PSCs (mPSCs) in LI neurons from naïve rats are mediated by glycine receptors (GlyRs) alone despite GABA and glycine corelease from local inhibitory interneurons (9; Fig.2a). While GluR-mediated mPSCs were unaffected by PNI (Fig.2b), in all cells tested from PNI rats, a population of outward mPSCs at 0 mV persisted in the presence of the GlyR antagonist strychnine (up to 1 μ M; $n = 4$). These remaining mPSCs were mediated by GABA_ARs, as they were blocked by bicuculline (10 μ M) and displayed prolonged decay kinetics compared to the GlyR-mediated component ($\tau_{D(GABA_A R)} = 34.0 \pm 2.9$ ms, $n = 5$, vs. $\tau_{D(GlyR)} = 11.3 \pm 1.3$ ms, $n = 6$; $p < 0.01$; Fig. 2C).

Kinetic analysis further revealed that the decay phase of $36.9 \pm 2.3\%$ of mPSCs followed a dual exponential function ($\tau_{D1} = 7.5 \pm 2.0$ ms and $\tau_{D2} = 51.3 \pm 7.9$ ms; $n = 6$; Fig.2c). These events possessed both a GABA_AR and a GlyR-mediated component, as either strychnine or bicuculline could lead to the abolition of their respective components ($n = 4$). Therefore, in parallel with the collapsed V_{anion} , PNI caused reorganization at LI synapses thereby unmasking GABA_AR-only and mixed GABA_AR/GlyR-mediated mPSCs, in addition to those mediated by GlyRs alone. This synaptic organization is similar to that observed in immature LI-II neurons (9). The net effect of this synaptic switch is that it yielded a

population of quantal synaptic events with significantly longer decay kinetics.

To examine the function of the PNI-induced GABA_AR-mediated contribution to mPSCs, we analysed both the peak
5 conductance and the frequency of mPSCs. This was performed using CsCl-filled pipettes to clamp the E_{anion} at 0 mV in both LI neurons taken from PNI and naïve rats to prevent biased detection of mPSCs resulting from changes in driving force. Peak conductance of GlyR-only mPSCs recorded in LI neurons
10 taken from PNI rats was significantly smaller (~2-fold) than that recorded from naïve rat LI neurons (Fig. 2d). The addition of GABA_AR-mediated events in the PNI condition, however, partially compensated the decrease in GlyR-only conductance. The peak conductance of GluR-mediated quantal
15 events was not significantly different between LI neurons taken from naïve and PNI rats (Fig. 2d).

Factoring together the changes in peak conductance, kinetics, and driving force, the net charge carried by GlyR-only mPSCs at resting membrane potential in LI neurons taken
20 from PNI rats was nearly 3-fold smaller than that in naïve rats (Fig. 2e). With the contribution of GABA_ARs, however, the net charge carried by mPSCs in PNI rats rose back to that mediated by GlyRs in naïve rats. This result suggests that, although equivalent in magnitude, hyperpolarizing charge in
25 naïve LI neurons was carried by GlyR-mediated mPSCs alone, whereas depolarizing charge was transferred predominantly via GABA_ARs in PNI rat LI neurons, due to the prolonged decay kinetics of GABA_AR-mediated mPSCs.

The frequency of GlyR-only mPSCs recorded in LI
30 neurons from PNI rats was observed to be significantly less (0.13 ± 0.04 Hz, $n = 5$) than that for GlyR-only mPSCs in naïve rat LI neurons (0.18 ± 0.04 Hz, $n = 6$; $p < 0.05$; Fig. 2f). As with peak conductance, however, the addition of the

GABA_AR-mediated mPSCs compensated the PNI-induced decrease in frequency (0.22 ± 0.10 Hz, $n = 4$, for all GABA_AR and/or GlyR-mediated events combined; $p > 0.5$). In contrast, there was no significant change in the frequency of GluR-mediated events
5 in LI neurons isolated from PNI rats (1.51 ± 0.90 Hz, $n = 9$) compared to LI neurons from naïve rats (0.82 ± 0.40 Hz, $n = 5$; $p > 0.3$; Fig.2f).

If depolarizing GABA_AR/GlyR-mediated postsynaptic currents exert a net excitatory influence in PNI LI neurons,
10 they should directly evoke action potentials, and consequently lead to Ca^{2+} influx. To test this hypothesis, we employed Ca^{2+} -imaging using fura-2-am loaded LI neurons in slice to obtain a large data set. Administration of exogenous GABA to neuronal somata caused a significant increase in the
15 concentration of intracellular Ca^{2+} ($[Ca^{2+}]_i$) in 19% of LI neurons ($n = 53$; Fig. 3a,c) lying ipsilateral to the site of PNI. This represents a seven-fold increase compared to LI neurons found in naïve and/or contralateral dorsal horn, where an increase in $[Ca^{2+}]_i$ to GABA application was observed
20 in only 1 of 37 neurons tested (Fig. 3b,c). These responses were blocked by bicuculline ($10 \mu M$; $n = 5$) and by the voltage sensitive sodium channel blocker tetrodotoxin (TTX; $1 \mu M$; $n = 31$). We then further confirmed electrophysiologically that applied GABA and synaptically elicited anionic postsynaptic
25 potentials can directly evoke action potentials (Fig. 3d,e). These results indicate that postsynaptic anion fluxes can cause net excitation in lamina I neurons in PNI rats. We then compared KCC2 protein levels by immunoblotting on horizontal slices of SDH. The KCC2 expression level in the
30 lumbar SDH ipsilateral to the PNI was significantly reduced (>2 -fold) relative to the side contralateral to the injury (Fig. 3f). In naïve rats, there was no significant difference between the two sides ($n = 3$).

If a decrease in the expression of the KCC2 exporter leads to an increase in neuronal $[Cl^-]_i$ and, in turn, GABA_AR-mediated depolarization, a pharmacological blockade of the KCC2 exporter in LI neurons from naïve rats should have the same effect. To test for this possibility, we bath applied the selective KCC2 blocker DIOA (30 μ M) to naïve spinal slices. As in the PNI condition, GABA application in the presence of DIOA caused an increase in $[Ca^{2+}]_i$ in 30% of naïve LI neurons tested (Fig. 3b,c).

To assess whether the empirically determined changes in GABA_AR/GlyR-mediated postsynaptic control were sufficient to account for the central sensitization which follows PNI, we simulated *in vivo* conditions using a biophysically-realistic neuron model (Fig. 5). The simulation confirmed that, after PNI, the extent of LI neuronal sensitization varied as a function of their E_{anion} , ranging from slight disinhibition to a net hyperexcitation.

To test whether this hyperexcitability (sensitization) would result in a decrease in the stimulus threshold to evoke a nociceptive withdrawal reflex, we administered DIOA (15-30 μ g) directly to the lumbar enlargement of the spinal cord in intact rats via an intrathecal catheter. DIOA caused a rapid and reversible decrease in nociceptive threshold to both mechanical and thermal stimuli (Fig. 4a-b). A similar decrease in nociceptive threshold was further obtained via selective knock-down of the exporter using spinal administration of an antisense oligodeoxynucleotide against KCC2 mRNA (Fig. 4e), further confirming the functional impact of KCC2 downregulation.

As shown in Figure 7, we demonstrate that in lamina I neurons taken from rats with peripheral neuropathy, the transmembrane anion reversal potential (E_{anion}) is

significantly more depolarized than that in lamina I neurons taken from naïve rats. The anion (bicarbonate and chloride) reversal potential (E_{anion}) of recorded from lamina I neurons taken from naïve rats was significantly less than that

5 recorded from the lamina I neurons of rats that had received a peripheral nerve injury (PNI). Bath application of both BDNF (50 ng/ml; N/BDNF) and NGF (50 ng/ml; N/NGF) caused the E_{anion} recorded from naïve rat lamina I neurons to become significantly depolarized, indicating a collapse of the

10 transmembrane anion gradient. Alternatively, bath application of the TrkB antagonist K-252a (200 nM; P/K252a) to lamina I neurons taken from a PNI rat caused a hyperpolarization of the E_{anion} to a level similar to that observed in lamina I neurons taken from naïve rats. All E_{anion}

15 values were confirmed using gramicidin-D perforated-patch voltage-clamp recordings. This depolarized E_{anion} is the result of a decreased expression of the KCC2 cotransporter in the lamina I neurons taken from neuropathic rats, as noted above. In lamina I neurons from naïve rats, it is further

20 shown herein that the E_{anion} may be depolarized significantly via the perfusion of the growth factors NGF and BDNF, suggesting that these growth factors may decrease the function and/or expression of the KCC2 protein in the superficial dorsal horn. Alternatively, blocking the BDNF

25 receptor, TrkB, in lamina I neurons taken from neuropathic rats using the protein kinase inhibitor K-252a, is shown herein to reverse the depolarization of the E_{anion} , returning this value to a level similar to that observed in lamina I neurons taken from naïve rats. Further, as shown in Figure

30 8, intrathecal administration of the receptor tyrosine kinase inhibitor K-252a (6 nM) (but not vehicle injection alone) resulted in an increase in the threshold for tactile nociceptive withdrawal in rats that had received peripheral

nerve injury. K-252a can thus reverse the hyperalgesia/allodynia after its development following peripheral nerve injury. K-252a did not produce any motor disturbances or sedation as assessed by grasping, righting and placing reflexes and behavioral observations. It is envisioned that this inhibitor reactivates the KCC2 cotransporter in lamina I neurons taken from neuropathic rats by blocking phosphorylation, perhaps at a protein tyrosine kinase site on the transporter or on its transcription factors (or other regulatory substrate).

The results herein show that the painful neuropathy that follows PNI can be explained by a downregulation of the KCC2 exporter and the resultant shift in the V_{anion} in spinal LI neurons. They also demonstrate that such a modification of V_{anion} in adult animals can occur in a neuron transsynaptic to an injury site. Previous efforts to identify a substrate underlying the hyperexcitability characteristic of peripheral neuropathy have focussed on measuring changes in number of GABAergic interneurons, GABA content or GABA_AR expression. The results have been contradictory (3-6). The findings presented herein provide a new avenue to understand such mechanisms of disinhibition. The conversion of the GABA_AR/GlyR-mediated postsynaptic action via a shift in V_{anion} provides a mechanistic basis for central sensitization, including increases in neuronal responsiveness and number of excitatory inputs.

A critical feature of the spinal cord is that it employs two very distinct GABAergic inhibitory mechanisms: GABAergic control of the central terminals of sensory fibres already involves a depolarizing mechanism (39), in contrast to dorsal horn cells where GABAergic inhibition involves hyperpolarization. Thus, the change in KCC2 expression reported here affects the polarity of GABA action in only one

of the two inhibitory mechanisms controlling sensory input. This is confirmed by the fact that primary afferents lack expression of KCC2 (Fig.4f, g; see also Fig. 6).

GABA/glycine-mediated depolarization may also serve as a
5 gating mechanism to enable excitation via voltage sensitive Ca^{2+} channels (VSCCs) and NMDA receptor/channels (10). Ca^{2+} influx via these channels is thought to be critical for the sensitization of spinal neurons (11). Indeed, blocking these Ca^{2+} channels in humans by drugs such as gabapentin and
10 ketamine has proven highly efficacious in the treatment of neuropathic pain (12-14). However, use of Ca^{2+} channel blockers, particularly ketamine and other NMDA antagonists, is associated with many undesirable side effects (14, 15).

15 **Example 3 - *In vitro* TrkB-dependent modulation of KCC2**

Parasagittal slices (250-300 microm) were made from the dorsal horn of naïve rats or PNI rats. Slices were continually perfused with an oxygenated Ringer's solution and
20 were permitted to equilibrate for at least 1.5 hours prior to manipulation. Unless otherwise specified, slices were further perfused with 10 microm CNQX, a blocker of non-NMDA ionotropic glutamate receptors. Recordings were made from visually-identified lamina I neurons using gramicidin-D
25 perforated-patch or whole-cell voltage-clamp recordings. In both cases, pipettes were filled with an intracellular solution containing either potassium methyl sulphate or cesium gluconate as the major ionic species. E_{anion} was measured by applying a series of brief (5-10 ms) applications
30 of exogenous GABA to the soma of the neurons of interest; by manipulating the membrane potential of the neuron, the point at which GABA elicited neither an inward nor an outward anion current was taken as E_{anion} . All measurements of membrane

potential were corrected for liquid junction potential, pipette offset, and resistances.

As shown in Figure 12, both brain-derived neurotrophic factor- (BDNF; 50 ng/ml in bath) mediated
5 activation of TrkB and nerve growth factor- (NGF; 50 ng/ml in bath) mediated activation of TrkA caused a significant depolarization of the anion reversal potential (E_{anion}) in lamina I neurons taken from naïve rats.

Using slices taken from peripheral nerve injured
10 (PNI) rats, where the E_{anion} is chronically depolarized, application of various inhibitors of components of an intracellular pathway coupled to TrkB receptors were shown to cause a significant hyperpolarization of the E_{anion} (bicarbonate and chloride), to levels similar to that
15 observed in slices taken from naïve rats (Figure 13). Agents that rendered this effect included, but are not limited to, an antibody directed against TrkB, (anti-TrkB-IgG 1 $\mu\text{g}/\text{ml}$ in bath); K-252a, an inhibitor of TrkA/B autophosphorylation (200 nM in bath); H-89, a membrane-permeable inhibitor of
20 cyclic AMP-dependent kinase (PKA); 15 μM in bath); and KN-93, a membrane permeable inhibitor of calmodulin-dependent kinase II and IV (5 μM in bath).

**Example 4 - TrkB-dependent modulation of nociceptive
25 threshold *in vivo*.**

All drugs used for local spinal delivery via intrathecal catheter were dissolved in 0.9% NaCl with or without 10% v/v DMSO. Intrathecal catheterization was
30 performed by creating a small opening at the cisterna magna, and inserting a short P10 polyethylene tube into the subarachnoid space, caudally directed ~ 8 cm to the lumbar enlargement (L4-5) of the spinal cord. No drug administered

produced motor disturbances or sedation, as assessed via analysis of grasping, righting and placing reflexes and other behavioral observations. Von Frey testing was used to assess the 50% withdrawal threshold to mechanical stimulation as previously described (41). All experiments were performed on intact, adult Sprague-Dawley rats.

Local spinal delivery of various agents using an intrathecal catheter led to the identification of several compounds that either effect a reduction of nociceptive threshold for tactile stimulation in naïve rats, or raise the nociceptive threshold in PNI rats.

Local spinal delivery of either an adenovirus transducing BDNF (Figure 14) or human recombinant BDNF (10 µg/day x 6 days), but not of an adenovirus transducing the green-fluorescent protein, caused a significant decrease in the nociceptive threshold for mechanical stimulation in naïve rats. Likewise, intrathecal delivery of human recombinant NGF (Figure 15; 10 µg/day x 6 days) to naïve rats caused a very similar decrease in the said nociceptive threshold.

On the other hand, serial administration of antibody directed against TrkB (anti-TrkB-IgG 12 µg/2 hrs x 3) via intrathecal catheter to PNI rats effected a significant increase in nociceptive threshold to mechanical stimulation (Figure 16). Local spinal delivery of the PKA inhibitor H-89 (380 nmol) also caused an increase in the nociceptive threshold (Figure 17).

Throughout this application, various references are cited, which describe more fully the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure.

REFERENCES

1. Melzack, R. & Wall, P.D. (1965) *Science* 150:971-979.
2. Woolf, C.J. & Salter, M.W. (2000) *Science* 288:1765-1769.
- 5 3. Kontinen, V.K., et al. (2001) *Anesthesiology* 94:333-339.
4. Moore, K.A. et al. (2002) *J. Neurosci* 22:6724-6731.
5. Somers, D.L. & Clemente, F.R. (2002) *Neurosci Lett* 323:171-174.
6. Polgar, E., et al. Soc Neurosci Abstr 28, 655.3. 6-11-2002.
- 10 7. Light, A.R. The initial processing of pain. Karger, Basel (1992).
8. Ebihara, S., et al. (1995) *J Physiol* 484 (Pt 1), 77-86.
9. Keller, A.F., et al. (2001) *J Neurosci* 21:7871-7880.
10. Staley, K.J., et al. (1995) *Science* 269:977-981.
- 15 11.Coderre, T.J. & Melzack, R. (1992) *J Neurosci* 12:3665-3670.
12. Serpell, M.G. (2002) *Pain* 99:557-566.
13. Rabben, T., et al. (1999) *J. Pharmacol. Exp. Ther.* 289:1060-1066.
14. Martin, T.J. & Eisenach, J.C. (2001) *J. Pharmacol. Exp.*
- 20 *Ther.* 299:811-817.
15. Farber, N.B., et al. (2002) *Mol. Psychiatry* 7:726-733.
16. Mosconi, T. & Kruger, L. (1996) *Pain* 64:37-57.
17. Coderre, T.J. & Van, E., I. (1994) *Pain* 59:345-352.
18. Rivera, C. et al. (1999) *Nature* 397:251-255.
- 25 19. Prescott, S.A. & de Koninck, Y. (2002) *J Physiol* 539:817-836.
20. Payne, J.A., et al. (1996) *J. Biol. Chem.* 271:16245-16252.
21. Mount, D.B. et al. (1999) *J. Biol. Chem.* 274:16355-
- 30 16362.
22. Kelsch, W. et al. (2001) *J Neurosci* 21:8339-8347.
23. Strange, K., et al. (2000) *Am. J. Physiol Cell Physiol* 279:C860-C867.

24. Shen, M.R. et al. (2001) *Proc. Natl. Acad. Sci. U. S. A* 98:14714-14719.
25. Gulyas, A.I., et al. (2001) *Eur. J. Neurosci.* 13:2205-2217.
- 5 26. Payne, J.A. (1997) *Am. J. Physiol* 273:C1516-C1525.
27. Flatman, P.W., et al. (1996) *Am. J. Physiol* 271:C255-C263.
28. Howard, H.C. et al. (2002) *Nat. Genet.* 32:384-392.
29. Sung, K.W., et al. (2000) *J. Neurosci.* 20:7531-7538.
- 10 30. Mainen, Z.F., et al. (1995) *Neuron* 15:1427-1439.
31. Traub, R.J. & Miles, R. *Neuronal Networks of the Hippocampus*. Cambridge, Cambridge, U.K. (1991).
32. Narikawa, K., et al. (2000) *J Neurophysiol* 84:2171-2174.
- 15 33. Furue, H., et al. (1999) *J Physiol* 521:529-535.
34. Ribeiro-da-Silva, A. & Coimbra, A. (1982) *J. Comp Neurol.* 209, 176-186.
35. Ribeiro-da-Silva, A. *The Rat Nervous System*. Paxinos, G. (ed.), pp. 47-59 (Academic Press, Sydney, Australia, 1995).
- 20 36. Sik, A., et al. (2000) *Neuroscience* 101, 51-65.
37. Gulyas, A.I., et al. (2001) *Eur. J. Neurosci.* 13, 2205-22 17.
38. Delpire, E. & Mount, D.B. (2002) *Annu. Rev. Physiol.* 64:803-403.
- 25 39. Woo, N-S., et al. (2002) *Hippocampus* 12:258-268.
40. Rudomin, P. & Schmidt, R.F. (1999) *Exp Brain Res* 129:1-37.
41. Chaplan et al., (1994) *J. Neuroscience Methods* 53:55-63.
- 30 42. Jarolimek et al. (1999) *J. Neuroscience* 19: 4695-704.

WHAT IS CLAIMED IS:

1. A method of treating or preventing pain in a subject, said method comprising decreasing an intracellular chloride level
5 in a central nervous system (CNS) neural cell of said subject.
2. The method of claim 1, wherein said method comprises modulating the activity or expression of a chloride transporter in said CNS cell, thereby to decrease said
10 chloride level.
3. The method of claim 2, wherein said chloride transporter is KCC2.
4. The method of claim 3, said method further comprises increasing said KCC2 activity or expression.
- 15 5. The method of claim 1, wherein said CNS neural cell is a spinal cord neural cell.
6. The method of claim 1, wherein the signal of said pain originates in a peripheral nervous system (PNS) cell or sensory fiber transsynaptic to said CNS neural cell.
- 20 7. The method of claim 1, wherein said pain is neuropathic pain.
8. The method of claim 7, wherein said neuropathic pain is associated with a nerve or tract injury.
9. The method of claim 7, wherein said neuropathic pain is
25 selected from the group consisting of somatic and visceral pain.
10. The method of claim 1, wherein said pain is selected from the group consisting of chronic inflammatory pain, pain associated with arthritis, fibromyalgia, back pain, cancer-associated pain, pain associated with digestive disease, pain
30 associated with Crohn's disease, pain associated with autoimmune disease, pain associated with endocrine disease, pain associated with diabetic neuropathy, phantom limb pain,

spontaneous pain, chronic post-surgical pain, chronic temporomandibular pain, causalgia, post-herpetic neuralgia, AIDS-related pain, complex regional pain syndromes type I and II, trigeminal neuralgia, chronic back pain, pain associated with spinal cord injury and recurrent acute pain.

11. The method of claim 1, wherein said method comprises administering to said subject a compound capable of decreasing said intracellular chloride level in said CNS cell.

12. The method of claim 11, wherein said compound is capable of modulating the activity or expression of a chloride transporter in said CNS cell.

13. The method of claim 12, wherein said chloride transporter is KCC2.

14. The method of claim 13, wherein said compound is capable of increasing said KCC2 activity or expression.

15. The method of claim 14, wherein said compound is an inhibitor of TrkB.

16. The method of claim 15, wherein said inhibitor is selected from the group consisting of K-252a and an anti-TrkB antibody.

17. The method of claim 13, wherein said compound is an inhibitor of cyclic AMP-dependent kinase (PKA).

18. The method of claim 17, wherein said inhibitor is H-89.

19. The method of claim 13, wherein said compound is an inhibitor of calmodulin-dependant kinase (CAM kinase).

20. The method of claim 19, wherein said inhibitor is KN-93.

21. The method of claim 3, wherein said KCC2 comprises an amino acid sequence substantially identical to a sequence selected from the group consisting of SEQ ID NO: 2, 4, 6 and a fragment thereof.

22. A composition for the treatment or the prevention of pain in a subject, said composition comprising:

(a) a compound capable of decreasing an intracellular chloride level in a CNS neural cell; and

(b) a pharmaceutically acceptable carrier.

23. The composition of claim 22, wherein said compound is
5 capable of modulating the activity or expression of a chloride transporter in said CNS neural cell.

24. The composition of claim 23, wherein said chloride transporter is KCC2.

25. The composition of claim 24, wherein said compound is
10 capable of increasing said KCC2 activity or expression.

26. A commercial package comprising the composition of claim 22 together with instructions for its use in the treatment or prevention of pain.

27. A commercial package comprising a compound capable of
15 decreasing an intracellular chloride level in a CNS neural cell together with instructions for its use the treatment or prevention of pain.

28. The commercial package of claim 27, wherein said compound is capable of modulating the activity or expression of a
20 chloride transporter in said CNS neural cell.

29. The commercial package of claim 28, wherein said chloride transporter is KCC2.

30. The commercial package of claim 29, wherein said compound is capable of increasing said KCC2 activity or expression.

25 31. Use of the composition of claim 22 for the treatment or prevention of pain.

32. Use of the composition of claim 22 for the preparation of a medicament for the treatment or prevention of pain.

33. Use of a compound capable of decreasing an intracellular
30 chloride level in a CNS neural cell for the treatment or prevention of pain.

34. Use of a compound capable of decreasing an intracellular chloride level in a CNS neural cell for the preparation of a medicament for the treatment or prevention of pain.

35. The use of claim 33, wherein said compound is capable of
5 modulating the activity or expression of a chloride transporter in said CNS cell.

36. The use of claim 35, wherein said chloride transporter is KCC2.

37. The use of claim 36, wherein said compound is capable of
10 increasing said KCC2 activity or expression.

38. The use of claim 37, wherein said compound is an inhibitor of TrkB.

39. The use of claim 38, wherein said inhibitor is selected from the group consisting of K-252a and an anti-TrkB
15 antibody.

40. The use of claim 37, wherein said compound is an inhibitor of cyclic AMP-dependent kinase (PKA).

41. The use of claim 40, wherein said inhibitor is H-89.

42. The use of claim 37, wherein said compound is an
20 inhibitor of calmodulin-dependant kinase.

43. The use of claim 42, wherein said inhibitor is KN-93.

44. A method of identifying or characterizing a compound for treatment or prevention of pain, said method comprising:

(a) contacting a test compound with a CNS-derived cell; and
25 (b) determining whether said intracellular chloride level is decreased in the presence of the test compound;

wherein said decrease is an indication that said test compound may be used for treatment or prevention of pain.

45. A method of identifying or characterizing a compound for
30 treatment or prevention of pain, said method comprising:

(c) contacting a test compound with a CNS-derived cell expressing a chloride transporter; and

(d) determining whether activity or expression of said chloride transporter is modulated in the presence of the test compound in such a way that the level intracellular chloride is decreased;

5 wherein said modulation is an indication that said test compound may be used for treatment or prevention of pain.

46. The method of claim 45, wherein said chloride transporter is KCC2.

47. The method of claim 46, wherein said method comprises
10 determining whether said KCC2 expression or activity is increased in the presence of the test compound and said modulation is an increase.

48. The method of claim 47, wherein said KCC2 activity is determined by measuring a parameter selected from the group
15 consisting of potassium transport, chloride transport, intracellular chloride level and anion reversal potential.

49. The method of claim 44, wherein said pain is selected from the group consisting of chronic inflammatory pain, pain associated with arthritis, fibromyalgia, back pain, cancer-
20 associated pain, pain associated with digestive disease, pain associated with Crohn's disease, pain associated with autoimmune disease, pain associated with endocrine disease, pain associated with diabetic neuropathy, phantom limb pain, spontaneous pain, chronic post-surgical pain, chronic
25 temporomandibular pain, causalgia, post-herpetic neuralgia, AIDS-related pain, complex regional pain syndromes type I and II, trigeminal neuralgia, chronic back pain, pain associated with spinal cord injury and recurrent acute pain.

50. A method of identifying or characterizing a compound for
30 treatment or prevention of pain, said method comprising:

(a) contacting a test compound with a CNS-derived cell comprising a first nucleic acid comprising a transcriptionally regulatory element normally associated with

a chloride transporter gene, operably linked to a second nucleic acid comprising a reporter gene capable of encoding a reporter protein; and

(b) determining whether reporter gene expression or
5 reporter protein activity is modulated in the presence of said test compound;

wherein said modulation in reporter gene expression or reporter protein activity being an indication that said test compound may be used for treatment or prevention of pain.

10 51. The method of claim 50, wherein said chloride transporter is KCC2.

52. The method of claim 51, wherein said reporter gene expression or reporter protein activity is increased in the presence of said test compound.

15 53. A method for decreasing nociception in a subject, said method comprising decreasing intracellular chloride in a CNS neural cell of said subject.

54. The method of claim 53, wherein said method comprises modulating chloride transporter activity or expression in
20 said CNS neural cell.

55. The method of claim 54, wherein said chloride transporter is KCC2.

56. The method of claim 55, said method further comprises increasing said KCC2 activity or expression.

25 57. The method of claim 55, wherein said method further comprises contacting said CNS neural cell with a compound capable of increasing KCC2 activity or expression.

58. The method of claim 57, wherein said compound is an inhibitor of TrkB.

30 59. The method of claim 58, wherein said inhibitor is selected from the group consisting of K-252a and an anti-TrkB antibody.

60. The method of claim 57, wherein said compound is an inhibitor of cyclic AMP-dependent kinase (PKA).

61. The method of claim 60, wherein said inhibitor is H-89.

62. The method of claim 57, wherein said compound is an inhibitor of calmodulin-dependant kinase.

63. The method of claim 62, wherein said inhibitor is KN-93.

64. The method of claim 55, wherein said KCC2 comprises an amino acid sequence substantially identical to a sequence selected from the group consisting of SEQ ID NO: 2, 4, 6 and a fragment thereof.

65. A method for diagnosing or prognosticating pain associated with CNS dysfunction in a subject experiencing pain, said method comprising determining whether a test CNS intracellular chloride level is increased relative to a corresponding control chloride level; wherein said increase is an indication that said subject is experiencing pain associated with CNS dysfunction.

66. The method of claim 65, said method further comprises determining whether CNS chloride transporter activity or expression is modulated relative to a control transporter activity or expression.

67. The method of claim 66, wherein said chloride transporter is KCC2.

68. The method of claim 67, said method further comprises determining whether said KCC2 activity or expression is decreased relative to said control activity or expression.

69. The method of claim 65, wherein said control intracellular chloride level is selected from the group consisting of:

- (a) an established standard;
- (b) a corresponding intracellular chloride level determined in said subject at an earlier time;

71

(c) a corresponding intracellular chloride level determined in said subject when said subject is experiencing less pain or substantially no pain; and

(d) a corresponding intracellular chloride level determined in a control subject experiencing less pain or substantially no pain.

70. The method of claim 68, wherein said control activity or expression is selected from the group consisting of:

(a) an established standard of KCC2 activity or expression;

10 (b) a corresponding level of KCC2 activity or expression determined in said subject at an earlier time;

(c) a corresponding level of KCC2 activity or expression determined in said subject when said subject is experiencing less pain or substantially no pain; and

15 (d) a corresponding level of KCC2 activity or expression determined in a control subject experiencing less pain or substantially no pain.

71. The method of claim 67, wherein said KCC2 activity is determined by measuring a parameter selected from the group consisting of potassium transport, chloride transport, intracellular chloride level and anion reversal potential.

72. The method of claim 65, wherein said intracellular chloride level is determined by:

25 (a) administering an indicator compound indicative of intracellular chloride level to said subject such that it is contacted with a CNS neural cell of said subject;

(b) assessing an *in vivo* signal associated with said indicator compound.

73. The method of claim 65, wherein said pain associated with CNS dysfunction is neuropathic pain.

74. The method of claim 73, wherein the indicator compound is a radionuclide.

72

75. The method of claim 75, wherein the radionuclide is selected from the group consisting of ^{201}Tl , ^{99}Tcm -tetrofosmin, ^{99}Tcm -MIBI, ^{99}Tcm -HMPAO and ^{36}Cl .

76. The method of claim 73, wherein said *in vivo* signal is
5 assessed by an imaging technique.

77. The method of claim 72, wherein said *in vivo* signal is the retention index of said indicator compound.

78. The method of claim 76, wherein the imaging technique is selected from the group consisting of single photon emission
10 computed tomography, positron emission tomography and magnetic resonance imaging.

79. The method of claim 73, wherein said indicator compound is indicative of KCC2 expression.



80. The method of claim 79, wherein said indicator compound
15 is an antibody directed against KCC2.

81. A method of treating pain associated with CNS dysfunction in a subject, said method comprising:



(a) diagnosing or prognosticating, according to the method of claim 65, pain associated with CNS dysfunction in
20 said subject;

(b) decreasing an intracellular chloride level in a CNS cell of said subject.

1/25

**FIG. 1A****FIG. 1B**

2/25

**FIG. 1C****FIG. 1D**

3/25

Naive

HP = 0 mV

HP = -60 mV

Control

Control

Strychnine

CNQX

FIG. 2A

PNI

Control

Control

Strychnine

CNQX

Strychnine + Bicuculline

FIG. 2B




FIG. 2C









FIG. 2D

4/25

**FIG. 2E****FIG. 2F**

5/25

**FIG. 3A****FIG. 3B****FIG. 3C**




FIG. 3D




FIG. 3E









FIG. 3F

7/25



**FIG. 4A****FIG. 4B**

8/25

**FIG. 4C****FIG. 4D**

**FIG. 4E**

Naive: SDH DRG

**FIG. 4F****FIG. 4G**

10/25




FIG. 5A

11/25




FIG. 5B

12/25




FIG. 6A






FIG. 6B

13/25

**FIG. 7**

14/25

**FIG. 8**

15/25

Human KCC2 polypeptide and DNA sequences

(Mount, D.B. and Song, L. (2002) Brain Res. Mol. Brain Res. 103 (1-2), 91-105; ACCESSION: AF208159)

Human KCC2 polypeptide (SEQ ID NO:2):

```

MPNNLTDCEDGDGGANPGDGNPKESSPFINSTDTEKGKEYDGKN
MALFEEEMDTSPMVSSILSGLANYTNLPQGSREHEEAENNEGGKKKPVQAPRMGTFMG
VYLPCLQNIFGVILFLRLTWVVGIAGIMESFCMVFICCSCTMLTAISMAIATNGVVP
AGGSYYMISRSLGPEFGGAVGLCFYLGTTFAGAMYILGTIEILLAYLFPAMAIFKAED
ASGEAAAMLNNMRVYGTCLVTCMATVVVGVGVYVNFALVFLGCVILSILAIYAGVIK
SAFDPPNFPICLLGNRTLSRHGFDVCAKLAWEGNETVTTRLWGLFCSSRFLNATCDEY
FTRNNVTEIQGIPGAASGLIKENLWSSYLTGKVIVERSGMTSVGLADGTPIDMDHPYV
FSDMTSYFTLLVGIYFPSVTGIMAGSNRSGDLRDAQKSIPTGTILAIATTSAVYISSV
VLFGACIEGVVLRDKFGEAVNGNLVVGTLAWPSPWVIVIGSFFSTCGAGLQSLTGAPR
LLQAISRDGIVPFLQVFGHGKANGEPTWALLLTACICEIGILIASLDEVAPILSMFFL
MCYMFVNLAQVQTLRLTPNWRPRFRYYHWTLSFLGMSLCLALMFICSWYYALVAMLI
AGLIYKYIEYRGAKEWGDGIRGLSLSAARYALLRLEEGPPHTKNWRPQLLVLRVDQ
DQNVVHPQLLSLTSQKAGKGLTIVGSVLEGTFLFNHPQAQRAEESIRRLMEAEKVKG
FCQVVISSNLRDGVSHLIQSGGLGGLQHNTVLVGWPRNWRQKEDHQTWRNFIELVRET
TAGHLALLVTKNVSMFPGNPERFSEGSIDVWVIVHDGGMMLLPPFLLRHHKVWRKCKM
RIFTVAQMDDNSIQMKKDLTTFLYHLRITAEVVEVMHESDISAYTYEKTLMVEQRSQ
ILKQMHILTNEREREIQSITDESRSIRRKNPANTRLRLNVPEETAGDSEEKPEEEVQ
LIHDQSAPSCPSSSPSPGEEPEGEGETDPEKVHLTWTCKDKSVAEKNKGSPVSSSEGIK
DFFSMKPEWENLNQSNVRRMHTAVRLNEVIVKKSRDAKLVLNMPGPPRNRNGDENYM
EFLEVLTEHLDRVMLVRGGGREVITIYS

```

Human KCC2 DNA (SEQ ID NO:1):

```

1 atgcccaaca acctgacgga ctgcgaggac ggcgatgggg gagccaaccc gggatgatggc
61 aacccaagg aaagcagtcc cttcatcaac agcaccgaca cagagaaggg aaaggagtat
121 gatggcaaga acatggcctt gtttgaggag gagatggaca ccagccctat ggtgtcctcc
181 ttgctcagtg gcctggccaa ctacaccaac ctgccccagg gaagtaggga gcatgaagag
241 gcagaaaaca atgaggggtg aaaaaagaag ccggtgcagg cccacgcat gggcaccttc
301 atgggcgtgt acctgccgtg cctgcagaac atctttggcg tcctcctctt cctgcggctc
361 acctgggtgg tgggcattgc aggcattcat gagtccttct gcatggtgtt catctgctgc

```

FIG. 9

16/25

```

421 tccgtgtaoga tgctcacggc catctccatg agtgcaattg caacgaatgg tgttgtgcct
481 gctgggtggct cctactacat gatttccagg tctctgggccc cagagtttgg ggggtgccgtg
541 ggccctctgct tctacctggg cactaccttt gcaggagcca tgtacatcct gggcaccatc
601 gaaatcctgc tggcttacct cttcccagcc atggccatct tcaaggcaga agatgccagt
661 gggggaggcag cagccatgct gaacaacatg cgtgtttacg gcacctgtgt gctcacctgc
721 atggccactg tgggtgtttgt ggggtgtcaag tatgtcaaca agtttgccct tgtcttcttg
781 gggtgtgtca tccctctccat cctggccatc tatgctgggg tcatcaagtc tgccttcgac
841 ccacccaact tcccgatctg cctcctgggt aaccgcacgc tgtctcgcca tggctttgat
901 gtctgtgcca agctggcctg ggaaggaaat gagacgggtg ccacacggct atggggcctt
961 ttctgctcct ctgccttctt caacgccacc tgtgatgaat acttcacccg aaacaatgtc
1021 acagagatcc agggcatccc tgggtgctgcc agtggcctca tcaaagagaa cctctggagc
1081 tctacactga ccaagggcgt gattgtggag aggagtggga tgacctcggg gggcctggcc
1141 gatggcactc ctatcgacat ggaccaccct tatgtcttca gtgatatgac ctccacttct
1201 accctgctgg ttggcatcta cttcccctca gtcacagggg tcatggctgg ttctaaccgc
1261 tctggggacc tgagggatgc ccagaagtca atccccactg gcaccatcct ggccatcgcc
1321 accacctctg ctgtctacat cagctccgtt gttctgtttg gggcctgcac tgagggggtc
1381 gtccctgcggg acaagtttgg cgaagctgtg aatggcaacc tctgtgtggg cactctggcc
1441 tggccatctc catgggtaat tgtcatcgga tccctcttct ccacctgtgg ggctgggctg
1501 cagagcctca cgggggcccc acgcctgctg caggccatct cgagggatgg catttgtgcc
1561 ttcttgccagg tctttggcca tggcaaggcc aatggagagc cgacctgggc cctgctcctg
1621 actgcctgca tctgcgagat tggcatcctc attgcatccc tcgacgaggt ggcccccatc
1681 ctctctatgt tcttctctgat gtgctacatg tttgtgaatc tggcctgtgc agtcagacg
1741 ctgctgagga caccacactg gaggccacgc tttcgataat accactggac cctctccttc
1801 ctgggcatga gcctctgcct ggccctcatg ttcatctgct cctgggtatta tgcactggta
1861 gccatgctca ttgctggact catctacaag tacattgagt accgtggggc agagaaggag
1921 tggggcgatg ggatacgagg tctgtctctc agtgccgctc gctatgccct cttacgcctg
1981 gaggaagggc cccacacacac caagaactgg aggccacagc tgcctgggtg ggtgcgtgtg
2041 gaccaagacc agaattgtgt gcacccccag ctgctctcac tgacctccca gctgaaggca
2101 gggaagggcc tgaccatcgt gggctctgtc cttgagggca cettcttggg aaatcatcca
2161 caggcccagc gggcagaaga gtctatcagg cgctgatgg aggcagagaa ggtgaagggc
2221 ttctgccagg tgggtgatctc ctccaacttg cgtgatggcg tgtccatct gatccagtc
2281 gggggcctcg gggggctgca gcacaacact gtgcttgttg gctggccccg caactggcgc
2341 cagaaggaag atcatcagac gtggaggaac ttcattgagc tggctcggga aaccacagct
2401 ggccacttag ccctgctggg caccaagaac gtttccatgt ttctgggaa ccttgagcgc
2461 ttctctgagg gcagcatcga cgtttgggtg attgtgcacg atggaggcat gctcatgctg
2521 ctgccttccc tgctgcggca ccacaaggtc tggcgggaag gcaagatgcg tatcttact
2581 gtggcccaga tggatgacaa tagcatccag atgaagaagg atctgaccac atttctgtat
2641 catttacgca tcaactgcgga ggtcgagggt gtggagatgc atgagagcga catctcagct
2701 tacacctatg agaagacggt ggtgatggag cagcgttccc agatcctcaa acagatgcat
2761 ttaaccaaga atgagcggga gcgggagatc cagagtatca cagatagtc acgaggtca
2821 atccggagaa agaatccagc caacacgcgg ctccgcctga acgtcccaga agagacggct
2881 ggtgacagtg aagagaagcc agaggaggag gtgcagctga tccacgatca gagtgtctcc
2941 agctgccccd gcagctcccc gtccccaggg gaggagcctg agggggaagg ggagacagat
3001 ccggagaagg tgcattctac ctggaccaag gacaagtccg tggcagagaa gaataagggc
3061 ccagtcctg tctcctctga gggcatcaag gacttcttca gcatgaagcc ggagtgggag
3121 aacttgaacc agtccaacgt gcggcgcatg cacacggccg tgcggctgaa cgaggtcatc
3181 gtgaagaaat cccgggacgc caagcttgtt ttgctcaaca tgccctgggc tcccgcacac
3241 cgcaatggtg atgaaaacta catggagtgt ctcgaggtcc tcacagagca cctggaccgg
3301 gtgatgtctg tccgcggtgg tggccgagag gtcataacca tctactcctg agaaccaggt
3361 cctgccaccc gggcccagac gcgcccggcc cgcggtccg gagccctcgc cgcgcccccc
3421 gccgctgtca ccgtttacat acagaccctg tgcccgtgtc ctggccccct accccgctgc
3481 ctgaagcccg gaggccacgc ctgttggggc tgattcggag agggcgcccc gccgcgcaga
3541 gaccagagct cctcagtgc agtttggccc ctgggtcttc gctgcctttt ttctaagccc
3601 ggcctcgtct cgcggagga gacgtgcga taaaggttg gagaaggcgc gaaaggaga
3661 ggagctgggg ccttggggac cccaggtag tccatgcggc ccattcctcc ccttcccact
3721 cccgcgcggc tccctcgtct gcgctcctcc ggcgctgctc cctggctccc ggcggcccg
3781 agggccgcgg ggtgggaagg ccgcgcttgc cgtctccgcc gcccttctc gccgagccgt
3841 ggggcgcggg cggccgagcc tatacatagt gtacaggaga catcgcggtg atttttaacg

```

FIG. 9 (Continued)

17/25

```

3901 tccccatatt tatgtgacta gaagcgcaac agacttctcg ccatagtoga gctctccgcg
3961 tggggggcact gcgggggaggg gaggcctcgg gaagctgaat tttccttgac gtccaagagt
4021 ttgagagcga aagtgcctta ggcccaggcg ggggtcgtgg cctcgttccc tcgacacctc
4081 cgtcctgctc tcgctcttc gccctttccg cgcgcccttg gcttcccacc ctctctcca
4141 gtccttttcc gagatgaggt gagacaaggg tccaactttt cctggattcg cctcccagcg
4201 gacgtgagct tccactgcgg ctgcagagac gcgagcaacc tcttctcatc ggctcttatg
4261 caagttgggg ccaggatagg ggaggggtgc tcctcaagag gaagaaaccg agaggcccgc
4321 gccccaccga ggaagccccg ccccggtgcc ttcgctgggg agcaggcgctc tctctcagt
4381 cggcttgctc cctgctcccc gtatcccatg gctcctcgcc aaagactgaa attgtggagc
4441 tggagggcgc cccctccccg gagtttcctc cctgggacaa gtgagggagg agggggccga
4501 ttctggttta ggggcgggac ccactgagag gccccagagc cgcccgatgat gttcctcccc
4561 cgtccccatc tggcagctcc tgtctcgctt gagggaccca gccgccttct ccgtgctctg
4621 gggccggggc tcgctgctta gcagcggcct ctagctccgt ctccggggga cctggacctg
4681 aggggaggct ggagtcagca cgcgctttgt ccttagcgcc tgtctgctct cctctaacta
4741 ggaccaggg cctttggctt cccagctca tccttgccc ttccgctcca ccagcctggt
4801 ctgaggcgct ctctgtcctt agagaaggcg cgggtggcgg gttcccttcc cctagggcac
4861 attactaagg gggtcaggca ctgcatgctc gttccagcac catctgggac tgggtacagt
4921 acctccagcc ccagggccct gacctgcgca cctagcttga catctcacgc acctcccaga
4981 gctggcgcca ctgagtaatc cggacctcac cacctctttt cctttgagcc caaggcagag
5041 ctagagctgg agctggcgcc accagacag cgtcaggtgt ggctggggta ggtttggagg
5101 tctgccagtt acgccaagtc cctctgaga ttcgatcagg ggactggata gattctttca
5161 ggtactcaat caggaagctg gaggtgttag acaccagccc cctgcacctc tcagtagacc
5221 tccctctgaa caccacagcc aggtcctgcc ttctgggggc ctgaatattc cagagctgat
5281 gtgatgggct gtgcagaagg gggctgtatc aacatcaatt agggaaccaa agttgcacta
5341 tctggggcca gattgtctgg ttggcaagag caaagtttcc gttgatgaaa cagacatccc
5401 acaacaaaaa cccaagtttt ctgtgctaca tgtgcaatat ttgttatgaa tgttatcaca
5461 agtcattcat caagttatct ttataatcac tgtagttaga tgtttcatgt ccattcaagt
5521 gacttttatt ctgagtgcaa tatttcaata gcctttagt gataactagt gttgcttttg
5581 tttagatgat ctatgtgcag ggcaatgcaa tgaagttgaa accccttggg aataggagag
5641 gttgcaaacc aaatcaagag tatttattac tattactgct attattatta ggccctgcctt
5701 taattttcag tgtaagtgtt cagtatgccg catcctgcct cagtattgat cttgtgttct
5761 ttgtgccaat atgaaaagga gaggggttgg tctttccttt attgttgaat gctccattt
5821 aatgctttat ggcttttact gtattacttt tttagactcc cgtctgcaca aaatgcaata
5881 aaaataattt tattataaaa aaaaaaa

```

FIG. 9 (Continued)

18/25

Mouse KCC2 (K-Cl cotransporter [Slc12a5])
polypeptide and DNA sequences

(Ehringer, M.A., et al. (2001) Mamm. Genome 12 (8), 657-663;
ACCESSION: AF332064)

Mouse KCC2 polypeptide (SEQ ID NO:4):

```
MLNNLTDCEDGDGGANPGDGNPKESSPFINSTDEKGREYDGRN
MALFEEEMDTSMPVSSLLSGLANYTNLPQGSREHEEAENNEGGKKKPVQAPRMGTFMG
VYLPCLQNIFGVILFLRLTWVVGIAGIMESFCMVFICCSCTMLTAISMSAIATNGVVP
AGGSYYMISRSLGPEFGGAVGLCFYLGTTFAGAMYILGTIEILLAYLFPAMAIFKAED
ASGEAAAMLNNMRVYGTCTVLTCTMATVVFVGKYNKFALVFLGCVILSILAIYAGVIK
SAFDPPNFPICLLGNRTLNRHGFDVCAKLAWEGNETVTTRLWGLFCSSRLNATCDEY
FTRNNVTEIQGIPGAASGLIKENLWSSYLTGKGVIVERRMPSVGLADGTPVDMHPYV
FSDMTSYFTLLVGIYFPSVTGIMAGSNRSGDLRDAQKS IPTGTILAIATTSAVYISSV
VLFGACIEGVVLRDKFGEAVNGNLVVGTLAWPSPWVIVIGSFFSTCGAGLQSLTGAPR
LLQAISRDLGIVPFLQVFGHGKANGEPTWALLLTACICEIGILIASLDEVAPILSMFFL
MCYMFVNLAQVQTLRLTPNWRPRFRYYHWTLSFLGMSLCLALMFICSWYYALVAMLI
AGLIYKYIEYRGAKEWGDGIRGLSLSAARYALLRLEEGPPHTKNWRPQLLVLRVDQ
DQNVVHPQLLSLTSQKAGKGLTIVGSVLEGTFLDNHPQAQRAEESIRRLMEAEKVKG
FCQVVISSNLRDGVSHLIQSGGLGGLQHNTVLVGWPRNWRQKEDHQTWRNFIELVRET
TAGHLALLVTKNVSMFPGNPERFSEGSIDVWWIVHDGGMMLLPFLLRHHKVWRKCKM
RIFTVAQMDDNSIQMKKDLTTFLYHLRITAEVEVVMHESDISAYTYEKTLMVEQRSQ
ILKQMHLTKNEREREIQSITDESRGSIRRNKNPANPRLRLNVPEETACDNEEKPEEEVQ
LIHDQSAPSCPSSSPSPGEEPEGERETDPEVHLTWTKDKSVAEKNKGPSPVSEGIKD
FFSMKPEWENLNQSNVRRMHTAVRLNEVIVNKS RDAKLVLNMPGPPRNRNGDENYME
FLEVLTEQLDRVMLVRGGGREVITIYS
```

Mouse KCC2 DNA (SEQ ID NO:3):

```
1 gagcaagcga gcgagcggag aaggcgggca gaggggcgcg ggcgaagcgg cgcagccatc
61 ccgagcccgg cgccgcgcag ccaccatgct caacaacctg acggactgcg aggacggcga
121 tgggggagcc aaccccgggtg atggcaacct caaagagagc agtcccttca tcaacagcac
181 ggacacggag aagggcagag agtacgatgg caggaacatg gccctgtttg aggaggagat
241 ggacaccagc cccatggtat cctccctgct cagtgggctg gccaaactaca ccaacctacc
301 ccagggaagt agagagcatg aagaagcaga aaataatgag ggtggaaaaa agaagccggt
```

FIG. 10

19/25

```

361 gcaggctcct cgaatgggca ccttcattggg tgtgtacctg ccgtgcctgc agaacatcctt
421 tgggtgtcatc ctcttcctgc ggctcacgtg ggtgggtgggc atcgccggga tcatggagtc
481 cttctgtatg gtcttcattt gctgctcctg tacgatgctc acagccattt ccatgagtg
541 aatcgcaacc aatgggtgtg tgctgtctgg tggctcgtac tacatgattt ccaggctctc
601 gggcccgag tttgggggag ccgtgggcct ctgcttctac ctgggcacca cctttgctgg
661 ggctatgtac atccttggca cgatcgagat cctgctggct tatctcttcc cagctatggc
721 catcttcaag gcagaagatg ccagtgggga ggccggccgc atgctgaaca acatgcgggt
781 gtatggcacc tgtgtgctca cctgcatggc caccgttgct tttgtgggtg tcaagtacgt
841 caacaagttt gccttgggtc tctgggttg egtcatcctg tccatcctgg ccatctatgc
901 aggggtcatc aagtctgcct tcgaccaccc caatttcccg atctgctcc tggggaaccg
961 cacgctgtct cgccatggct ttgatgtctg tgccaagctg gcttgggaa gaaatgagac
1021 agtgaccaca cggctctggg gccttttctg ctctcccgcc ctctcaatg ccacctgtga
1081 tgagtacttc acccgaaaca atgtcacaga gatccagggc attcctgggt ctgccagtg
1141 tctcatcaaa gagaacctgt ggagtcttta cctgacaaa ggggtgattg tcgagaggcg
1201 tgggatgccc tctgtgggcc tggcagacgg taccctcgta gacatggacc accctatgt
1261 cttcagtgat atgacctcct acttcacctt gctcgttgg atctacttcc cctcagtcac
1321 agggatcatg gctggctcaa accgatctgg agacctgagg gatgcccaga agtctatccc
1381 tactggaact atcctggcca ttgtaccac ctctgctgtc tacatcagct ctgttgttct
1441 gtttggagcc tgcacgagg gggctcgtctt acgggacaag tttggggaag ctgtgaatgg
1501 caacttggtg gtgggcaccc tggcctggcc ttctccctgg gtcacgtca taggtcttt
1561 cttctctacc tgtggggctg gattacagag cctcacaggg gcccacgtc tgtcgcaggc
1621 catctcccg gatggcatag tgcccttctt gcaggctttt ggccatggca aagctaattg
1681 agagccaacc tgggcgctgc tgctgactgc ctgcatctgt gagatcgga tcctcatagc
1741 ctccctggat gaggtcgccc ctatacttcc catgttcttc ctaatgtgtt acatgtttgt
1801 gaacttggt tgtgcgggtc agacgctgct gaggacaccc aactggaggc cacgatttct
1861 ctattaccac tggactctct ccttccctgg catgagcctc tgccctggcc tcatgttcat
1921 ttgctcctgg tactacgcac tgggtggccat gctcattgcc ggactcattt ataagtacat
1981 cgagtaccgg ggggcccaga aggagtgggg ggatggaatc cgaggcctgt ctctcagtc
2041 agcacgctat gctctcttgc gcctggagga aggacctccg catacgaaag atggaggcc
2101 ccagctgctg gtgctgggtg gtgtggacca ggatcagaac gtgggtgcat cgcagctgct
2161 ctccctgacc tcccagctca aggcagggaa gggcctgacc attgtgggct ccgtccttga
2221 gggcaccttt ctggacaacc atccacaggc tcagcgggca gaggagtcta tcaggcgctt
2281 gatggaggct gagaagggtg agggcttctg ccaggtagtg atctcctcca acctgcgtga
2341 tgggtgtgtc caoctgatcc agtctggggg cctcggggga ttgcaacaca ataccgtgct
2401 ggtgggctgg cctcgcaact ggaggcagaa ggaggatcat cagacatgga ggaacttcat
2461 cgaactggtc cgggaaacta cagccggcca cctcgccctg ctgggtacca gaaatgttct
2521 catgtttccc ggggaacctg agcgttctc ggagggcagc attgacgtgt ggtggattgt
2581 gcacgacggg ggcattgctc tgctgctgcc cttcctgctg cgacaccaca aggtctggag
2641 gaaatgcaaa atgcggatct tcaccgtggc ccagatggac gataacagta tccagatgaa
2701 gaaggacctg accacgtttc tgtaccactt acgcattact gcagagggtg aggtgggtga
2761 gatgcatgag agcgacatct cggcatacac ctacgagaag acattagtaa tggagcaacg
2821 atctcagatc ctcaaacaga tgcacctcac caagaacgag cgggaacggg agatccagag
2881 catcacagac gagtctcggt gctccattcg gaggaagaat ccagccaacc cccggctccg
2941 cctcaatgtt cccgaagaga cagcgtgtga caatgaggag aagccagagg aggaggtgca
3001 gctgatccat gaccagagtg ctcccagctg ccctagcagc tcgcatctc caggggagga
3061 gcccaggggg gagagggaga cagaccaga ggtgcatctt acctggacca aggataagtc
3121 agtggcagag aagaataaag gccccagtc cgtctcctcc gagggcatca aggacttctt
3181 cagcatgaag ccggagtggg aaaacttgaa ccagtccaat gtacggcgca tgcacacagc
3241 tgtgcggctg aacgaggtca tegtgaataa atctcgggat gccaaagtag ttttgcctaa
3301 catgcccggg cctcccgcga accgcaatgg ggatgaaaac tacatggaat tcttggaggt
3361 cctcactgag caactggacc ggggtgatgt ggtccgcggt ggccggccgag aggtcatcac
3421 catctactcc tgaaggccag gacctgccac tcgggcccga gcgcgcccgg cccgcggccc
3481 ccagagccct cgcgcgcct cccgcgcgt gtcaccgttt acataagacc cagttgcccc
3541 tgccctggcc cctttccttc ccgtgcctg cagccctgag gccttggccg tcggggctga
3601 cccgcagggc ggcccgtag gccccttttc tgagcctggc ctgcgccgc cggagc

```

FIG. 10 (Continued)

20/25

Rat KCC2 polypeptide and DNA sequences

(Payne, J.A., et al., (1996) J. Biol. Chem. 271 (27), 16245-16252; Gillen, C.M., et al., (1996) J. Biol. Chem. 271 (27), 16237-16244; ACCESSION: U55816)

Rat KCC2 polypeptide (SEQ ID NO:6):

MLNNLTDCEDGDGGANPGDGNPKESSPFINSTDEKGREYDGRN
MALFEEEMDTSPMVSSLLSGLANYTNLPQGSKEHEEAENNEGKKKPVQAPRMGTFMG
VYLPCLQNIQFVILFLRLTWVVGIAGIMESFCMVFICCSCTMLTAISMSAIATNGVVP
AGGSYYMISRSLGPEFGGAVGLCFYLGTTFAGAMYILGTIEILLAYLFPAMAIKFAED
ASGEAAAMLNNMRVYGTCVLTCMATVVFVGKYNKFALVFLGCVILSILAIYAGVIK
SAFDPPNFPICLLGNRTLSRHGFVCAKLAWEGETVTTTLWGLFCSSRLLNATCDEY
FTRNNVTEIQGIPGAASGLIKENLWSSYLTGKGVIVERRGMPVGLADGTPVMDHPYV
FSDMTSYFTLLVGIYFPSVTGIMAGSNRSGDLRDAQSIPTGTILAIATTSAYVISSV
VLFGACIEGVVLRDKFGEAVNGNLVVGTLAWPSPWVIVIGSFFSTCGAGLQSLTGAPR
LLQAI SRDGIVPFLQVFGHGKANGEPTWALLLTACICEIGILIASLDEVAPILSMFFL
MCYMFVNLAQVQTLRLTPNWRPRFRYYHWTL SFLGMSLCLALMFICSWYYALVAMLI
AGLIYKYIEYRGAKEWGDGIRGLSLSAARYALLRLEEGPHTKNWRPQLLVLRVDQ
DQNVVHPQLLSLTSQLKAGKGLTIVGSVLEGTFLDNHPQAQRAEESIRRLMEAEKVKG
FCQVVISSNLRDGVSHLIQSGGLGGLQHNTVLVGWPRNWRQKEDHQTWRNFIELVRET
TAGHLA LLVTKNVSMFPGNPERFSEGSIDVWWIVHDGGM LMLLPFLLRHHKVWRKCKM
RIFTVAQMDDNSIQMKKDLTTFLYHLRITAEVEVVMHESDISAYTYEKTLMVEQRSQ
ILKQMH LTKNEREREIQSITDES RGSIRRKNPANTRLRLNVP EETACDNEEKPEEEVQ
LIHDQSAPSCPSSSPSPGEEPEGEGETDPEKVHLTWTKDKSAAQKNKGSPVSSEGIK
DFFSMKPEWENLNQSNVRRMHTAVRLNEVIVNKS RDAKLVL LNMPGPPRNRNGDENYM
EFLEVLTEQLDRVMLVRGGGREVITIYS

Rat KCC2 DNA (SEQ ID NO:5):

1 ccgctccacg gagagcaagc gacagagctc gagcaagcga gcgagcggcg aaggcgggca
61 gaggggcgcg ggcgagagg cgcagccatc ccgagcccgg cgccgcgcag ccaccatgct
121 caacaacctg acggactgcg aggacggcga tgggggagcc aaccgggtg acggcaatcc
181 caaggagagc agccccttca tcaacagcac ggacacggag aaggggagag agtatgatgg
241 caggaacatg gccctgtttg aggaggagat ggacaccagc cccatggtat cctccctgct

FIG. 11

21/25

```

301 cagtgggctg gccaaactaca ccaacctgcc tcaggggaagc aaagagcacg aagaagcaga
361 aaacaatgag ggcggaaaga agaagccggg gcaggcccca cgcattgggca ccttcatggg
421 cgtgtacctc ccgtgcctgc agaacatctt tgggtgttatc ctctttctgc ggctcaacttg
481 ggtggtggga atcgccaggca tcatggagtc cttctgcatg gtcttcatct gctgctcctg
541 cacgatgctc acagccattt ccatgagcgc aattgcaacc aatggtgttg tgctgctgg
601 tggctcctac tacatgattt ccaggtctct gggcccgagc ttggggggcg ccgtgggcct
661 ctgcttctac ctgggcacta cctttgctgg ggctatgtac atcctgggca ccatcgagat
721 cctgctggct tacctcttcc cagcgatggc catcttcaag gcagaagatg ccagtgggga
781 ggcagccgcc atggtgaata acatgocggg gtatggcacc tgtgtgctca cctgcatggc
841 caccgtagtc tttgtgggcy tcaagtacgt gaacaagtct gccctggtct tccctgggtg
901 cgtgatcctc tccatcctgg ccatctacgc aggggtcatc aagtctgcct tcgatccacc
961 caatttcccg atttgcttcc tggggaaccg cacgctgtct cgccatggct ttgatgtctg
1021 tgccaagctg gcttgggaag gaaatgagac agtgaccaca cggctctggg gcctattctg
1081 ttcctcccg ctcctcaatg ccacctgtga tgagtacttc accgaaaca atgtcacaga
1141 gatccagggc attcctggtg ctgcaagtgg cctcatcaaa gagaacctgt ggagttccta
1201 cctgaccaag ggggtgatcg tggagaggcg tgggatgccc tctgtgggct tggcagatgg
1261 taccctcggt gacatggacc acccctatgt cttcagtgat atgacctcct acttcacctt
1321 gcttgttggc atctatttcc cctcagtcac agggatcatg gctggctcga accggtccgg
1381 agacctgcgg gatgcccaga agtctatccc tactggaact atcttggcca ttgctacgac
1441 ctctgctgtc tacatcagct ctgttgttct gttcggagcc tgcacgaag gggctgctct
1501 acgggacaag tttggggaag ctgtgaatgg caatctggtg gtgggcaccc tggcctggcc
1561 tctccttgg gtcatgttca taggtctctt cttctctacc tgcggagctg gactacagag
1621 cctcacaggg gccccacgcc tgtgcaggc catctcccg gatggcatag tgcccttccct
1681 gcaggtcttt ggccatggca aagccaacgg agagccaacc tgggcgctgc tgcgtactgc
1741 ctgcatctgt gagatcggca tctcatcgc ctccctggat gagtgcgcc ctatccttct
1801 catgttcttc ctgatgtgtt acatgtttgt gaacttggct tgcgcgggtg agacactgct
1861 gaggacgccc aactggaggc caegcttccg atattaccac tggaccctct ccttccctgg
1921 catgagcctc tgccctggcc tgatgttcat ttgctcctgg tattatgcgc tggtagctat
1981 gctcatcgct ggccctcatc ataagtacat cgagtaccgg ggggcagaga aggagtgggg
2041 ggatgggatc cgaggcctgt ctctcagtc agctcgctat gctctcttgc gtctggagga
2101 aggacccccg catacaaaga actggaggcc ccagctactg gtgctgggtg gtgtggacca
2161 ggaccagaac gtggtgcacc cgcagctgct gtccttgacc tcccagctca aggcagggaa
2221 gggcctgacc attgtgggct ctgtccttga gggcacctt ctggacaacc accctcaggc
2281 tcagcgggca gaggagtcta tccggcgctt gatggaggct gagaagggtg agggcttctg
2341 ccaggtagtg atctcctcca aocctgcgtg cgggtgtgtcc caoctgatcc aatccggggg
2401 cctcgggggc ctgcaacaca acactgtgct agtgggctgg cctcgcaact ggcgacagaa
2461 ggaggatcat cagacatgga ggaacttcat cgaactcgtc cgggaaacta cagctggcca
2521 cctcgccctg ctggtcacca agaattgttc catgttcccc gggaaacctg agcgtttctc
2581 tgaggggcagc attgacgtgt ggtggatcgt gcacgacggg ggcattgctc tgctgttgcc
2641 cttcctcctg cgtcaccaca aggtctggag gaaatgcaa atgcggtatc tcaccgtggc
2701 gcagatggat gacaacagca ttcagatgaa gaaagacctg accacgttct tgtaccactt
2761 acgaattact gcagaggtgg aagtcgtgga gatgcacgag agcgacatct cagcatacac
2821 ctacgagaag acattggtaa tggaaacaac ttctcagatc ctcaaacaga tgcacctcac
2881 caagaacgag cgggaacggg agatccagag catcacagat gaatctcggg gctccattcg
2941 gaggaagaat ccagccaaca ctcggtctcg cctcaatgtt cccgaagaga dagcttgtga
3001 caacgaggag aagccagaag aggaggtgca gctgatccat gaccagagtg ctcccagctg
3061 cctagcagc tcgccgtctc caggggagga gcctgagggg gagggggaga cagaccaga
3121 gaagggtgcat ctcaoctgga ccaaggataa gtcagcggct cagaagaaca aagccccag
3181 tcccgtctcc tcggagggga tcaaggactt cttcagcatg aagccggagt gggaaaactt
3241 gaaccagtcc aacgtgcggc gcatgcacac agctgtgcgg ctgaacgagg tcatcgtgaa
3301 taaatcccg gatgccaaat tgggtgttgc caacatgccc gggcctcccc gcaaccgcaa
3361 tggagatgaa aactacatgg aattcctgga ggtcctcact gagcaactgg accgggtgat
3421 gctggtccgc ggtggtggcc gagaggtcat caccatctac tccagaggc caggacctgc
3481 cactccggcc cgagcgagcc cggcccgcg ccccgaggcc ctgcgcgcgc ccccccgcc
3541 ctgtcaccgt ttacataaga ccccgttgcc cgtgccttgg cctcttctcc tccgctgcc
3601 tgccggcccg aggccttgcc cgtcggggct gaccggagg gcggcccggt ggccctttt
3661 ctgagcccg cctcgccctg ccggagtaga cgttgcaata aaggtggcga ggcggcgtgg
3721 agaggagcgg aaccgtggtc ccgggcccgg gagccccgag cccgtccctc cccacgcccc

```

FIG. 11 (Continued)

22/25



```

3781 gccgcgctcc ccccggaacc tggtcgctga gcccgggcgc cgctcggtcg cgctatacat
3841 agtggtacagg agacatcgag tgtatTTTTa atgtcccat atttctgtaa actagaaacg
3901 caacggactc ctgccacgg ccgcgctctc ccgctgcgg gcgcccagga aggcggagac
3961 ccgggaagcc agggttccct gcgctccga gctgagagcc aagtgttta aggcggcgc
4021 tctcctttcc ctttcctgtc cacggcccgg gcttccctct cttccctcca gttcttggcg
4081 aacacagggtg aagccctgcc cgggtgcctt gtggaggagc aggcgtctct cctctgttgg
4141 cttgcgcctt gctccccctg tcccggtggc cctcgccaaa gactgaattt gtggagctgg
4201 agggcacacc ctccccactt tcttcctgg gacaggtgag gggccaatgc cagtctaggg
4261 gccgactcac aggaggcctc gcgcagcctc ttggtcccca ctctgcaagt cctgcctggg
4321 gacccagccc ccctggtggt tctggggcgg agctttgctg cctagcagca agtccttagt
4381 tactgtctcc agataccagg acctggagta gggaaatggag tcatatgggt tcagttgttc
4441 ctggcgcttc tctgccccct gctccccctc tccccctctc gtaggacaca aggactttgg
4501 ctttcttaac tcatccttgg cgcttcgct ccaccacgcc cacctgtggg gaggagccct
4561 cagccctaga gaggcgtttg gctgggtccc tccccagg gcacgttact aagaggacag
4621 gcactgcatg ctcccttaag cgccctctgg gactgggtac agtgccctca gccccagggc
4681 cctggtctgc gcacctagt agacatcatt gccactcca gggccagggc cactagctga
4741 cctcaccacc tttttccttg agcccaaggc agagagagct gcagctggtg ccatctagac
4801 aggtcaagt gtggccagt gcagggctcg agggccactg ccctgttctg tggctcagga
4861 cctctctgag atttgatgg gactggatat tcttcagggt agtagccatc aagtcggaag
4921 tgttgggacc aggacctgac attccttcaa gactgccctc ccttgcctg gttttgcctt
4981 ttggggcaag agaggggctg ggcaaacggg gaggaggcag tatcaacacc gattagggaa
5041 ccaaagttag actacctggg ccagcctct gggtggcaag agcaaagttt ctggtgatga
5101 aaacaacag cccacaacaa cccccccc cccgttttct gtgctccatg tgcaatatTT
5161 gttatgaacc ttgtgtcgtt caagtccct ttataatcac tgtagctaga tgttccatgt
5221 ccatccaggt gactttactc tgagtgcaat atttcaatag cctggtagtg agaagagtgt
5281 tgcttttgtt tcagccgacc tatgtgcagg gcaatgcaat gcagtcctaa acccttgtaa
5341 ataggagagg ttgcaagcca aatcaagagt atttatcggt attactatta ttattaggcc
5401 tgcccttaat tttagtgttt cggtatctcg catcctgcct cggtatgat cgtgtgtct
5461 ctgtgccaat atgcaaagga gaggatcagt tctttccttt actgttgaat gctcccattt
5521 actgctttaa ggcttttact gtgttcattt tttagatacc tgtctg

```

FIG. 11 (Continued)

23/25

**FIG. 12****FIG. 13**

24/25




FIG. 14




FIG. 15

25/25




FIG. 16




FIG. 17

1/36

SEQUENCE LISTING

<110> Université Laval
De Koninck, Yves
De Koninck, Paul
Coull, Jeffrey

<120> CNS chloride modulation and uses thereof

<130> 85409-29

<150> US 60/470,885

<151> 2003-05-16

<160> 8

<170> PatentIn version 3.2

<210> 1

<211> 5907

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(3351)

<400> 1

atg	ccc	aac	aac	ctg	acg	gac	tgc	gag	gac	ggc	gat	ggg	gga	gcc	aac	48
Met	Pro	Asn	Asn	Leu	Thr	Asp	Cys	Glu	Asp	Gly	Asp	Gly	Gly	Ala	Asn	
1				5				10						15		

ccg	ggt	gat	ggc	aac	ccc	aag	gaa	agc	agt	ccc	ttc	atc	aac	agc	acc	96
Pro	Gly	Asp	Gly	Asn	Pro	Lys	Glu	Ser	Ser	Pro	Phe	Ile	Asn	Ser	Thr	
			20					25						30		

gac	aca	gag	aag	gga	aag	gag	tat	gat	ggc	aag	aac	atg	gcc	ttg	ttt	144
Asp	Thr	Glu	Lys	Gly	Lys	Glu	Tyr	Asp	Gly	Lys	Asn	Met	Ala	Leu	Phe	
			35				40					45				

gag	gag	gag	atg	gac	acc	agc	cct	atg	gtg	tcc	tcc	ttg	ctc	agt	ggc	192
Glu	Glu	Glu	Met	Asp	Thr	Ser	Pro	Met	Val	Ser	Ser	Leu	Leu	Ser	Gly	
			50			55					60					

ctg	gcc	aac	tac	acc	aac	ctg	ccc	cag	gga	agt	agg	gag	cat	gaa	gag	240
Leu	Ala	Asn	Tyr	Thr	Asn	Leu	Pro	Gln	Gly	Ser	Arg	Glu	His	Glu	Glu	
65					70					75				80		

gca	gaa	aac	aat	gag	ggt	gga	aaa	aag	aag	ccg	gtg	cag	gcc	cca	cgc	288
Ala	Glu	Asn	Asn	Glu	Gly	Gly	Lys	Lys	Lys	Pro	Val	Gln	Ala	Pro	Arg	
				85					90					95		

atg	ggc	acc	ttc	atg	ggc	gtg	tac	ctg	ccg	tgc	ctg	cag	aac	atc	ttt	336
Met	Gly	Thr	Phe	Met	Gly	Val	Tyr	Leu	Pro	Cys	Leu	Gln	Asn	Ile	Phe	
				100				105						110		

2/36

ggc gtc atc ctc ttc ctg cgg ctc acc tgg gtg gtg ggc att gca ggc Gly Val Ile Leu Phe Leu Arg Leu Thr Trp Val Val Gly Ile Ala Gly 115 120 125	384
atc atg gag tcc ttc tgc atg gtg ttc atc tgc tgc tcc tgt acg atg Ile Met Glu Ser Phe Cys Met Val Phe Ile Cys Cys Ser Cys Thr Met 130 135 140	432
ctc acg gcc atc tcc atg agt gca att gca acg aat ggt gtt gtg cct Leu Thr Ala Ile Ser Met Ser Ala Ile Ala Thr Asn Gly Val Val Pro 145 150 155 160	480
gct ggt ggc tcc tac tac atg att tcc agg tct ctg ggc cca gag ttt Ala Gly Gly Ser Tyr Tyr Met Ile Ser Arg Ser Leu Gly Pro Glu Phe 165 170 175	528
ggg ggt gcc gtg ggc ctc tgc ttc tac ctg ggc act acc ttt gca gga Gly Gly Ala Val Gly Leu Cys Phe Tyr Leu Gly Thr Thr Phe Ala Gly 180 185 190	576
gcc atg tac atc ctg ggc acc atc gaa atc ctg ctg gct tac ctc ttc Ala Met Tyr Ile Leu Gly Thr Ile Glu Ile Leu Leu Ala Tyr Leu Phe 195 200 205	624
cca gcc atg gcc atc ttc aag gca gaa gat gcc agt ggg gag gca gca Pro Ala Met Ala Ile Phe Lys Ala Glu Asp Ala Ser Gly Glu Ala Ala 210 215 220	672
gcc atg ctg aac aac atg cgt gtt tac ggc acc tgt gtg ctc acc tgc Ala Met Leu Asn Asn Met Arg Val Tyr Gly Thr Cys Val Leu Thr Cys 225 230 235 240	720
atg gcc act gtg gtg ttt gtg ggt gtc aag tat gtc aac aag ttt gcc Met Ala Thr Val Val Phe Val Gly Val Lys Tyr Val Asn Lys Phe Ala 245 250 255	768
ctt gtc ttc ctg ggt tgt gtc atc ctc tcc atc ctg gcc atc tat gct Leu Val Phe Leu Gly Cys Val Ile Leu Ser Ile Leu Ala Ile Tyr Ala 260 265 270	816
ggg gtc atc aag tct gcc ttc gac cca ccc aac ttc ccg atc tgc ctc Gly Val Ile Lys Ser Ala Phe Asp Pro Pro Asn Phe Pro Ile Cys Leu 275 280 285	864
ctg ggt aac cgc acg ctg tct cgc cat ggc ttt gat gtc tgt gcc aag Leu Gly Asn Arg Thr Leu Ser Arg His Gly Phe Asp Val Cys Ala Lys 290 295 300	912
ctg gct tgg gaa gga aat gag acg gtg acc aca cgg cta tgg ggc ctt Leu Ala Trp Glu Gly Asn Glu Thr Val Thr Thr Arg Leu Trp Gly Leu 305 310 315 320	960
ttc tgc tcc tct cgc ttc ctc aac gcc acc tgt gat gaa tac ttc acc Phe Cys Ser Ser Arg Phe Leu Asn Ala Thr Cys Asp Glu Tyr Phe Thr 325 330 335	1008

3/36

cga aac aat gtc aca gag atc cag ggc atc cct ggt gct gcc agt ggc Arg Asn Asn Val Thr Glu Ile Gln Gly Ile Pro Gly Ala Ala Ser Gly 340 345 350	1056
ctc atc aaa gag aac ctc tgg agc tcc tac ctg acc aag ggc gtg att Leu Ile Lys Glu Asn Leu Trp Ser Ser Tyr Leu Thr Lys Gly Val Ile 355 360 365	1104
gtg gag agg agt ggg atg acc tcg gtg ggc ctg gcc gat ggc act cct Val Glu Arg Ser Gly Met Thr Ser Val Gly Leu Ala Asp Gly Thr Pro 370 375 380	1152
atc gac atg gac cac cct tat gtc ttc agt gat atg acc tcc tac ttc Ile Asp Met Asp His Pro Tyr Val Phe Ser Asp Met Thr Ser Tyr Phe 385 390 395 400	1200
acc ctg ctg gtt ggc atc tac ttc ccc tca gtc aca ggg atc atg gct Thr Leu Leu Val Gly Ile Tyr Phe Pro Ser Val Thr Gly Ile Met Ala 405 410 415	1248
ggt tct aac cgc tct ggg gac ctg agg gat gcc cag aag tca atc ccc Gly Ser Asn Arg Ser Gly Asp Leu Arg Asp Ala Gln Lys Ser Ile Pro 420 425 430	1296
act ggc acc atc ctg gcc atc gcc acc acc tct gct gtc tac atc agc Thr Gly Thr Ile Leu Ala Ile Ala Thr Thr Ser Ala Val Tyr Ile Ser 435 440 445	1344
tcc gtt gtt ctg ttt ggg gcc tgc att gag ggg gtc gtc ctg cgg gac Ser Val Val Leu Phe Gly Ala Cys Ile Glu Gly Val Val Leu Arg Asp 450 455 460	1392
aag ttt ggc gaa gct gtg aat ggc aac ctc gtg gtg ggc act ctg gcc Lys Phe Gly Glu Ala Val Asn Gly Asn Leu Val Val Gly Thr Leu Ala 465 470 475 480	1440
tgg cca tct cca tgg gta att gtc atc gga tcc ttc ttc tcc acc tgt Trp Pro Ser Pro Trp Val Ile Val Ile Gly Ser Phe Phe Ser Thr Cys 485 490 495	1488
ggg gct ggg ctg cag agc ctc acg ggg gcc cca cgc ctg ctg cag gcc Gly Ala Gly Leu Gln Ser Leu Thr Gly Ala Pro Arg Leu Leu Gln Ala 500 505 510	1536
atc tcg agg gat ggc att gtg ccc ttc ctg cag gtc ttt ggc cat ggc Ile Ser Arg Asp Gly Ile Val Pro Phe Leu Gln Val Phe Gly His Gly 515 520 525	1584
aag gcc aat gga gag ccg acc tgg gcc ctg ctc ctg act gcc tgc atc Lys Ala Asn Gly Glu Pro Thr Trp Ala Leu Leu Leu Thr Ala Cys Ile 530 535 540	1632
tgc gag att ggc atc ctc att gca tcc ctc gac gag gtg gcc ccc atc Cys Glu Ile Gly Ile Leu Ile Ala Ser Leu Asp Glu Val Ala Pro Ile 545 550 555 560	1680

ctc tct atg ttc ttc ctg atg tgc tac atg ttt gtg aat ctg gcc tgt	1728
Leu Ser Met Phe Phe Leu Met Cys Tyr Met Phe Val Asn Leu Ala Cys	
565 570 575	
gca gtg cag acg ctg ctg agg aca ccc aac tgg agg cca cgc ttt cga	1776
Ala Val Gln Thr Leu Leu Arg Thr Pro Asn Trp Arg Pro Arg Phe Arg	
580 585 590	
tat tac cac tgg acc ctc tcc ttc ctg ggc atg agc ctc tgc ctg gcc	1824
Tyr Tyr His Trp Thr Leu Ser Phe Leu Gly Met Ser Leu Cys Leu Ala	
595 600 605	
ctc atg ttc atc tgc tcc tgg tat tat gca ctg gta gcc atg ctc att	1872
Leu Met Phe Ile Cys Ser Trp Tyr Tyr Ala Leu Val Ala Met Leu Ile	
610 615 620	
gct gga ctc atc tac aag tac att gag tac cgt ggg gca gag aag gag	1920
Ala Gly Leu Ile Tyr Lys Tyr Ile Glu Tyr Arg Gly Ala Glu Lys Glu	
625 630 635 640	
tgg ggc gat ggg ata cga ggt ctg tct ctc agt gcg gct cgc tat gcc	1968
Trp Gly Asp Gly Ile Arg Gly Leu Ser Leu Ser Ala Ala Arg Tyr Ala	
645 650 655	
ctc tta cgc ctg gag gaa ggg ccc cca cac acc aag aac tgg agg cca	2016
Leu Leu Arg Leu Glu Glu Gly Pro Pro His Thr Lys Asn Trp Arg Pro	
660 665 670	
cag ctg ctg gtg ctg gtg cgt gtg gac caa gac cag aat gtg gtg cac	2064
Gln Leu Leu Val Leu Val Arg Val Asp Gln Asp Gln Asn Val Val His	
675 680 685	
ccc cag ctg ctc tca ctg acc tcc cag ctg aag gca ggg aag ggc ctg	2112
Pro Gln Leu Leu Ser Leu Thr Ser Gln Leu Lys Ala Gly Lys Gly Leu	
690 695 700	
acc atc gtg ggc tct gtc ctt gag ggc acc ttt ctg gaa aat cat cca	2160
Thr Ile Val Gly Ser Val Leu Glu Gly Thr Phe Leu Glu Asn His Pro	
705 710 715 720	
cag gcc cag cgg gca gaa gag tct atc agg cgc ctg atg gag gca gag	2208
Gln Ala Gln Arg Ala Glu Glu Ser Ile Arg Arg Leu Met Glu Ala Glu	
725 730 735	
aag gtg aag ggc ttc tgc cag gtg gtg atc tcc tcc aac ttg cgt gat	2256
Lys Val Lys Gly Phe Cys Gln Val Val Ile Ser Ser Asn Leu Arg Asp	
740 745 750	
ggc gtg tcc cat ctg atc cag tcc ggg ggc ctc ggg ggg ctg cag cac	2304
Gly Val Ser His Leu Ile Gln Ser Gly Gly Leu Gly Gly Leu Gln His	
755 760 765	
aac act gtg ctt gtt ggc tgg ccc cgc aac tgg cgc cag aag gaa gat	2352
Asn Thr Val Leu Val Gly Trp Pro Arg Asn Trp Arg Gln Lys Glu Asp	
770 775 780	

5/36

cat cag acg tgg agg aac ttc att gag ctg gtc cgg gaa acc aca gct His Gln Thr Trp Arg Asn Phe Ile Glu Leu Val Arg Glu Thr Thr Ala 785 790 795 800	2400
ggc cac tta gcc ctg ctg gtc acc aag aac gtt tcc atg ttt cct ggg Gly His Leu Ala Leu Leu Val Thr Lys Asn Val Ser Met Phe Pro Gly 805 810 815	2448
aac cct gag cgc ttc tct gag ggc agc atc gac gtt tgg tgg att gtg Asn Pro Glu Arg Phe Ser Glu Gly Ser Ile Asp Val Trp Trp Ile Val 820 825 830	2496
cac gat gga ggc atg ctc atg ctg ctg ccc ttc ctg ctg cgg cac cac His Asp Gly Gly Met Leu Met Leu Leu Pro Phe Leu Leu Arg His His 835 840 845	2544
aag gtc tgg cgg aag tgc aag atg cgt atc ttc act gtg gcc cag atg Lys Val Trp Arg Lys Cys Lys Met Arg Ile Phe Thr Val Ala Gln Met 850 855 860	2592
gat gac aat agc atc cag atg aag aag gat ctg acc aca ttt ctg tat Asp Asp Asn Ser Ile Gln Met Lys Lys Asp Leu Thr Thr Phe Leu Tyr 865 870 875 880	2640
cat tta cgc atc act gcg gag gtc gag gtg gtg gag atg cat gag agc His Leu Arg Ile Thr Ala Glu Val Glu Val Val Glu Met His Glu Ser 885 890 895	2688
gac atc tca gct tac acc tat gag aag acg ttg gtg atg gag cag cgt Asp Ile Ser Ala Tyr Thr Tyr Glu Lys Thr Leu Val Met Glu Gln Arg 900 905 910	2736
tcc cag atc ctc aaa cag atg cat tta acc aag aat gag cgg gag cgg Ser Gln Ile Leu Lys Gln Met His Leu Thr Lys Asn Glu Arg Glu Arg 915 920 925	2784
gag atc cag agt atc aca gat gag tca cga ggc tca atc cgg aga aag Glu Ile Gln Ser Ile Thr Asp Glu Ser Arg Gly Ser Ile Arg Arg Lys 930 935 940	2832
aat cca gcc aac acg cgg ctc cgc ctg aac gtc cca gaa gag acg gct Asn Pro Ala Asn Thr Arg Leu Arg Leu Asn Val Pro Glu Glu Thr Ala 945 950 955 960	2880
ggg gac agt gaa gag aag cca gag gag gag gtg cag ctg atc cac gat Gly Asp Ser Glu Glu Lys Pro Glu Glu Glu Val Gln Leu Ile His Asp 965 970 975	2928
cag agt gct ccc agc tgc ccc agc agc tcc ccg tcc cca ggg gag gag Gln Ser Ala Pro Ser Cys Pro Ser Ser Ser Pro Ser Pro Gly Glu Glu 980 985 990	2976
cct gag ggg gaa ggg gag aca gat ccg gag aag gtg cat ctc acc tgg Pro Glu Gly Glu Gly Glu Thr Asp Pro Glu Lys Val His Leu Thr Trp 995 1000 1005	3024

6/36

acc aag gac aag tcg gtg gca gag aag aat aag ggc ccc agt cct	3069
Thr Lys Asp Lys Ser Val Ala Glu Lys Asn Lys Gly Pro Ser Pro	
1010 1015 1020	
gtc tcc tct gag ggc atc aag gac ttc ttc agc atg aag ccg gag	3114
Val Ser Ser Glu Gly Ile Lys Asp Phe Phe Ser Met Lys Pro Glu	
1025 1030 1035	
tgg gag aac ttg aac cag tcc aac gtg cgg cgc atg cac acg gcc	3159
Trp Glu Asn Leu Asn Gln Ser Asn Val Arg Arg Met His Thr Ala	
1040 1045 1050	
gtg cgg ctg aac gag gtc atc gtg aag aaa tcc cgg gac gcc aag	3204
Val Arg Leu Asn Glu Val Ile Val Lys Lys Ser Arg Asp Ala Lys	
1055 1060 1065	
ctt gtt ttg ctc aac atg cct ggg cct ccc cgc aac cgc aat ggt	3249
Leu Val Leu Leu Asn Met Pro Gly Pro Pro Arg Asn Arg Asn Gly	
1070 1075 1080	
gat gaa aac tac atg gag ttt ctc gag gtc ctc aca gag cac ctg	3294
Asp Glu Asn Tyr Met Glu Phe Leu Glu Val Leu Thr Glu His Leu	
1085 1090 1095	
gac cgg gtg atg ctg gtc cgc ggt ggt ggc cga gag gtc atc acc	3339
Asp Arg Val Met Leu Val Arg Gly Gly Gly Arg Glu Val Ile Thr	
1100 1105 1110	
atc tac tcc tga gaaccaggtc ctgccacccg ggcccagagcg cgcccggccc	3391
Ile Tyr Ser	
1115	
gcgggtccgg agccctcgcc gcgccccccg ccgctgtcac cgtttacata cagaccctgt	3451
gcccggtgcc tggcccotta ccccgctgcc tgaagcccgg aggccacgcc tgttggggct	3511
gattcggaga gggcgccccg ccgcgagag accagagctc ctcaagtcca gtttggcccc	3571
tgggtcttcg ctgccctttt tctaagcccg gcctcgtctc gccggaggag acgctgcaat	3631
aaaggttggg agaaggcgcg gaaaggagag gagctggggc cttggggacc ccaggtagt	3691
ccatgcggcc cattcctccc ctcccactc ccgcccgggt cctcgctctg cgctcctccg	3751
gcgctgctcc ctggctcccg gcggcccga ggcccgcggg gtgggaaggc cgcgcttgcc	3811
gtctccgccg ccccttctcg ccgagccgtg gggcggggc ggccgagcct atacatagt	3871
tacaggagac atcgctgta tttttaacgt ccccatatct atgtgactag aagcgcaaca	3931
gacttctcgc catagtcgag ctctcccgtt gggggcactg cggggaggcg aggcctcggg	3991
aagctgaatt ttcttgacg tccaagagtt tgagagcgaa agtgctttag gccagggcg	4051
gggtcgtggc ctcgttccct cgacaacctc gtctgctct cgctcttcg ccccttcgc	4111
gcgcccttgg ctcccaccc tcctctccag tccttttcg agatgaggtg agacaagggt	4171

ccaactttttc ctggattcgc ctcccagcgg acgtgagctt ccactgcggc tgcagagacg 4231
 cgagcaacct cttctcatcg gctcttatgc aagttggggc caggataggg gaggggtgct 4291
 cctcaagagg aagaaaccga gagggccgcg cccaccgag gaagccccgc cccggtgcct 4351
 tcgctgggga gcaggcgtct ctctcagtc ggcttgctgc ctgctccccg tatcccatgg 4411
 ctctctgcca aagactgaaa ttgtggagct ggagggcgcc ccctccccgg agtttcctcc 4471
 ctgggacaag tgagggagga gggggccgat tctggtttag gggccggacc cactgagagg 4531
 cccagagacc gcccgatgatg ttctctcccc gtcccatctt ggcagctcct gtctcgctg 4591
 agggaccocag ccgccttctc cgtgctctgg ggccgggcct cgctgcttag cagcggcctc 4651
 tagctcogtc tcccggggac ctgggcctga gggagggctg gagtcagcac gcgctttgtc 4711
 cttagcgctt gtctgctctc ctctaactag gaccagggc ctttggttcc cccagctcat 4771
 ccttgccctt tccgctccac cagcctggtc tgaggcgtgc tctgtcctta gagaaggcgc 4831
 ggtggccggg ttcccttccc ctagggcaca ttactaaggg ggtcaggcac tgcattgctg 4891
 ttccagcacc atctgggact gggtagagta cctccagccc cagggccctg acctgcgcac 4951
 ctagcttgac atctcagca cctcccagag ctggcgccac tgagtaatcc ggacctcacc 5011
 acctcttttc ctttgagccc aaggcagagc tagagctgga gctggcgcca cccagacagc 5071
 gtcagggtgtg gctggggtag gtttgagagt ctgccagtta cgccaagtcc cctctgagat 5131
 tcgatcaggg gactggatag attctttcag gtactcaatc aggaagctgg aggtgttaga 5191
 caccagcccc ctgcctcctt cagtagacct ccctctgaac accacagcca ggtcctgcct 5251
 tctgggggccc tgaatatctc agagctgatg tgatgggctg tgcagaaggg ggctgtatca 5311
 acatcaatta gggaaccaa gttgcactat ctggggccag attgtctggt tggcaagagc 5371
 aaagtttccg ttgatgaaac agacatccca caacaaaaac ccaagttttc tgtgctacat 5431
 gtgcaatatt tgttatgaat gttatcacia gtcattcatt aagttatctt tataatcact 5491
 gtagttagat gtttcatgtc cattcaagtg acttttattc tgagtgcaat atttcaatag 5551
 ccttgtagtg ataactagtg ttgcttttgt ttagatgata tatgtgcagg gcaatgcaat 5611
 gaagttgaaa ccccttggtg ataggagagg ttgcaaacca aatcaagagt atttattact 5671
 attactgcta ttattattag gcctgccttt aattttcagt gtaagtgttc agtatgccgc 5731
 atcctgcctc agtattgatc ttgtgttctt tgtgccaata tgaaaaggag agggttggtt 5791
 ctttccttta ttgttgaaat ctcccattta atgctttatg gcttttactg tattactttt 5851

8/36

ttagactccc gtctgcacaa aatgcaataa aaataatttt attataaaaa aaaaaa

<210> 2
 <211> 1116
 <212> PRT
 <213> Homo sapiens

<400> 2

Met Pro Asn Asn Leu Thr Asp Cys Glu Asp Gly Asp Gly Gly Ala Asn
 1 5 10 15

Pro Gly Asp Gly Asn Pro Lys Glu Ser Ser Pro Phe Ile Asn Ser Thr
 20 25 30

Asp Thr Glu Lys Gly Lys Glu Tyr Asp Gly Lys Asn Met Ala Leu Phe
 35 40 45

Glu Glu Glu Met Asp Thr Ser Pro Met Val Ser Ser Leu Leu Ser Gly
 50 55 60

Leu Ala Asn Tyr Thr Asn Leu Pro Gln Gly Ser Arg Glu His Glu Glu
 65 70 75 80

Ala Glu Asn Asn Glu Gly Gly Lys Lys Lys Pro Val Gln Ala Pro Arg
 85 90 95

Met Gly Thr Phe Met Gly Val Tyr Leu Pro Cys Leu Gln Asn Ile Phe
 100 105 110

Gly Val Ile Leu Phe Leu Arg Leu Thr Trp Val Val Gly Ile Ala Gly
 115 120 125

Ile Met Glu Ser Phe Cys Met Val Phe Ile Cys Cys Ser Cys Thr Met
 130 135 140

Leu Thr Ala Ile Ser Met Ser Ala Ile Ala Thr Asn Gly Val Val Pro
 145 150 155 160

Ala Gly Gly Ser Tyr Tyr Met Ile Ser Arg Ser Leu Gly Pro Glu Phe
 165 170 175

Gly Gly Ala Val Gly Leu Cys Phe Tyr Leu Gly Thr Thr Phe Ala Gly
 180 185 190

9/36

Ala Met Tyr Ile Leu Gly Thr Ile Glu Ile Leu Leu Ala Tyr Leu Phe
 195 200 205

Pro Ala Met Ala Ile Phe Lys Ala Glu Asp Ala Ser Gly Glu Ala Ala
 210 215 220

Ala Met Leu Asn Asn Met Arg Val Tyr Gly Thr Cys Val Leu Thr Cys
 225 230 235 240

Met Ala Thr Val Val Phe Val Gly Val Lys Tyr Val Asn Lys Phe Ala
 245 250 255

Leu Val Phe Leu Gly Cys Val Ile Leu Ser Ile Leu Ala Ile Tyr Ala
 260 265 270

Gly Val Ile Lys Ser Ala Phe Asp Pro Pro Asn Phe Pro Ile Cys Leu
 275 280 285

Leu Gly Asn Arg Thr Leu Ser Arg His Gly Phe Asp Val Cys Ala Lys
 290 295 300

Leu Ala Trp Glu Gly Asn Glu Thr Val Thr Thr Arg Leu Trp Gly Leu
 305 310 315 320

Phe Cys Ser Ser Arg Phe Leu Asn Ala Thr Cys Asp Glu Tyr Phe Thr
 325 330 335

Arg Asn Asn Val Thr Glu Ile Gln Gly Ile Pro Gly Ala Ala Ser Gly
 340 345 350

Leu Ile Lys Glu Asn Leu Trp Ser Ser Tyr Leu Thr Lys Gly Val Ile
 355 360 365

Val Glu Arg Ser Gly Met Thr Ser Val Gly Leu Ala Asp Gly Thr Pro
 370 375 380

Ile Asp Met Asp His Pro Tyr Val Phe Ser Asp Met Thr Ser Tyr Phe
 385 390 395 400

Thr Leu Leu Val Gly Ile Tyr Phe Pro Ser Val Thr Gly Ile Met Ala
 405 410 415

10/36

Gly Ser Asn Arg Ser Gly Asp Leu Arg Asp Ala Gln Lys Ser Ile Pro
 420 425 430

Thr Gly Thr Ile Leu Ala Ile Ala Thr Thr Ser Ala Val Tyr Ile Ser
 435 440 445

Ser Val Val Leu Phe Gly Ala Cys Ile Glu Gly Val Val Leu Arg Asp
 450 455 460

Lys Phe Gly Glu Ala Val Asn Gly Asn Leu Val Val Gly Thr Leu Ala
 465 470 475 480

Trp Pro Ser Pro Trp Val Ile Val Ile Gly Ser Phe Phe Ser Thr Cys
 485 490 495

Gly Ala Gly Leu Gln Ser Leu Thr Gly Ala Pro Arg Leu Leu Gln Ala
 500 505 510

Ile Ser Arg Asp Gly Ile Val Pro Phe Leu Gln Val Phe Gly His Gly
 515 520 525

Lys Ala Asn Gly Glu Pro Thr Trp Ala Leu Leu Leu Thr Ala Cys Ile
 530 535 540

Cys Glu Ile Gly Ile Leu Ile Ala Ser Leu Asp Glu Val Ala Pro Ile
 545 550 555 560

Leu Ser Met Phe Phe Leu Met Cys Tyr Met Phe Val Asn Leu Ala Cys
 565 570 575

Ala Val Gln Thr Leu Leu Arg Thr Pro Asn Trp Arg Pro Arg Phe Arg
 580 585 590

Tyr Tyr His Trp Thr Leu Ser Phe Leu Gly Met Ser Leu Cys Leu Ala
 595 600 605

Leu Met Phe Ile Cys Ser Trp Tyr Tyr Ala Leu Val Ala Met Leu Ile
 610 615 620

Ala Gly Leu Ile Tyr Lys Tyr Ile Glu Tyr Arg Gly Ala Glu Lys Glu
 625 630 635 640

11/36

Trp Gly Asp Gly Ile Arg Gly Leu Ser Leu Ser Ala Ala Arg Tyr Ala
 645 650 655

Leu Leu Arg Leu Glu Glu Gly Pro Pro His Thr Lys Asn Trp Arg Pro
 660 665 670

Gln Leu Leu Val Leu Val Arg Val Asp Gln Asp Gln Asn Val Val His
 675 680 685

Pro Gln Leu Leu Ser Leu Thr Ser Gln Leu Lys Ala Gly Lys Gly Leu
 690 695 700

Thr Ile Val Gly Ser Val Leu Glu Gly Thr Phe Leu Glu Asn His Pro
 705 710 715 720

Gln Ala Gln Arg Ala Glu Glu Ser Ile Arg Arg Leu Met Glu Ala Glu
 725 730 735

Lys Val Lys Gly Phe Cys Gln Val Val Ile Ser Ser Asn Leu Arg Asp
 740 745 750

Gly Val Ser His Leu Ile Gln Ser Gly Gly Leu Gly Gly Leu Gln His
 755 760 765

Asn Thr Val Leu Val Gly Trp Pro Arg Asn Trp Arg Gln Lys Glu Asp
 770 775 780

His Gln Thr Trp Arg Asn Phe Ile Glu Leu Val Arg Glu Thr Thr Ala
 785 790 795 800

Gly His Leu Ala Leu Leu Val Thr Lys Asn Val Ser Met Phe Pro Gly
 805 810 815

Asn Pro Glu Arg Phe Ser Glu Gly Ser Ile Asp Val Trp Trp Ile Val
 820 825 830

His Asp Gly Gly Met Leu Met Leu Leu Pro Phe Leu Leu Arg His His
 835 840 845

Lys Val Trp Arg Lys Cys Lys Met Arg Ile Phe Thr Val Ala Gln Met
 850 855 860

12/36

Asp Asp Asn Ser Ile Gln Met Lys Lys Asp Leu Thr Thr Phe Leu Tyr
 865 870 875 880

His Leu Arg Ile Thr Ala Glu Val Glu Val Val Glu Met His Glu Ser
 885 890 895

Asp Ile Ser Ala Tyr Thr Tyr Glu Lys Thr Leu Val Met Glu Gln Arg
 900 905 910

Ser Gln Ile Leu Lys Gln Met His Leu Thr Lys Asn Glu Arg Glu Arg
 915 920 925

Glu Ile Gln Ser Ile Thr Asp Glu Ser Arg Gly Ser Ile Arg Arg Lys
 930 935 940

Asn Pro Ala Asn Thr Arg Leu Arg Leu Asn Val Pro Glu Glu Thr Ala
 945 950 955 960

Gly Asp Ser Glu Glu Lys Pro Glu Glu Glu Val Gln Leu Ile His Asp
 965 970 975

Gln Ser Ala Pro Ser Cys Pro Ser Ser Ser Pro Ser Pro Gly Glu Glu
 980 985 990

Pro Glu Gly Glu Gly Glu Thr Asp Pro Glu Lys Val His Leu Thr Trp
 995 1000 1005

Thr Lys Asp Lys Ser Val Ala Glu Lys Asn Lys Gly Pro Ser Pro
 1010 1015 1020

Val Ser Ser Glu Gly Ile Lys Asp Phe Phe Ser Met Lys Pro Glu
 1025 1030 1035

Trp Glu Asn Leu Asn Gln Ser Asn Val Arg Arg Met His Thr Ala
 1040 1045 1050

Val Arg Leu Asn Glu Val Ile Val Lys Lys Ser Arg Asp Ala Lys
 1055 1060 1065

Leu Val Leu Leu Asn Met Pro Gly Pro Pro Arg Asn Arg Asn Gly
 1070 1075 1080

13/36

Asp Glu Asn Tyr Met Glu Phe Leu Glu Val Leu Thr Glu His Leu
 1085 1090 1095

Asp Arg Val Met Leu Val Arg Gly Gly Gly Arg Glu Val Ile Thr
 1100 1105 1110

Ile Tyr Ser
 1115

<210> 3
 <211> 3656
 <212> DNA
 <213> Mus musculus

<220>
 <221> CDS
 <222> (86)..(3433)

<400> 3
 gagcaagcga gcgagcggag aaggcgggca gaggggcgcg ggcgaagcgg cgcagccatc 60
 ccgagcccgg cgccgcgcag ccacc atg ctc aac aac ctg acg gac tgc gag 112
 Met Leu Asn Asn Leu Thr Asp Cys Glu
 1 5
 gac ggc gat ggg gga gcc aac ccc ggt gat ggc aac ccc aaa gag agc 160
 Asp Gly Asp Gly Gly Ala Asn Pro Gly Asp Gly Asn Pro Lys Glu Ser
 10 15 20 25
 agt ccc ttc atc aac agc acg gac acg gag aag ggc aga gag tac gat 208
 Ser Pro Phe Ile Asn Ser Thr Asp Thr Glu Lys Gly Arg Glu Tyr Asp
 30 35 40
 ggc agg aac atg gcc ctg ttt gag gag gag atg gac acc agc ccc atg 256
 Gly Arg Asn Met Ala Leu Phe Glu Glu Glu Met Asp Thr Ser Pro Met
 45 50 55
 gta tcc tcc ctg ctc agt ggg ctg gcc aac tac acc aac cta ccc cag 304
 Val Ser Ser Leu Leu Ser Gly Leu Ala Asn Tyr Thr Asn Leu Pro Gln
 60 65 70
 gga agt aga gag cat gaa gaa gca gaa aat aat gag ggt gga aaa aag 352
 Gly Ser Arg Glu His Glu Glu Ala Glu Asn Asn Glu Gly Gly Lys Lys
 75 80 85
 aag ccg gtg cag gct cct cga atg ggc acc ttc atg ggt gtg tac ctg 400
 Lys Pro Val Gln Ala Pro Arg Met Gly Thr Phe Met Gly Val Tyr Leu
 90 95 100 105
 ccg tgc ctg cag aac atc ttt ggt gtc atc ctc ttc ctg cgg ctc acg 448
 Pro Cys Leu Gln Asn Ile Phe Gly Val Ile Leu Phe Leu Arg Leu Thr
 110 115 120

14/36

tgg gtg gtg ggc atc gcg ggc atc atg gag tcc ttc tgt atg gtc ttc'	496
Trp Val Val Gly Ile Ala Gly Ile Met Glu Ser Phe Cys Met Val Phe	
125 130 135	
att tgc tgc tcc tgt acg atg ctc aca gcc att tcc atg agt gca atc	544
Ile Cys Cys Ser Cys Thr Met Leu Thr Ala Ile Ser Met Ser Ala Ile	
140 145 150	
gca acc aat ggt gtt gtg cct gct ggt ggc tcg tac tac atg att tcc	592
Ala Thr Asn Gly Val Val Pro Ala Gly Gly Ser Tyr Tyr Met Ile Ser	
155 160 165	
agg tct ctg ggc ccg gag ttt ggg ggc gcc gtg ggc ctc tgc ttc tac	640
Arg Ser Leu Gly Pro Glu Phe Gly Gly Ala Val Gly Leu Cys Phe Tyr	
170 175 180 185	
ctg ggc acc acc ttt gct ggg gct atg tac atc ctt ggc acg atc gag	688
Leu Gly Thr Thr Phe Ala Gly Ala Met Tyr Ile Leu Gly Thr Ile Glu	
190 195 200	
atc ctg ctg gct tat ctc ttc cca gct atg gcc atc ttc aag gca gaa	736
Ile Leu Leu Ala Tyr Leu Phe Pro Ala Met Ala Ile Phe Lys Ala Glu	
205 210 215	
gat gcc agt ggg gag gcg gcc gcc atg ctg aac aac atg cgg gtg tat	784
Asp Ala Ser Gly Glu Ala Ala Ala Met Leu Asn Asn Met Arg Val Tyr	
220 225 230	
ggc acc tgt gtg ctc acc tgc atg gcc acc gtt gtc ttt gtg ggt gtc	832
Gly Thr Cys Val Leu Thr Cys Met Ala Thr Val Val Phe Val Gly Val	
235 240 245	
aag tac gtc aac aag ttt gcc ttg gtc ttc ctg ggt tgc gtc atc ctg	880
Lys Tyr Val Asn Lys Phe Ala Leu Val Phe Leu Gly Cys Val Ile Leu	
250 255 260 265	
tcc atc ctg gcc atc tat gca ggg gtc atc aag tct gcc ttc gac cca	928
Ser Ile Leu Ala Ile Tyr Ala Gly Val Ile Lys Ser Ala Phe Asp Pro	
270 275 280	
ccc aat ttc ccg atc tgc ctc ctg ggg aac cgc acg ctg tct cgc cat	976
Pro Asn Phe Pro Ile Cys Leu Leu Gly Asn Arg Thr Leu Ser Arg His	
285 290 295	
ggc ttt gat gtc tgt gcc aag ctg gct tgg gaa gga aat gag aca gtg	1024
Gly Phe Asp Val Cys Ala Lys Leu Ala Trp Glu Gly Asn Glu Thr Val	
300 305 310	
acc aca cgg ctc tgg ggc ctt ttc tgc tcc tcc cgc ctc ctc aat gcc	1072
Thr Thr Arg Leu Trp Gly Leu Phe Cys Ser Ser Arg Leu Leu Asn Ala	
315 320 325	
acc tgt gat gag tac ttc acc cga aac aat gtc aca gag atc cag ggc	1120
Thr Cys Asp Glu Tyr Phe Thr Arg Asn Asn Val Thr Glu Ile Gln Gly	
330 335 340 345	

15/36

att cct ggt gct gcc agt ggt ctc atc aaa gag aac ctg tgg agt tct	1168
Ile Pro Gly Ala Ala Ser Gly Leu Ile Lys Glu Asn Leu Trp Ser Ser	
350 355 360	
tac ctg acc aaa ggg gtg att gtc gag agg cgt ggg atg ccc tct gtg	1216
Tyr Leu Thr Lys Gly Val Ile Val Glu Arg Arg Gly Met Pro Ser Val	
365 370 375	
ggc ctg gca gac ggt acc ccc gta gac atg gac cac ccc tat gtc ttc	1264
Gly Leu Ala Asp Gly Thr Pro Val Asp Met Asp His Pro Tyr Val Phe	
380 385 390	
agt gat atg acc tcc tac ttc acc ctg ctc gtt ggt atc tac ttc ccc	1312
Ser Asp Met Thr Ser Tyr Phe Thr Leu Leu Val Gly Ile Tyr Phe Pro	
395 400 405	
tca gtc aca ggg atc atg gct ggc tca aac cga tct gga gac ctg cgg	1360
Ser Val Thr Gly Ile Met Ala Gly Ser Asn Arg Ser Gly Asp Leu Arg	
410 415 420 425	
gat gcc cag aag tct atc cct act gga act atc ctg gcc att gct acc	1408
Asp Ala Gln Lys Ser Ile Pro Thr Gly Thr Ile Leu Ala Ile Ala Thr	
430 435 440	
acc tct gct gtc tac atc agc tct gtt gtt ctg ttt gga gcc tgc atc	1456
Thr Ser Ala Val Tyr Ile Ser Ser Val Val Leu Phe Gly Ala Cys Ile	
445 450 455	
gag ggg gtc gtc tta cgg gac aag ttt ggg gaa gct gtg aat ggc aac	1504
Glu Gly Val Val Leu Arg Asp Lys Phe Gly Glu Ala Val Asn Gly Asn	
460 465 470	
ttg gtg gtg ggc acc ctg gcc tgg cct tct ccc tgg gtc atc gtc ata	1552
Leu Val Val Gly Thr Leu Ala Trp Pro Ser Pro Trp Val Ile Val Ile	
475 480 485	
ggc tct ttc ttc tct acc tgt ggg gct gga tta cag agc ctc aca ggg	1600
Gly Ser Phe Phe Ser Thr Cys Gly Ala Gly Leu Gln Ser Leu Thr Gly	
490 495 500 505	
gcc cca cgt ctg ctg cag gcc atc tcc cgg gat ggc ata gtg ccc ttc	1648
Ala Pro Arg Leu Leu Gln Ala Ile Ser Arg Asp Gly Ile Val Pro Phe	
510 515 520	
ctg cag gtc ttt ggc cat ggc aaa gct aat gga gag cca acc tgg gcg	1696
Leu Gln Val Phe Gly His Gly Lys Ala Asn Gly Glu Pro Thr Trp Ala	
525 530 535	
ctg ctg ctg act gcc tgc atc tgt gag atc ggc atc ctc ata gcc tcc	1744
Leu Leu Leu Thr Ala Cys Ile Cys Glu Ile Gly Ile Leu Ile Ala Ser	
540 545 550	
ctg gat gag gtc gcc cct ata ctt tcc atg ttc ttc cta atg tgt tac	1792
Leu Asp Glu Val Ala Pro Ile Leu Ser Met Phe Phe Leu Met Cys Tyr	
555 560 565	

16/36

atg ttt gtg aac ttg gct tgt gcg gtg cag acg ctg ctg agg aca ccc	1840
Met Phe Val Asn Leu Ala Cys Ala Val Gln Thr Leu Leu Arg Thr Pro	
570 575 580 585	
aac tgg agg cca cga ttt cgc tat tac cac tgg act ctc tcc ttc ctg	1888
Asn Trp Arg Pro Arg Phe Arg Tyr Tyr His Trp Thr Leu Ser Phe Leu	
590 595 600	
ggc atg agc ctc tgc ctg gcc ctc atg ttc att tgc tcc tgg tac tac	1936
Gly Met Ser Leu Cys Leu Ala Leu Met Phe Ile Cys Ser Trp Tyr Tyr	
605 610 615	
gca ctg gtg gcc atg ctc att gcc gga ctc att tat aag tac atc gag	1984
Ala Leu Val Ala Met Leu Ile Ala Gly Leu Ile Tyr Lys Tyr Ile Glu	
620 625 630	
tac cgg ggg gcg gag aag gag tgg ggg gat gga atc cga ggc ctg tct	2032
Tyr Arg Gly Ala Glu Lys Glu Trp Gly Asp Gly Ile Arg Gly Leu Ser	
635 640 645	
ctc agt gca gca cgc tat gct ctc ttg cgc ctg gag gaa gga cct ccg	2080
Leu Ser Ala Ala Arg Tyr Ala Leu Leu Arg Leu Glu Glu Gly Pro Pro	
650 655 660 665	
cat acg aag aac tgg agg ccc cag ctg ctg gtg ctg gtg cgt gtg gac	2128
His Thr Lys Asn Trp Arg Pro Gln Leu Leu Val Leu Val Arg Val Asp	
670 675 680	
cag gat cag aac gtg gtg cat ccg cag ctg ctc tcc ctg acc tcc cag	2176
Gln Asp Gln Asn Val Val His Pro Gln Leu Leu Ser Leu Thr Ser Gln	
685 690 695	
ctc aag gca ggg aag ggc ctg acc att gtg ggc tcc gtc ctt gag ggc	2224
Leu Lys Ala Gly Lys Gly Leu Thr Ile Val Gly Ser Val Leu Glu Gly	
700 705 710	
acc ttt ctg gac aac cat cca cag gct cag cgg gca gag gag tct atc	2272
Thr Phe Leu Asp Asn His Pro Gln Ala Gln Arg Ala Glu Glu Ser Ile	
715 720 725	
agg cgc ctg atg gag gct gag aag gtg aag ggc ttc tgc cag gta gtg	2320
Arg Arg Leu Met Glu Ala Glu Lys Val Lys Gly Phe Cys Gln Val Val	
730 735 740 745	
atc tcc tcc aac ctg cgt gat ggt gtg tcc cac ctg atc cag tct ggg	2368
Ile Ser Ser Asn Leu Arg Asp Gly Val Ser His Leu Ile Gln Ser Gly	
750 755 760	
ggc ctc ggg gga ttg caa cac aat acc gtg ctg gtg ggc tgg cct cgc	2416
Gly Leu Gly Gly Leu Gln His Asn Thr Val Leu Val Gly Trp Pro Arg	
765 770 775	
aac tgg agg cag aag gag gat cat cag aca tgg agg aac ttc atc gaa	2464
Asn Trp Arg Gln Lys Glu Asp His Gln Thr Trp Arg Asn Phe Ile Glu	
780 785 790	

17/36

ctg gtc cgg gaa act aca gcc ggc cac ctc gcc ctg ctg gtc acc aag Leu Val Arg Glu Thr Thr Ala Gly His Leu Ala Leu Leu Val Thr Lys 795 800 805	2512
aat gtt tcc atg ttt ccc ggg aac cct gag cgc ttc tcg gag ggc agc Asn Val Ser Met Phe Pro Gly Asn Pro Glu Arg Phe Ser Glu Gly Ser 810 815 820 825	2560
att gac gtg tgg tgg att gtg cac gac ggg ggc atg ctc atg ctg ctg Ile Asp Val Trp Trp Ile Val His Asp Gly Gly Met Leu Met Leu Leu 830 835 840	2608
ccc ttc ctg ctg cga cac cac aag gtc tgg agg aaa tgc aaa atg cgg Pro Phe Leu Leu Arg His His Lys Val Trp Arg Lys Cys Lys Met Arg 845 850 855	2656
atc ttc acc gtg gcc cag atg gac gat aac agt atc cag atg aag aag Ile Phe Thr Val Ala Gln Met Asp Asp Asn Ser Ile Gln Met Lys Lys 860 865 870	2704
gac ctg acc acg ttt ctg tac cac tta cgc att act gca gag gtg gag Asp Leu Thr Thr Phe Leu Tyr His Leu Arg Ile Thr Ala Glu Val Glu 875 880 885	2752
gtg gtg gag atg cat gag agc gac atc tcg gca tac acc tac gag aag Val Val Glu Met His Glu Ser Asp Ile Ser Ala Tyr Thr Tyr Glu Lys 890 895 900 905	2800
aca tta gta atg gag caa cga tct cag atc ctc aaa cag atg cac ctc Thr Leu Val Met Glu Gln Arg Ser Gln Ile Leu Lys Gln Met His Leu 910 915 920	2848
acc aag aac gag cgg gaa cgg gag atc cag agc atc aca gac gag tct Thr Lys Asn Glu Arg Glu Arg Glu Ile Gln Ser Ile Thr Asp Glu Ser 925 930 935	2896
cgg ggc tcc att cgg agg aag aat cca gcc aac ccc cgg ctc cgc ctc Arg Gly Ser Ile Arg Arg Lys Asn Pro Ala Asn Pro Arg Leu Arg Leu 940 945 950	2944
aat gtt ccc gaa gag aca gcg tgt gac aat gag gag aag cca gag gag Asn Val Pro Glu Glu Thr Ala Cys Asp Asn Glu Glu Lys Pro Glu Glu 955 960 965	2992
gag gtg cag ctg atc cat gac cag agt gct ccc agc tgc cct agc agc Glu Val Gln Leu Ile His Asp Gln Ser Ala Pro Ser Cys Pro Ser Ser 970 975 980 985	3040
tcg cca tct cca ggg gag gag ccc gag ggg gag agg gag aca gac cca Ser Pro Ser Pro Gly Glu Glu Pro Glu Gly Glu Arg Glu Thr Asp Pro 990 995 1000	3088

18/36

gag gtg cat ctt acc tgg acc aag gat aag tca gtg gca gag aag 3133
 Glu Val His Leu Thr Trp Thr Lys Asp Lys Ser Val Ala Glu Lys
 1005 1010 1015
 aat aaa ggc ccc agt ccc gtc tcc tcc gag ggc atc aag gac ttc 3178
 Asn Lys Gly Pro Ser Pro Val Ser Ser Glu Gly Ile Lys Asp Phe
 1020 1025 1030
 ttc agc atg aag ccg gag tgg gaa aac ttg aac cag tcc aat gta 3223
 Phe Ser Met Lys Pro Glu Trp Glu Asn Leu Asn Gln Ser Asn Val
 1035 1040 1045
 cgg cgc atg cac aca gct gtg cgg ctg aac gag gtc atc gtg aat 3268
 Arg Arg Met His Thr Ala Val Arg Leu Asn Glu Val Ile Val Asn
 1050 1055 1060
 aaa tct cgg gat gcc aag cta gtt ttg ctc aac atg ccc ggg cct 3313
 Lys Ser Arg Asp Ala Lys Leu Val Leu Leu Asn Met Pro Gly Pro
 1065 1070 1075
 ccc cgc aac cgc aat ggg gat gaa aac tac atg gaa ttc ttg gag 3358
 Pro Arg Asn Arg Asn Gly Asp Glu Asn Tyr Met Glu Phe Leu Glu
 1080 1085 1090
 gtc ctc act gag caa ctg gac cgg gtg atg ctg gtc cgc ggt ggc 3403
 Val Leu Thr Glu Gln Leu Asp Arg Val Met Leu Val Arg Gly Gly
 1095 1100 1105
 ggc cga gag gtc atc acc atc tac tcc tga aggccaggac ctgccactcc 3453
 Gly Arg Glu Val Ile Thr Ile Tyr Ser
 1110 1115
 ggcccagagcg cgcccggccc gcgcccccca gagccctcgc cgcgcctccc cgccgctgtc 3513
 accgtttaca taagaccag ttgcccattgc cctggcccct ttccttcccg ctgcctgcag 3573
 ccctgaggcc ttgcccgtcg gggctgacct gcagggcggc ccgtgaggcc ccttttctga 3633
 gcctggcctc gcccgcggc agc 3656

<210> 4
 <211> 1115
 <212> PRT
 <213> Mus musculus

<400> 4

Met Leu Asn Asn Leu Thr Asp Cys Glu Asp Gly Asp Gly Gly Ala Asn
 1 5 10 15

Pro Gly Asp Gly Asn Pro Lys Glu Ser Ser Pro Phe Ile Asn Ser Thr
 20 25 30

19/36

Asp Thr Glu Lys Gly Arg Glu Tyr Asp Gly Arg Asn Met Ala Leu Phe
 35 40 45

Glu Glu Glu Met Asp Thr Ser Pro Met Val Ser Ser Leu Leu Ser Gly
 50 55 60

Leu Ala Asn Tyr Thr Asn Leu Pro Gln Gly Ser Arg Glu His Glu Glu
 65 70 75 80

Ala Glu Asn Asn Glu Gly Gly Lys Lys Lys Pro Val Gln Ala Pro Arg
 85 90 95

Met Gly Thr Phe Met Gly Val Tyr Leu Pro Cys Leu Gln Asn Ile Phe
 100 105 110

Gly Val Ile Leu Phe Leu Arg Leu Thr Trp Val Val Gly Ile Ala Gly
 115 120 125

Ile Met Glu Ser Phe Cys Met Val Phe Ile Cys Cys Ser Cys Thr Met
 130 135 140

Leu Thr Ala Ile Ser Met Ser Ala Ile Ala Thr Asn Gly Val Val Pro
 145 150 155 160

Ala Gly Gly Ser Tyr Tyr Met Ile Ser Arg Ser Leu Gly Pro Glu Phe
 165 170 175

Gly Gly Ala Val Gly Leu Cys Phe Tyr Leu Gly Thr Thr Phe Ala Gly
 180 185 190

Ala Met Tyr Ile Leu Gly Thr Ile Glu Ile Leu Leu Ala Tyr Leu Phe
 195 200 205

Pro Ala Met Ala Ile Phe Lys Ala Glu Asp Ala Ser Gly Glu Ala Ala
 210 215 220

Ala Met Leu Asn Asn Met Arg Val Tyr Gly Thr Cys Val Leu Thr Cys
 225 230 235 240

Met Ala Thr Val Val Phe Val Gly Val Lys Tyr Val Asn Lys Phe Ala
 245 250 255

20/36

Leu Val Phe Leu Gly Cys Val Ile Leu Ser Ile Leu Ala Ile Tyr Ala
 260 265 270

Gly Val Ile Lys Ser Ala Phe Asp Pro Pro Asn Phe Pro Ile Cys Leu
 275 280 285

Leu Gly Asn Arg Thr Leu Ser Arg His Gly Phe Asp Val Cys Ala Lys
 290 295 300

Leu Ala Trp Glu Gly Asn Glu Thr Val Thr Thr Arg Leu Trp Gly Leu
 305 310 315 320

Phe Cys Ser Ser Arg Leu Leu Asn Ala Thr Cys Asp Glu Tyr Phe Thr
 325 330 335

Arg Asn Asn Val Thr Glu Ile Gln Gly Ile Pro Gly Ala Ala Ser Gly
 340 345 350

Leu Ile Lys Glu Asn Leu Trp Ser Ser Tyr Leu Thr Lys Gly Val Ile
 355 360 365

Val Glu Arg Arg Gly Met Pro Ser Val Gly Leu Ala Asp Gly Thr Pro
 370 375 380

Val Asp Met Asp His Pro Tyr Val Phe Ser Asp Met Thr Ser Tyr Phe
 385 390 395 400

Thr Leu Leu Val Gly Ile Tyr Phe Pro Ser Val Thr Gly Ile Met Ala
 405 410 415

Gly Ser Asn Arg Ser Gly Asp Leu Arg Asp Ala Gln Lys Ser Ile Pro
 420 425 430

Thr Gly Thr Ile Leu Ala Ile Ala Thr Thr Ser Ala Val Tyr Ile Ser
 435 440 445

Ser Val Val Leu Phe Gly Ala Cys Ile Glu Gly Val Val Leu Arg Asp
 450 455 460

Lys Phe Gly Glu Ala Val Asn Gly Asn Leu Val Val Gly Thr Leu Ala
 465 470 475 480

21/36

Trp Pro Ser Pro Trp Val Ile Val Ile Gly Ser Phe Phe Ser Thr Cys
 485 490 495

Gly Ala Gly Leu Gln Ser Leu Thr Gly Ala Pro Arg Leu Leu Gln Ala
 500 505 510

Ile Ser Arg Asp Gly Ile Val Pro Phe Leu Gln Val Phe Gly His Gly
 515 520 525

Lys Ala Asn Gly Glu Pro Thr Trp Ala Leu Leu Leu Thr Ala Cys Ile
 530 535 540

Cys Glu Ile Gly Ile Leu Ile Ala Ser Leu Asp Glu Val Ala Pro Ile
 545 550 555 560

Leu Ser Met Phe Phe Leu Met Cys Tyr Met Phe Val Asn Leu Ala Cys
 565 570 575

Ala Val Gln Thr Leu Leu Arg Thr Pro Asn Trp Arg Pro Arg Phe Arg
 580 585 590

Tyr Tyr His Trp Thr Leu Ser Phe Leu Gly Met Ser Leu Cys Leu Ala
 595 600 605

Leu Met Phe Ile Cys Ser Trp Tyr Tyr Ala Leu Val Ala Met Leu Ile
 610 615 620

Ala Gly Leu Ile Tyr Lys Tyr Ile Glu Tyr Arg Gly Ala Glu Lys Glu
 625 630 635 640

Trp Gly Asp Gly Ile Arg Gly Leu Ser Leu Ser Ala Ala Arg Tyr Ala
 645 650 655

Leu Leu Arg Leu Glu Glu Gly Pro Pro His Thr Lys Asn Trp Arg Pro
 660 665 670

Gln Leu Leu Val Leu Val Arg Val Asp Gln Asp Gln Asn Val Val His
 675 680 685

Pro Gln Leu Leu Ser Leu Thr Ser Gln Leu Lys Ala Gly Lys Gly Leu
 690 695 700

22/36

Thr Ile Val Gly Ser Val Leu Glu Gly Thr Phe Leu Asp Asn His Pro
 705 710 715 720
 Gln Ala Gln Arg Ala Glu Glu Ser Ile Arg Arg Leu Met Glu Ala Glu
 725 730 735
 Lys Val Lys Gly Phe Cys Gln Val Val Ile Ser Ser Asn Leu Arg Asp
 740 745 750
 Gly Val Ser His Leu Ile Gln Ser Gly Gly Leu Gly Gly Leu Gln His
 755 760 765
 Asn Thr Val Leu Val Gly Trp Pro Arg Asn Trp Arg Gln Lys Glu Asp
 770 775 780
 His Gln Thr Trp Arg Asn Phe Ile Glu Leu Val Arg Glu Thr Thr Ala
 785 790 795 800
 Gly His Leu Ala Leu Leu Val Thr Lys Asn Val Ser Met Phe Pro Gly
 805 810 815
 Asn Pro Glu Arg Phe Ser Glu Gly Ser Ile Asp Val Trp Trp Ile Val
 820 825 830
 His Asp Gly Gly Met Leu Met Leu Leu Pro Phe Leu Leu Arg His His
 835 840 845
 Lys Val Trp Arg Lys Cys Lys Met Arg Ile Phe Thr Val Ala Gln Met
 850 855 860
 Asp Asp Asn Ser Ile Gln Met Lys Lys Asp Leu Thr Thr Phe Leu Tyr
 865 870 875 880
 His Leu Arg Ile Thr Ala Glu Val Glu Val Val Glu Met His Glu Ser
 885 890 895
 Asp Ile Ser Ala Tyr Thr Tyr Glu Lys Thr Leu Val Met Glu Gln Arg
 900 905 910
 Ser Gln Ile Leu Lys Gln Met His Leu Thr Lys Asn Glu Arg Glu Arg
 915 920 925

23/36

Glu Ile Gln Ser Ile Thr Asp Glu Ser Arg Gly Ser Ile Arg Arg Lys
 930 935 940

Asn Pro Ala Asn Pro Arg Leu Arg Leu Asn Val Pro Glu Glu Thr Ala
 945 950 955 960

Cys Asp Asn Glu Glu Lys Pro Glu Glu Glu Val Gln Leu Ile His Asp
 965 970 975

Gln Ser Ala Pro Ser Cys Pro Ser Ser Ser Pro Ser Pro Gly Glu Glu
 980 985 990

Pro Glu Gly Glu Arg Glu Thr Asp Pro Glu Val His Leu Thr Trp Thr
 995 1000 1005

Lys Asp Lys Ser Val Ala Glu Lys Asn Lys Gly Pro Ser Pro Val
 1010 1015 1020

Ser Ser Glu Gly Ile Lys Asp Phe Phe Ser Met Lys Pro Glu Trp
 1025 1030 1035

Glu Asn Leu Asn Gln Ser Asn Val Arg Arg Met His Thr Ala Val
 1040 1045 1050

Arg Leu Asn Glu Val Ile Val Asn Lys Ser Arg Asp Ala Lys Leu
 1055 1060 1065

Val Leu Leu Asn Met Pro Gly Pro Pro Arg Asn Arg Asn Gly Asp
 1070 1075 1080

Glu Asn Tyr Met Glu Phe Leu Glu Val Leu Thr Glu Gln Leu Asp
 1085 1090 1095

Arg Val Met Leu Val Arg Gly Gly Gly Arg Glu Val Ile Thr Ile
 1100 1105 1110

Tyr Ser
 1115

<210> 5
 <211> 5566
 <212> DNA
 <213> Rattus norvegicus

24/36

<220>

<221> CDS

<222> (116)..(3466)

<400> 5

ccgctccacg gagagcaagc gacagagctc gagcaagcga gcgagcggcg aaggcgggca 60

gaggggcgcg ggcgaagagg cgcagccatc ccgagcccgg cgccgcgcag ccacc atg 118
 Met
 1

ctc aac aac ctg acg gac tgc gag gac ggc gat ggg gga gcc aac ccg 166
 Leu Asn Asn Leu Thr Asp Cys Glu Asp Gly Asp Gly Gly Ala Asn Pro
 5 10 15

ggt gac ggc aat ccc aag gag agc agc ccc ttc atc aac agc acg gac 214
 Gly Asp Gly Asn Pro Lys Glu Ser Ser Pro Phe Ile Asn Ser Thr Asp
 20 25 30

acg gag aag ggg aga gag tat gat ggc agg aac atg gcc ctg ttt gag 262
 Thr Glu Lys Gly Arg Glu Tyr Asp Gly Arg Asn Met Ala Leu Phe Glu
 35 40 45

gag gag atg gac acc agc ccc atg gta tcc tcc ctg ctc agt ggg ctg 310
 Glu Glu Met Asp Thr Ser Pro Met Val Ser Ser Leu Leu Ser Gly Leu
 50 55 60 65

gcc aac tac acc aac ctg cct cag gga agc aaa gag cac gaa gaa gca 358
 Ala Asn Tyr Thr Asn Leu Pro Gln Gly Ser Lys Glu His Glu Glu Ala
 70 75 80

gaa aac aat gag ggc gga aag aag aag ccg gtg cag gcc cca cgc atg 406
 Glu Asn Asn Glu Gly Gly Lys Lys Lys Pro Val Gln Ala Pro Arg Met
 85 90 95

ggc acc ttc atg ggc gtg tac ctc ccg tgc ctg cag aac atc ttt ggt 454
 Gly Thr Phe Met Gly Val Tyr Leu Pro Cys Leu Gln Asn Ile Phe Gly
 100 105 110

gtt atc ctc ttt ctg cgg ctc act tgg gtg gtg gga atc gca ggc atc 502
 Val Ile Leu Phe Leu Arg Leu Thr Trp Val Val Gly Ile Ala Gly Ile
 115 120 125

atg gag tcc ttc tgc atg gtc ttc atc tgc tgc tcc tgc acg atg ctc 550
 Met Glu Ser Phe Cys Met Val Phe Ile Cys Cys Ser Cys Thr Met Leu
 130 135 140 145

aca gcc att tcc atg agc gca att gca acc aat ggt gtt gtg cct gct 598
 Thr Ala Ile Ser Met Ser Ala Ile Ala Thr Asn Gly Val Val Pro Ala
 150 155 160

ggt ggc tcc tac tac atg att tcc agg tct ctg ggc ccg gag ttt ggg 646
 Gly Gly Ser Tyr Tyr Met Ile Ser Arg Ser Leu Gly Pro Glu Phe Gly
 165 170 175

25/36

ggc gcc gtg ggc ctc tgc ttc tac ctg ggc act acc ttt gct ggg gct Gly Ala Val Gly Leu Cys Phe Tyr Leu Gly Thr Thr Phe Ala Gly Ala 180 185 190	694
atg tac atc ctg ggc acc atc gag atc ctg ctg gct tac ctc ttc cca Met Tyr Ile Leu Gly Thr Ile Glu Ile Leu Leu Ala Tyr Leu Phe Pro 195 200 205	742
gcg atg gcc atc ttc aag gca gaa gat gcc agt ggg gag gca gcc gcc Ala Met Ala Ile Phe Lys Ala Glu Asp Ala Ser Gly Glu Ala Ala Ala 210 215 220 225	790
atg ttg aat aac atg cgg gtg tat ggc acc tgt gtg ctc acc tgc atg Met Leu Asn Asn Met Arg Val Tyr Gly Thr Cys Val Leu Thr Cys Met 230 235 240	838
gcc acc gta gtc ttt gtg ggc gtc aag tac gtg aac aag ttt gcc ctg Ala Thr Val Val Phe Val Gly Val Lys Tyr Val Asn Lys Phe Ala Leu 245 250 255	886
gtc ttc ctg ggt tgc gtg atc ctc tcc atc ctg gcc atc tac gca ggg Val Phe Leu Gly Cys Val Ile Leu Ser Ile Leu Ala Ile Tyr Ala Gly 260 265 270	934
gtc atc aag tct gcc ttc gat cca ccc aat ttc ccg att tgc ctc ctg Val Ile Lys Ser Ala Phe Asp Pro Pro Asn Phe Pro Ile Cys Leu Leu 275 280 285	982
ggg aac cgc acg ctg tct cgc cat ggc ttt gat gtc tgt gcc aag ctg Gly Asn Arg Thr Leu Ser Arg His Gly Phe Asp Val Cys Ala Lys Leu 290 295 300 305	1030
gct tgg gaa gga aat gag aca gtg acc aca cgg ctc tgg ggc cta ttc Ala Trp Glu Gly Asn Glu Thr Val Thr Thr Arg Leu Trp Gly Leu Phe 310 315 320	1078
tgt tcc tcc cgc ctc ctc aat gcc acc tgt gat gag tac ttc acc cga Cys Ser Ser Arg Leu Leu Asn Ala Thr Cys Asp Glu Tyr Phe Thr Arg 325 330 335	1126
aac aat gtc aca gag atc cag ggc att cct ggt gct gca agt ggc ctc Asn Asn Val Thr Glu Ile Gln Gly Ile Pro Gly Ala Ala Ser Gly Leu 340 345 350	1174
atc aaa gag aac ctg tgg agt tcc tac ctg acc aag ggg gtg atc gtg Ile Lys Glu Asn Leu Trp Ser Ser Tyr Leu Thr Lys Gly Val Ile Val 355 360 365	1222
gag agg cgt ggg atg ccc tct gtg ggc ctg gca gat ggt acc ccc gtt Glu Arg Arg Gly Met Pro Ser Val Gly Leu Ala Asp Gly Thr Pro Val 370 375 380 385	1270
gac atg gac cac ccc tat gtc ttc agt gat atg acc tcc tac ttc acc Asp Met Asp His Pro Tyr Val Phe Ser Asp Met Thr Ser Tyr Phe Thr 390 395 400	1318

26/36

ctg ctt gtt ggc atc tat ttc ccc tca gtc aca ggg atc atg gct ggc Leu Leu Val Gly Ile Tyr Phe Pro Ser Val Thr Gly Ile Met Ala Gly 405 410 415	1366
tcg aac cgg tcc gga gac ctg cgg gat gcc cag aag tct atc cct act Ser Asn Arg Ser Gly Asp Leu Arg Asp Ala Gln Lys Ser Ile Pro Thr 420 425 430	1414
gga act atc ttg gcc att gct acg acc tct gct gtc tac atc agc tct Gly Thr Ile Leu Ala Ile Ala Thr Thr Ser Ala Val Tyr Ile Ser Ser 435 440 445	1462
gtt gtt ctg ttc gga gcc tgc atc gaa ggg gtc gtc cta cgg gac aag Val Val Leu Phe Gly Ala Cys Ile Glu Gly Val Val Leu Arg Asp Lys 450 455 460 465	1510
ttt ggg gaa gct gtg aat ggc aat ctg gtg gtg ggc acc ctg gcc tgg Phe Gly Glu Ala Val Asn Gly Asn Leu Val Val Gly Thr Leu Ala Trp 470 475 480	1558
cct tct cct tgg gtc att gtc ata ggc tct ttc ttc tct acc tgc gga Pro Ser Pro Trp Val Ile Val Ile Gly Ser Phe Phe Ser Thr Cys Gly 485 490 495	1606
gct gga cta cag agc ctc aca ggg gcc cca cgc ctg ctg cag gcc atc Ala Gly Leu Gln Ser Leu Thr Gly Ala Pro Arg Leu Leu Gln Ala Ile 500 505 510	1654
tcc cgg gat ggc ata gtg ccc ttc ctg cag gtc ttt ggc cat ggc aaa Ser Arg Asp Gly Ile Val Pro Phe Leu Gln Val Phe Gly His Gly Lys 515 520 525	1702
gcc aac gga gag cca acc tgg gcg ctg ctg ctg act gcc tgc atc tgt Ala Asn Gly Glu Pro Thr Trp Ala Leu Leu Leu Thr Ala Cys Ile Cys 530 535 540 545	1750
gag atc ggc atc ctc atc gcc tcc ctg gat gag gtc gcc cct atc ctt Glu Ile Gly Ile Leu Ile Ala Ser Leu Asp Glu Val Ala Pro Ile Leu 550 555 560	1798
tcc atg ttc ttc ctg atg tgt tac atg ttt gtg aac ttg gct tgc gcg Ser Met Phe Phe Leu Met Cys Tyr Met Phe Val Asn Leu Ala Cys Ala 565 570 575	1846
gtg cag aca ctg ctg agg acg ccc aac tgg agg cca cgc ttc cga tat Val Gln Thr Leu Leu Arg Thr Pro Asn Trp Arg Pro Arg Phe Arg Tyr 580 585 590	1894
tac cac tgg acc ctc tcc ttc ctg ggc atg agc ctc tgc ctg gcc ctg Tyr His Trp Thr Leu Ser Phe Leu Gly Met Ser Leu Cys Leu Ala Leu 595 600 605	1942
atg ttc att tgc tcc tgg tat tat gcg ctg gta gct atg ctc atc gct Met Phe Ile Cys Ser Trp Tyr Tyr Ala Leu Val Ala Met Leu Ile Ala 610 615 620 625	1990

27/36

ggc ctc atc tat aag tac atc gag tac cgg ggg gca gag aag gag tgg Gly Leu Ile Tyr Lys Tyr Ile Glu Tyr Arg Gly Ala Glu Lys Glu Trp 630 635 640	2038
ggg gat ggg atc cga ggc ctg tct ctc agt gca gct cgc tat gct ctc Gly Asp Gly Ile Arg Gly Leu Ser Leu Ser Ala Ala Arg Tyr Ala Leu 645 650 655	2086
ttg cgt ctg gag gaa gga ccc ccg cat aca aag aac tgg agg ccc cag Leu Arg Leu Glu Glu Gly Pro His Thr Lys Asn Trp Arg Pro Gln 660 665 670	2134
cta ctg gtg ctg gtg cgt gtg gac cag gac cag aac gtg gtg cac ccg Leu Leu Val Leu Val Arg Val Asp Gln Asp Gln Asn Val Val His Pro 675 680 685	2182
cag ctg ctg tcc ttg acc tcc cag ctc aag gca ggg aag ggc ctg acc Gln Leu Leu Ser Leu Thr Ser Gln Leu Lys Ala Gly Lys Gly Leu Thr 690 695 700 705	2230
att gtg ggc tct gtc ctt gag ggc acc ttt ctg gac aac cac cct cag Ile Val Gly Ser Val Leu Glu Gly Thr Phe Leu Asp Asn His Pro Gln 710 715 720	2278
gct cag cgg gca gag gag tct atc cgg cgc ctg atg gag gct gag aag Ala Gln Arg Ala Glu Glu Ser Ile Arg Arg Leu Met Glu Ala Glu Lys 725 730 735	2326
gtg aag ggc ttc tgc cag gta gtg atc tcc tcc aac ctg cgt gac ggt Val Lys Gly Phe Cys Gln Val Val Ile Ser Ser Asn Leu Arg Asp Gly 740 745 750	2374
gtg tcc cac ctg atc caa tcc ggg ggc ctc ggg ggc ctg caa cac aac Val Ser His Leu Ile Gln Ser Gly Gly Leu Gly Glu Leu Gln His Asn 755 760 765	2422
act gtg cta gtg ggc tgg cct cgc aac tgg cga cag aag gag gat cat Thr Val Leu Val Gly Trp Pro Arg Asn Trp Arg Gln Lys Glu Asp His 770 775 780 785	2470
cag aca tgg agg aac ttc atc gaa ctc gtc cgg gaa act aca gct ggc Gln Thr Trp Arg Asn Phe Ile Glu Leu Val Arg Glu Thr Thr Ala Gly 790 795 800	2518
cac ctc gcc ctg ctg gtc acc aag aat gtt tcc atg ttc ccc ggg aac His Leu Ala Leu Leu Val Thr Lys Asn Val Ser Met Phe Pro Gly Asn 805 810 815	2566
cct gag cgt ttc tct gag ggc agc att gac gtg tgg tgg atc gtg cac Pro Glu Arg Phe Ser Glu Gly Ser Ile Asp Val Trp Trp Ile Val His 820 825 830	2614
gac ggg ggc atg ctc atg ctg ttg ccc ttc ctc ctg cgt cac cac aag Asp Gly Gly Met Leu Met Leu Leu Pro Phe Leu Leu Arg His His Lys 835 840 845	2662

28/36

gtc tgg agg aaa tgc aaa atg cgg atc ttc acc gtg gcg cag atg gat Val Trp Arg Lys Cys Lys Met Arg Ile Phe Thr Val Ala Gln Met Asp 850 855 860 865	2710
gac aac agc att cag atg aag aaa gac ctg acc acg ttt ctg tac cac Asp Asn Ser Ile Gln Met Lys Lys Asp Leu Thr Thr Phe Leu Tyr His 870 875 880	2758
tta cga att act gca gag gtg gaa gtc gtg gag atg cac gag agc gac Leu Arg Ile Thr Ala Glu Val Glu Val Val Glu Met His Glu Ser Asp 885 890 895	2806
atc tca gca tac acc tac gag aag aca ttg gta atg gaa caa cgt tct Ile Ser Ala Tyr Thr Tyr Glu Lys Thr Leu Val Met Glu Gln Arg Ser 900 905 910	2854
cag atc ctc aaa cag atg cac ctc acc aag aac gag cgg gaa cgg gag Gln Ile Leu Lys Gln Met His Leu Thr Lys Asn Glu Arg Glu Arg Glu 915 920 925	2902
atc cag agc atc aca gat gaa tct cgg ggc tcc att cgg agg aag aat Ile Gln Ser Ile Thr Asp Glu Ser Arg Gly Ser Ile Arg Arg Lys Asn 930 935 940 945	2950
cca gcc aac act cgg ctc cgc ctc aat gtt ccc gaa gag aca gct tgt Pro Ala Asn Thr Arg Leu Arg Leu Asn Val Pro Glu Glu Thr Ala Cys 950 955 960	2998
gac aac gag gag aag cca gaa gag gag gtg cag ctg atc cat gac cag Asp Asn Glu Glu Lys Pro Glu Glu Glu Val Gln Leu Ile His Asp Gln 965 970 975	3046
agt gct ccc agc tgc cct agc agc tcg ccg tct cca ggg gag gag cct Ser Ala Pro Ser Cys Pro Ser Ser Ser Pro Ser Pro Gly Glu Glu Pro 980 985 990	3094
gag ggg gag ggg gag aca gac cca gag aag gtg cat ctc acc tgg acc Glu Gly Glu Gly Glu Thr Asp Pro Glu Lys Val His Leu Thr Trp Thr 995 1000 1005	3142
aag gat aag tca gcg gct cag aag aac aaa ggc ccc agt ccc gtc Lys Asp Lys Ser Ala Ala Gln Lys Asn Lys Gly Pro Ser Pro Val 1010 1015 1020	3187
tcc tcg gag ggg atc aag gac ttc ttc agc atg aag ccg gag tgg Ser Ser Glu Gly Ile Lys Asp Phe Phe Ser Met Lys Pro Glu Trp 1025 1030 1035	3232
gaa aac ttg aac cag tcc aac gtg cgg cgc atg cac aca gct gtg Glu Asn Leu Asn Gln Ser Asn Val Arg Arg Met His Thr Ala Val 1040 1045 1050	3277
cgg ctg aac gag gtc atc gtg aat aaa tcc cgg gat gcc aag ttg Arg Leu Asn Glu Val Ile Val Asn Lys Ser Arg Asp Ala Lys Leu 1055 1060 1065	3322

[illegible]

30/36

cattgcccac tccagggcca gggccactag ctgacctcac cacctttttc cttgagccca 4766
 aggcagagag agctgcagct ggtgccatct agacaggctc aagtgtggcc agtggcaggg 4826
 ctcgaggggcc actgccctgt tgcttggtc aggacctctc tgagatttga tggggactgg 4886
 atattcttcc aggtagtagc catcaagtcg gaagtgttgg acccaggacc tgacattcct 4946
 tcaagactgc cctcccttgc tgtggttttg ctttttgggg caagagaggg gctgggcaaa 5006
 cggggaggag gcagtatcaa caccgattag ggaaccaaag ttgcactacc tggggccagc 5066
 ctctggttgg caagagcaaa gtttctgttg atgaaaacaa acagcccaca acaacacccc 5126
 ccccccggtt ttctgtgctc catgtgcaat atttgttatg aaccttgtgt cgttcaagtc 5186
 acctttataa tcaactgtagc tagatgttcc atgtccatcc aggtgacttt actctgagtg 5246
 caatatttca atagcctggt agtgagaaga gtgttgcttt tgtttcagcc gacctatgtg 5306
 cagggcaatg caatgcagtc caaaaccctt gtaaatagga gaggttgcaa gccaaatcaa 5366
 gagtatttat cgttattact attattatta ggctgcctt taattttagt gtttcggtat 5426
 ttgcacacct gcctcggtat tgatcggtg ttctctgtgc caatatgcaa aggagaggat 5486
 cagttctttc ctttactgtt gaatgctccc atttactgct ttaaggcttt tactgtgttc 5546
 attttttaga tacctgtctg 5566

<210> 6
 <211> 1116
 <212> PRT
 <213> Rattus norvegicus

<400> 6

Met Leu Asn Asn Leu Thr Asp Cys Glu Asp Gly Asp Gly Gly Ala Asn
1 5 10 15

Pro Gly Asp Gly Asn Pro Lys Glu Ser Ser Pro Phe Ile Asn Ser Thr
20 25 30

Asp Thr Glu Lys Gly Arg Glu Tyr Asp Gly Arg Asn Met Ala Leu Phe
35 40 45

Glu Glu Glu Met Asp Thr Ser Pro Met Val Ser Ser Leu Leu Ser Gly
50 55 60

Leu Ala Asn Tyr Thr Asn Leu Pro Gln Gly Ser Lys Glu His Glu Glu
65 70 75 80

32/36

Leu Ala Trp Glu Gly Asn Glu Thr Val Thr Thr Arg Leu Trp Gly Leu
 305 310 315 320

Phe Cys Ser Ser Arg Leu Leu Asn Ala Thr Cys Asp Glu Tyr Phe Thr
 325 330 335

Arg Asn Asn Val Thr Glu Ile Gln Gly Ile Pro Gly Ala Ala Ser Gly
 340 345 350

Leu Ile Lys Glu Asn Leu Trp Ser Ser Tyr Leu Thr Lys Gly Val Ile
 355 360 365

Val Glu Arg Arg Gly Met Pro Ser Val Gly Leu Ala Asp Gly Thr Pro
 370 375 380

Val Asp Met Asp His Pro Tyr Val Phe Ser Asp Met Thr Ser Tyr Phe
 385 390 395 400

Thr Leu Leu Val Gly Ile Tyr Phe Pro Ser Val Thr Gly Ile Met Ala
 405 410 415

Gly Ser Asn Arg Ser Gly Asp Leu Arg Asp Ala Gln Lys Ser Ile Pro
 420 425 430

Thr Gly Thr Ile Leu Ala Ile Ala Thr Thr Ser Ala Val Tyr Ile Ser
 435 440 445

Ser Val Val Leu Phe Gly Ala Cys Ile Glu Gly Val Val Leu Arg Asp
 450 455 460

Lys Phe Gly Glu Ala Val Asn Gly Asn Leu Val Val Gly Thr Leu Ala
 465 470 475 480

Trp Pro Ser Pro Trp Val Ile Val Ile Gly Ser Phe Phe Ser Thr Cys
 485 490 495

Gly Ala Gly Leu Gln Ser Leu Thr Gly Ala Pro Arg Leu Leu Gln Ala
 500 505 510

Ile Ser Arg Asp Gly Ile Val Pro Phe Leu Gln Val Phe Gly His Gly
 515 520 525

33/36

Lys Ala Asn Gly Glu Pro Thr Trp Ala Leu Leu Leu Thr Ala Cys Ile
 530 535 540

Cys Glu Ile Gly Ile Leu Ile Ala Ser Leu Asp Glu Val Ala Pro Ile
 545 550 555 560

Leu Ser Met Phe Phe Leu Met Cys Tyr Met Phe Val Asn Leu Ala Cys
 565 570 575

Ala Val Gln Thr Leu Leu Arg Thr Pro Asn Trp Arg Pro Arg Phe Arg
 580 585 590

Tyr Tyr His Trp Thr Leu Ser Phe Leu Gly Met Ser Leu Cys Leu Ala
 595 600 605

Leu Met Phe Ile Cys Ser Trp Tyr Tyr Ala Leu Val Ala Met Leu Ile
 610 615 620

Ala Gly Leu Ile Tyr Lys Tyr Ile Glu Tyr Arg Gly Ala Glu Lys Glu
 625 630 635 640

Trp Gly Asp Gly Ile Arg Gly Leu Ser Leu Ser Ala Ala Arg Tyr Ala
 645 650 655

Leu Leu Arg Leu Glu Glu Gly Pro Pro His Thr Lys Asn Trp Arg Pro
 660 665 670

Gln Leu Leu Val Leu Val Arg Val Asp Gln Asp Gln Asn Val Val His
 675 680 685

Pro Gln Leu Leu Ser Leu Thr Ser Gln Leu Lys Ala Gly Lys Gly Leu
 690 695 700

Thr Ile Val Gly Ser Val Leu Glu Gly Thr Phe Leu Asp Asn His Pro
 705 710 715 720

Gln Ala Gln Arg Ala Glu Glu Ser Ile Arg Arg Leu Met Glu Ala Glu
 725 730 735

Lys Val Lys Gly Phe Cys Gln Val Val Ile Ser Ser Asn Leu Arg Asp
 740 745 750

34/36

Gly Val Ser His Leu Ile Gln Ser Gly Gly Leu Gly Gly Leu Gln His
 755 760 765

Asn Thr Val Leu Val Gly Trp Pro Arg Asn Trp Arg Gln Lys Glu Asp
 770 775 780

His Gln Thr Trp Arg Asn Phe Ile Glu Leu Val Arg Glu Thr Thr Ala
 785 790 795 800

Gly His Leu Ala Leu Leu Val Thr Lys Asn Val Ser Met Phe Pro Gly
 805 810 815

Asn Pro Glu Arg Phe Ser Glu Gly Ser Ile Asp Val Trp Trp Ile Val
 820 825 830

His Asp Gly Gly Met Leu Met Leu Leu Pro Phe Leu Leu Arg His His
 835 840 845

Lys Val Trp Arg Lys Cys Lys Met Arg Ile Phe Thr Val Ala Gln Met
 850 855 860

Asp Asp Asn Ser Ile Gln Met Lys Lys Asp Leu Thr Thr Phe Leu Tyr
 865 870 875 880

His Leu Arg Ile Thr Ala Glu Val Glu Val Val Glu Met His Glu Ser
 885 890 895

Asp Ile Ser Ala Tyr Thr Tyr Glu Lys Thr Leu Val Met Glu Gln Arg
 900 905 910

Ser Gln Ile Leu Lys Gln Met His Leu Thr Lys Asn Glu Arg Glu Arg
 915 920 925

Glu Ile Gln Ser Ile Thr Asp Glu Ser Arg Gly Ser Ile Arg Arg Lys
 930 935 940

Asn Pro Ala Asn Thr Arg Leu Arg Leu Asn Val Pro Glu Glu Thr Ala
 945 950 955 960

Cys Asp Asn Glu Glu Lys Pro Glu Glu Glu Val Gln Leu Ile His Asp
 965 970 975

35/36

Gln Ser Ala Pro Ser Cys Pro Ser Ser Ser Pro Ser Pro Gly Glu Glu
 980 985 990

Pro Glu Gly Glu Gly Glu Thr Asp Pro Glu Lys Val His Leu Thr Trp
 995 1000 1005

Thr Lys Asp Lys Ser Ala Ala Gln Lys Asn Lys Gly Pro Ser Pro
 1010 1015 1020

Val Ser Ser Glu Gly Ile Lys Asp Phe Phe Ser Met Lys Pro Glu
 1025 1030 1035

Trp Glu Asn Leu Asn Gln Ser Asn Val Arg Arg Met His Thr Ala
 1040 1045 1050

Val Arg Leu Asn Glu Val Ile Val Asn Lys Ser Arg Asp Ala Lys
 1055 1060 1065

Leu Val Leu Leu Asn Met Pro Gly Pro Pro Arg Asn Arg Asn Gly
 1070 1075 1080

Asp Glu Asn Tyr Met Glu Phe Leu Glu Val Leu Thr Glu Gln Leu
 1085 1090 1095

Asp Arg Val Met Leu Val Arg Gly Gly Gly Arg Glu Val Ile Thr
 1100 1105 1110

Ile Tyr Ser
 1115

<210> 7

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic oligonucleotide

<400> 7

tctccttggg attgccgtca

20

<210> 8

<211> 20

<212> DNA

36/36

<213> Artificial sequence

<220>

<223> Synthetic oligonucleotide

<400> .8

tcttcttgag actgcagtca

20

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA2004/000726

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61P25/00 A61P23/00 A61K39/395 A61K31/00 G01N33/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE, EMBASE, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>US 2002/028779 A1 (HIGH KARIN WESTLUND ET AL) 7 March 2002 (2002-03-07)</p> <p>paragraph '0010! - paragraph '0012! paragraph '0023! paragraph '0028! - paragraph '0029! paragraph '0041! paragraph '0050! - paragraph '0051! example 2 claims 4,12,19</p> <p>----- -/--</p>	<p>1-16, 21-39, 53-59,64</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

23 September 2004

Date of mailing of the international search report

08/10/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Irion, A

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA2004/000726

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 02/102232 A (UNIV CALIFORNIA ; LEVINE JON DAVID (US); MESSING ROBERT O (US)) 27 December 2002 (2002-12-27)</p> <p>page 7, line 4 - line 8 page 3, line 1 - line 2 page 10, line 20 - line 23 page 14, line 7 - line 9 page 56, line 17 - line 20 claim 94</p>	<p>1-13,17, 18, 21-37, 40,41, 53-57, 60,61,64</p>
X	<p>-----</p> <p>ALEY KOCHUVELIKAKAM O ET AL: "Role of protein kinase A in the maintenance of inflammatory pain" JOURNAL OF NEUROSCIENCE, vol. 19, no. 6, 15 March 1999 (1999-03-15), pages 2181-2186, XP002297725 ISSN: 0270-6474 abstract</p>	<p>1-13,17, 18, 21-37, 40,41, 53-57, 60,61,64</p>
X	<p>-----</p> <p>HUA XIAO-YING ET AL: "Inhibition of spinal protein kinase C reduces nerve injury-induced tactile allodynia in neuropathic rats" NEUROSCIENCE LETTERS, vol. 276, no. 2, 3 December 1999 (1999-12-03), pages 99-102, XP002297726 ISSN: 0304-3940 abstract</p>	<p>1-13,17, 18, 21-37, 40,41, 53-57, 60,61,64</p>
X	<p>-----</p> <p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2001, FANG L ET AL: "CaMK II signaling in central sensitization in a rat model of visceral pain" XP002297727 Database accession no. PREV200200002912 abstract & SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 2, 2001, page 2163, 31ST ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; SAN DIEGO, CALIFORNIA, USA; NOVEMBER 10-15, 2001 ISSN: 0190-5295</p> <p>-----</p> <p style="text-align: center;">-/--</p>	<p>1-7,9, 11-13, 19-37, 42,43, 53-57, 62-64</p>

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA2004/000726

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 2004/032870 A (RINAT NEUROSCIENCE CORP ; SHELTON DAVID L (US); VERGARA GERMAN J (US)) 22 April 2004 (2004-04-22) paragraph '0042!; figure 9 paragraph '0128! paragraph '0185!; example 5 -----	1-16, 21-39, 53-59,64
P,X	COULL JEFFREY A M ET AL: "Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain." NATURE (LONDON), vol. 424, no. 6951, 21 August 2003 (2003-08-21), pages 938-942, XP002294556 ISSN: 0028-0836 the whole document -----	44-52, 65-81
P,A	-----	1-43, 53-64
A	WO 93/00909 A (REGENERON PHARMA) 21 January 1993 (1993-01-21) the whole document -----	1-16, 21-39, 53-59,64
A	WO 01/85151 A (RAYCHAUDHURI SIBA P ; RAYCHAUDHURI SMRITI K (US); FARBER EUGENE M (US)) 15 November 2001 (2001-11-15) the whole document -----	1-16, 21-39, 53-59,64
A	DE PLATER G M ET AL: "Venom from the platypus, Ornithorhynchus anatinus, induces a calcium-dependent current in cultured dorsal root ganglion cells" JOURNAL OF NEUROPHYSIOLOGY (BETHESDA), vol. 85, no. 3, March 2001 (2001-03), pages 1340-1345, XP002294557 ISSN: 0022-3077 the whole document -----	1-16, 21-39, 53-59,64

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2004/000726

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-21, 31, 33, 35-43, 53-81 (all partially)
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Continuation of Box II.1

Although claims 1-21,31,33,35-43,53-81 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claims 65-81 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/CA2004/000726

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 2002028779	A1	07-03-2002	NONE	
WO 02102232	A	27-12-2002	WO 02102232 A2	27-12-2002
			US 2003008807 A1	09-01-2003
WO 2004032870	A	22-04-2004	WO 2004032870 A2	22-04-2004
WO 9300909	A	21-01-1993	AU 2322392 A	11-02-1993
			CA 2112799 A1	21-01-1993
			EP 0593663 A1	27-04-1994
			IE 921315 A1	13-01-1993
			JP 6509333 T	20-10-1994
			NZ 242467 A	27-06-1995
			PT 100424 A	29-10-1993
			WO 9300909 A1	21-01-1993
			ZA 9202946 A	30-12-1992
WO 0185151	A	15-11-2001	AU 6132401 A	20-11-2001
			WO 0185151 A2	15-11-2001